piperacillin has been researched along with piperacillin, tazobactam drug combination in 867 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 47 (5.42) | 18.2507 |
| 2000's | 219 (25.26) | 29.6817 |
| 2010's | 500 (57.67) | 24.3611 |
| 2020's | 101 (11.65) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, CY; Lui, WY; Shyr, YM; Su, CH; Wang, LS | 1 |
| Baron, EJ; Jones, RN | 1 |
| Aldridge, KE; Allen, SD; Fuchs, PC; Gerlach, EH; Jones, RN; Marshall, SA | 1 |
| Danziger, LH; Occhipinti, DJ; Rodvold, KA; Schoonover, LL | 1 |
| Maclaren, DM; Schmitz, PI; Stobberingh, EE | 1 |
| Calandra, T; Cometta, A; de Bock, R; Gaya, H; Glauser, MP; Klastersky, J; Langenaeken, J; Paesmans, M; Viscoli, C; Zinner, S | 1 |
| Bansal, S; Doepner, M; Halstenson, CE; Johnson, CA; Keane, WF; Onorato, JJ; Sia, L; Tantillo, K; Wong, MO; Zimmerman, SW | 1 |
| Louie, L; Louie, M; Simor, AE | 1 |
| Jakob, E; Jáuregui, A; Rojas, JJ; Ruíz-Palacios, GM; Sifuentes-Osornio, J; Villalobos, Y | 1 |
| Murray, BE; Okhuysen, PC; Singh, KV | 1 |
| Martinez, JF; Trissel, LA | 1 |
| Adams, LB; Harris, EB; Hastings, RC; Prabhakaran, K; Randhawa, B; Williams, DL | 1 |
| Bonomo, RA; Carias, LL; Rice, LB; Shlaes, DM | 1 |
| Barkan, L; Clara, L; Conde-Carmona, I; Dain, A; de la Cabada, FJ; Durlach, R; Froiler, C; Fuentes del Toro, S; Gamboa, MA; Jakob, E; Jáuregui, A; Lamberghini, R; Maglio, F; Quiroga, JV; Rodríguez-Toledo, A; Rojas, JJ; Ruìz-Palacios, GM; Sáenz-Aguirre, C; Sifuentes-Osornio, J; Villalobos, Y; Zavala-Trujillo, I | 1 |
| Arguedas, A; Corrales, JC; Herrera, M; Loaiza, C; Mohs, E; Sifuentes-Osornio, J | 1 |
| Schwenk, MH; Wang, F | 1 |
| Gel'fand, BR; Gel'fand, EB; Lapshina, IIu; Topazova, EN | 1 |
| Blatun, LA; Iakovlev, VP; Izotova, GN; Svetukhin, AM; Terekhova, RP | 1 |
| Dvoretskiĭ, LI; Eremina, LV; Iakovlev, SV; Kaĭnov, MS; Koroleva, TA; Orlova, EA; Romanovskiĭ, IuIa; Shakhova, TV; Zhulin, SL | 1 |
| Iurlova, MI; Maschan, AA; Rumiantseva, TA | 1 |
| Chernen'kaia, TV; Lobakov, AI; Nasonov, VN; Rusanova, EV; Savitskaia, KI; Savov, AM; Silkina, TA | 1 |
| Iakovlev, SV | 1 |
| Erwin, ME; Jones, RN; Worth, S | 1 |
| Dickinson, JP; Graham, J; Hazel, DL; Kelsey, SM; Newland, AC | 1 |
| Falagas, ME; McDermott, L; Snydman, DR | 1 |
| Fraser, SL; Jorgensen, JH | 1 |
| Bourget, P; Fernandez, H; Lesne-Hulin, A; Sertin, A; Van Peborgh, P; Ville, Y | 1 |
| Brière, S; Brun-Buisson, C; Petit, C; Schweich, H; Sollet, JP | 1 |
| Mokaddas, E; Rotimi, VO; Sanyal, SC | 1 |
| Asuka, T; Chiba, C; Kitazawa, J; Okamoto, T; Saito, T; Sato, Y; Takahashi, Y; Tateyama, N; Tsushima, T; Waga, S; Yokoyama, M | 1 |
| Takamuro, M; Watanabe, A | 1 |
| Ishihara, T; Nakamura, H; Tezuka, T; Toyonaga, Y | 1 |
| Iwai, N; Miyazu, M; Nakamura, H | 1 |
| Grossenbacher, M; Imhof, E; Speich, R; Vogt, M; Zimmerli, W | 1 |
| Hayakawa, F; Itomi, K; Kato, T; Kuno, K; Miyajima, Y; Ogawa, A; Okumura, A; Takahashi, H | 1 |
| Ihara, T; Kamiya, H; Kitamura, K; Nishimori, H | 1 |
| Aida, K; Aramaki, M; Fukuda, T; Hayashi, M; Hoshuyama, A; Ikezawa, S; Imai, S; Kato, H; Matsuo, Y; Morita, J; Motohiro, T; Nagai, K; Oda, K; Oki, S; Sakata, Y; Takahgashi, K; Tananari, Y; Tsumura, N; Tsutsumi, T; Yamada, T; Yamakawa, R; Yamashita, Y; Yoshinaga, Y | 1 |
| Haruta, T; Kobayashi, Y; Nishio, T | 1 |
| Birawska, I; Fuchs, J; Szulakowska, E | 1 |
| Rokosz, A; Sawicka-Grzelak, A | 1 |
| Mokaddas, EM; Sanyal, SC | 1 |
| Elhelali, N; Jacolot, A; Laurent, F; Léotard, S; Mimoz, O; Nordmann, P; Petitjean, O; Samii, K | 1 |
| Alarcón, T; de la Obra, P; de las Cuevas, C; López-Brea, M; López-Hernandez, S | 1 |
| Buchman, TG; Cheadle, WG; Cohn, SM; Haverstock, DC; Jungerwirth, S; Kowalsky, SF; Lipsett, PA; Milsom, JW; O'Marro, S; Rochefort, EV; Yellin, AE | 1 |
| Alkan, ML; Faivisevitz, A; Zuabi, T | 1 |
| Bolsoni, AP; Mendes, RE; Roland, RK; Sader, HS; Silbert, S | 1 |
| Daschner, F; Dietrich, ES; Ebner, W; Schubert, B | 1 |
| Alvarez-Lerma, F; Barcenilla, F; Insausti-Ordeñana, J; Jordá-Marcos, R; Maraví-Poma, E; Martínez-Pellús, A; Nava, J; Palomar, M; Torres-Martí, A | 1 |
| Arranz, R; de La Cámara, R; Font, P; Leyra, F; María Fernández Rañada, J; Pajuelo, F; Rivero, N | 1 |
| Carinder, JE; Chua, JD; Corales, RB; Procop, GW; Taege, AJ | 1 |
| Kim, MK; Nicolau, DP; Nightingale, CH; Quintiliani, R; Xuan, D | 1 |
| Anastasio, P; Casoli, E; De Santo, NG; Molino, D | 1 |
| Bucaneve, G; D'Antonio, D; Del Favero, A; Furno, P; Gentile, G; Mandelli, F; Martino, B; Martino, P; Menichetti, F; Micozzi, A; Ricci, P; Russo, D | 1 |
| Dubau, B; Frappier, S; Hernandez, V; Pédeboscq, S; Pometan, JP; Veyssières, D; Winnock, S | 1 |
| Plosker, GL; Young, M | 1 |
| Bossuyt, X; Peetermans, WE | 1 |
| LaFleur, BJ; Siami, FS; Siami, GA | 1 |
| Allaouchiche, B; Bel, JC; Boselli, E; Breilh, D; Chassard, D; Debon, R; Duflo, F; Saux, MC | 1 |
| Grant, EM; Kuti, JL; Nicolau, DP; Nightingale, C; Quintiliani, R | 1 |
| Drewelow, B; Francke, A; Hickstein, H; Majcher-Peszynska, J; Mueller, SC; Mundkowski, R; Pertschy, A; Schulz, M | 1 |
| Capitano, B; Kim, MK; Mattoes, HM; Nicolau, DP; Nightingale, CH; Quintiliani, R; Xuan, D | 1 |
| Biedenbach, DJ; Johnson, DM; Jones, RN | 1 |
| Archontaki, HA; Marselos, SC | 1 |
| Gilsdorf, JR | 1 |
| Chua, A; Jimenez, VE; Tortora, G; Younus, F | 1 |
| Evans, ME | 1 |
| Dul, MJ; Hoyen, C; Salvator, A; Toltzis, H; Toltzis, P; Walsh, M; Zetts, L | 1 |
| Goenaga Sánchez, MA | 1 |
| Friedland, I; Majumdar, A; Mixson, LA; Motyl, M; Woods, GL | 1 |
| Carides, A; Choe, KA; Christou, NV; Dellinger, EP; Fernandez, A; Malafaia, O; Rotstein, OD; Satishchandran, V; Solomkin, JS; Tellado, JM; Teppler, H; Yellin, AE | 1 |
| García-Rodríguez, JA; Trujillano, I | 1 |
| Beilman, GJ; Feltis, BA; Lee, DA | 1 |
| Powell, LL; Wilson, SE | 1 |
| Babini, GS; Hall, LM; Livermore, DM; Yuan, M | 1 |
| Brun-Buisson, C | 1 |
| Barr, J; Flavin, KE; Fowler, RA; Gould, MK; Parsonnet, J; Weinacker, AB | 1 |
| Paniara, O; Platsouka, E; Portolos, J; Zissis, NP | 1 |
| Gesser, R; McCarroll, K; Tellado, J; Teppler, H; Woods, GL | 1 |
| Gesser, RM; McCarroll, K; Teppler, H; Woods, GL | 1 |
| Ambrose, PG; Bhavnani, SM; Jones, RN | 1 |
| Esposito, S; Ianniello, F; Leone, S; Maiello, A; Marvaso, A; Noviello, S; Petronella, P | 1 |
| Carmeli, Y; Gold, HS; Graham, CS; Sands, BE; Schwaber, MJ | 1 |
| Charlett, A; Henwood, CJ; James, D; Johnson, AP; Livermore, DM; Mushtaq, S; Potz, N; Walker, RA; Warburton, F; Warner, M | 1 |
| Dowzicky, MJ; Jones, ME; Karlowsky, JA; Sahm, DF; Thornsberry, C; Weaver, MK | 1 |
| Akan, H; Calandra, T; Cometta, A; Crokaert, F; De Bock, R; Engelhard, D; Gaya, H; Glauser, MP; Kern, WV; Klastersky, J; Korten, V; Marchetti, O; Padmos, A; Paesmans, M; Skoutelis, A; Vandenbergh, M; Vandercam, M; Viscoli, C; Zinner, S | 1 |
| Fung, CP; Hsueh, PR; Lan, CK; Lau, YT; Su, CC; Wong, WW; Yeung, JY; Young, GT | 1 |
| Burroughs, A; Fisher, N; Hastings, M; Kibbler, C; Mutimer, D; O'Grady, J; Patch, D; Philpott-Howard, J; Rolando, N; Wade, J; Wendon, J | 1 |
| Arjona, R; Pena, MA; Peralta, FG; Roíz, MP; Sánchez, MB; Tejero, MA | 1 |
| Daschner, FD; Frank, U; Mutter, J; Schmidt-Eisenlohr, E | 1 |
| Bardenstein, R; Flidel-Rimon, O; Friedman, S; Gradstein, S; Shinwell, ES | 1 |
| Florea, NR; Geissler, EC; Kotapati, S; Kuti, JL; Nicolau, DP; Nightingale, CH | 1 |
| Ceran, N; Erdem, I; Kucukercan, M | 1 |
| Bonet, A; García-Oria, M; Rodríguez, I; Rodríguez, JI; Roig, J; Sirvent, JM | 1 |
| Arango, C; Bantar, C; Coassolo, MA; Duret, F; Fiorillo, A; Franco, D; Gomez, H; Heft, C; Krayeski, M; Oliva, ME; Salamone, F; Vesco, E | 1 |
| Bacigalupo, A; Bruzzi, P; Bucci, B; Cappellano, P; Machetti, M; Van Lint, MT; Viscoli, C | 1 |
| Adam, O; Aupérin, A; Bourhis, JH; Chachaty, E; Gachot, B; Wilquin, F | 1 |
| Ford, HR; Gaines, BA; Nadler, EP; Reblock, KK | 1 |
| Allaouchiche, B; Boselli, E; Breilh, D; Cannesson, M; Chassard, D; Rimmelé, T; Saux, MC; Xuereb, F | 1 |
| Meibohm, AR; Teppler, H; Woods, GL | 1 |
| Hoven, AD; LeClaire, AC; Martin, CA | 1 |
| Chmela, Z; Hejnar, P; Kolár, M | 1 |
| Gesser, RM; Graham, DR; Meibohm, AR; Roy, S; Solomkin, J; Teppler, H; Woods, GL | 1 |
| Friedland, IR; Gesser, RM; Herman, G; Isaacs, R; Meibohm, A; Mistry, G; Teppler, H; Woods, GL | 1 |
| Brown, A; Corrado, O; Donaldson, K; Fawley, W; Freeman, J; MacKinlay, S; Wilcox, MH | 1 |
| Gesser, RM; McCarroll, KA; Woods, GL | 1 |
| Arto, MA; Campos, B; Gracia, O; Gutiérrez, JA; Sanjuán, A | 1 |
| Shingadia, D; Walls, T | 1 |
| Maertens, J; Theunissen, K; Van Eldere, J; Verhoef, G | 1 |
| Bernaldez, R; Collado, D; Rodrigo, JP; Sŭrez, C | 1 |
| Bacher, J; Kelaher, A; Murray, H; Mya-San, C; Petraitiene, R; Petraitis, V; Schaufele, R; Sein, T; Shoham, S; Walsh, TJ | 1 |
| Penack, O; Schwartz, S; Thiel, E; Wolfgang Blau, I | 1 |
| Cipriani, P; Nicoletti, M; Petrucca, A; Pustorino, R; Santapaola, D; Sessa, R; Teggi, A | 1 |
| Helfand, MS; Hutton-Thomas, R; Lakticová, V; Rice, LB | 1 |
| Crisostomo, AC; Erasmo, AA; Hong, YS; Lee, KU; Lo, CM; Yan, LN | 1 |
| Bangsberg, DR; Chambers, HF; Charlebois, ED; Pang, S; Perdreau-Remington, F; Winston, LG | 1 |
| Ibero, C; Masedo, A; Sáchez-Pobre, P; Sáenz-López, S; Salto, E; Sanjuán, R; Solís Herruzo, JA | 1 |
| Giltri, G; Isella, M; Larocca, A; Marinoni, S; Miccolis, I; Parma, M; Pogliani, EM; Rossini, F; Terruzzi, E; Verga, L | 1 |
| Ackermann, T; Bertram, N; Buck, C; Derendorf, H; Paar, WD; Sauerbruch, T | 1 |
| Baysallar, M; Doğanci, L; Kiliç, A; Küçükkaraaslan, A; Senses, Z | 1 |
| Olweny, J; Stucki, ZN; Torbert, DP; WaKabongo, M | 1 |
| Evangelista, AT; Jones, ME; Karlowsky, JA; Sahm, DF; Thornsberry, C; Yee, YC | 1 |
| Ford, HR; Gaines, BA; Meza, MP; Nadler, EP; Reblock, KK; Vaughan, KG | 1 |
| Geissler, EC; Kotapati, S; Kuti, JL; Nicolau, DP; Nightingale, CH | 1 |
| Bottoni, U; Calvieri, S; Cantisani, C; Grieco, T; Innocenzi, D | 1 |
| Dias, MA; Konefal, SH; McLaughlin, MR; Wadie, GM | 1 |
| Athanasiou, A; Chalkiopoulou, I; Christakis, GB; Legakis, NJ; Perlorentzou, SP | 1 |
| Burgess, DS; Frei, CR | 1 |
| Boghossian, J; Caputo, W; Dana, A; Gray, S; Harkless, L; Pollak, R; Wu, D | 1 |
| Dzierzanowska, D; Dzierzanowska-Fangrat, K; Kurlenda, J; Małafiej, E; Puacz, E; Semczuk, K; Stalmaska-Dworak, E; Łopaciuk, U | 1 |
| Jones, RN; Rhomberg, PR | 1 |
| Fei, Y; Hongwen, Z; Minggang, D; Peiyuan, X; Rujia, Y; Sufang, C; Weiming, Z; Wenxiang, H; Xianghui, J; Xiaoju, L; Xingping, Z; Xueqin, F; Yanbin, L; Yao, Y; Yongchuan, C; Zebo, Y; Zhiyong, Z; Zongzan, N | 1 |
| Farga, A; Faus, F; Gimeno, C; Gómez, C; Goterris, R; Gutierrez, A; Martinez, F; Muñoz, I; Navarro, D; Solano, C | 1 |
| Bordigoni, P; Chastagner, P; Fouyssac, F; Mansuy, L; Salmon, A; Schmitt, C | 1 |
| Chan, CY; Dinubile, MJ; Friedland, I; Giezek, H; Motyl, MR; Quinn, JP; Shivaprakash, M; Weinstein, RA | 1 |
| Burgess, DS; Frei, CR; Reese, AM | 1 |
| Abramson, MA; Chow, JW; DiNubile, MJ; Motyl, MR; Polis, A; Satishchandran, V; Teppler, H | 1 |
| Furfaro, E; Machetti, M; Viscoli, C | 1 |
| Almassi, GH; Brown, KR; Edmiston, CE; Kehl, KS; Krepel, CJ; Lewis, BD; Loehrl, TA; Seabrook, GR; Smith, TL; Somberg, LB; Towne, JB | 1 |
| Kotapati, S; Kuti, JL; Nicolau, DP | 1 |
| Kuti, JL; Nicolau, DP; Sun, HK | 1 |
| Giordano, P; Herrington, J; Kowalsky, S; Pertel, P; Song, J | 1 |
| Fukasawa, C; Hishiki, H; Hoshino, T; Inami, Y; Ishiwada, N; Kohno, Y; Kurosaki, T; Sudo, F; Takeda, N | 1 |
| Carmeli, Y; Flores, EL; Lin, MY; Sreeramoju, P; Tolentino, J; Weber, SG; Zumsteg, J | 1 |
| Abramson, MA; Armstrong, DG; Citron, DM; Lipsky, BA; Morgenstern, DE; Tice, AD | 1 |
| Bettaccini, AA; Brigante, G; Endimiani, A; Grossi, P; Luzzaro, F; Toniolo, AQ | 1 |
| Flidel-Rimon, O; Friedman, S; Leibovitz, E; Shinwell, ES | 1 |
| Borzsei, L; Horváth, A; Kocsis, B; Koós, Z; Mintál, T; Nyárády, J | 1 |
| Bassoul, B; Causse, L; Dareau, S; Delire, V; Eledjam, JJ; Gros, T; Javitary, W | 1 |
| Kuti, JL; Nicolau, DP; Ong, CT | 1 |
| Lewis, AM | 1 |
| Das, BK; Dhawan, B; Kapil, A; Mohanty, S; Singhal, R; Sood, S | 1 |
| Gibbs, L; Guglielmo, BJ; Jacobs, RA; McCulloch, CE; Mendez, MN; Winston, L | 1 |
| Börzsei, L; Helyes, Z; Kereskai, L; Kocsis, B; Koós, Z; Mintál, T; Nyárády, J | 1 |
| Crinnion, JN; Pencavel, TD; Singh-Ranger, G | 1 |
| Al-Ebous, AD; Al-Jahmi, M; Al-Zuriqat, AN; Hiasat, B; Sarayrah, M | 1 |
| Hughes, C; Kitchen, J; Lambourne, J; Merry, C | 1 |
| Asperger, W; Chan, CY; Dela Pena, AS; DiNubile, MJ; Giezek, H; Kafka, R; Köckerling, F; Raz, R; Shivaprakash, M; Vrijens, F; Warren, B | 1 |
| Mannaerts, L; Van der Wurff, AA; Wolfhagen, FH | 1 |
| Greenberg, A; Muallem-Zilcha, E; Raveh, D; Schlesinger, Y; Wiener-Well, Y; Yinnon, AM | 1 |
| Elsayed, S; Zhang, K | 1 |
| Ariano, R; Bow, E; Wlodarczyk, K; Zarychanski, R | 1 |
| Adam, HJ; Laing, N; Mayer, M; Zhanel, GG | 1 |
| Aslanzadeh, J; Brecher, S; Brossette, SE; Gavin, PJ; Gaydos, JM; Halstead, DC; Peterson, LR; Pierson, CL; Rotstein, C; Suseno, MT; Thomson, RB | 1 |
| Alvarez, G; Bombuy, E; Charco, R; Ferrer, J; Fondevila, C; Fuster, J; García-Valdecasas, JC | 1 |
| Bow, EJ; Laverdiere, M; Noskin, GA; Rotstein, C; Sanche, S; Schwarer, AP; Segal, BH; Seymour, JF; Szer, J | 1 |
| Fahim, S; Jain, V; Pierscianowski, T; Victor, G | 1 |
| Alexaki, P; Christakis, GB; Megalakaki, A; Perlorentzou, S; Zarkadis, IK | 1 |
| Choudhri, S; Herrington, J; Malangoni, MA; Pertel, P; Song, J | 1 |
| Chun, BC; Jeong, HW; Kim, MJ; Park, DW; Sohn, JW; Yang, JA | 1 |
| Gurkan, E; Hutton-Thomas, R; Lakticová, V; Meyer, M; Rice, LB | 1 |
| Bardenstein, R; Carmeli, Y; Chmelnitsky, I; Goland, S; Hammer Muntz, O; Navon Venezia, S; Zimhony, O | 1 |
| Cafiero, F; Furfaro, E; Machetti, M; Majabo, MJ; Novelli, A; Solari, N; Viscoli, C | 1 |
| Agarwal, N; Agarwal, S; Arya, SC | 1 |
| Burgess, DS; Frei, CR; Hampton, SL | 1 |
| Borbone, S; Cascone, C; Mezzatesta, ML; Santagati, M; Stefani, S | 1 |
| Ammann, RA; Bode, U; Engelhart, S; Fleischhack, G; Gröger, N; Hasan, C; Kramer, MH; Simon, A; Wilkesmann, A; Wiszniewsky, G | 1 |
| Antoine, TL; Blumberg, HM; Cardo, D; Curtis, AB; Desilva, K; Fransua, M; Gaynes, RP; Gould, CV; Jernigan, JA; King, M; Kraman, AA; Pack, J; Ribner, B; Seybold, U; Sinkowitz-Cochran, RL; Steinberg, JP; Wells, JB | 1 |
| de Cueto, M; Hernández, JR; Muniain, MA; Navarro, MD; Pascual, A; Ríos, MJ; Rodríguez-Baño, J; Romero, L | 1 |
| Bellitti, F; Cuniato, V; Esposito, S; Ianniello, F; Leone, S; Marvaso, A; Noviello, S | 1 |
| Concia, E; Marchetti, F | 1 |
| Fritsche, TR; Hsiung, A; Jones, RN; Sader, HS | 1 |
| Drusano, GL; Lodise, TP; Lomaestro, B | 1 |
| Harris, J | 1 |
| Broide, E; Raveh, D; Rudensky, B; Yinnon, AM | 1 |
| Abramson, MA; Jensen, EH; Namias, N; Solomkin, JS; Tomassini, JE | 1 |
| Abramson, MA; Armstrong, DG; Lipsky, BA; Polis, AB; Sheehan, P; Tice, AD | 1 |
| Araujo, VR; Carvalho-Dias, VM; Cunha, CA; de Souza, CA; de Souza, M; Godoy, C; Lotfi, CJ; Maiolino, A; Nucci, M; Oliveira, AL; Pasquini, R; Ruiz, MA; Seber, A; Silla, L; Simões, BP; Tanaka, PY; Trabasso, P; Urakawa, P; Zanichelli, MA | 1 |
| Hawkey, PM; Hsueh, PR | 1 |
| Abramson, MA; Hoey, CT; Lipsky, BA; Tice, AD; Turpin, RS; Wu, J | 1 |
| Cheng, CJ; Chou, CH; Lin, CS; Lin, SH | 1 |
| Apolônio, ACM; Coutinho, SC; Diniz, CG; Farias, LM; Geralda de Sousa-Gaia, L; Nicoli, JR; Roque de Carvalho, MA; Valéria Dos Santos, K | 1 |
| Agarwal, N; Agarwal, S; Arya, SC; Solanki, BS | 1 |
| Dilay, L; Gin, A; Karlowsky, JA; Rubinstein, E; Walkty, A; Zhanel, GG | 1 |
| Donskey, CJ; Pultz, MJ | 1 |
| Amital, H; Bernheim, J; Dovrish, Z; Edelstein, E; Hadari, R; Ish-Hurwitz, S | 1 |
| Alhambra, A; Cuétara, MS; del Palacio, A; Moreno, JM; Ortiz, MC; Pontón, J | 1 |
| Park, MA; Rank, MA | 1 |
| Afonso, MR; Albertoni, Ade C; Arkader, R; Cabral, EA; da Silva, DC; de Araujo, OR; Diegues, AR; Louzada, ME | 1 |
| Alexander, JJ; Gobburu, JV; Imoisili, MA; Korth-Bradley, JM; Tornøe, CW; Tworzyanski, JJ | 1 |
| Bode, U; Fleischhack, G; Groll, AH; Laws, HJ; Lehrnbecher, T; Molitor, E; Simon, A; Tramsen, L; Wieland, R | 1 |
| Akova, M; Altun, B; Gürkan Aydin, N; Hasçelik, G; Metan, G; Zarakolu, P | 1 |
| Aydin, K; Caylan, R; Koksal, I; Ozgumus, OB; Sandalli, C; Tosun, I | 1 |
| Kim, A; Kuti, JL; Nicolau, DP; Sutherland, CA | 1 |
| Ernst, ME; Philbrick, AM | 1 |
| Apolônio, ACM; Carvalho, MAR; Coutinho, SC; Diniz, CG; Farias, LM; Martins, WA; Nicoli, JR; Santos, KVD | 1 |
| Howell, JM; Mohammadi, A | 1 |
| Hoda, MQ; Hussein, K; Manasia, R; Salahuddin, N; Samad, A; Siddiqui, S; Zafar, A | 1 |
| Cirioni, O; Ghiselli, R; Giacometti, A; Giovanni, M; Kamysz, E; Kamysz, W; Minardi, D; Orlando, F; Parri, G; Saba, V; Scalise, G; Silvestri, C | 1 |
| Aron, DC; Bonomo, RA; Capitano, B; Donskey, CJ; Linden, PK; Muto, CA; Ndirangu, M; Paterson, DL; Potoski, BA | 1 |
| Bai, YL; Chen, BY; Chu, YZ; Li, JB; Li, LY; Wan, JH; Wang, Q; Wang, X; Zhang, JP; Zhao, ZM | 1 |
| Peterson, LR | 1 |
| Ayling, RM; Brown, A; Jeffery, J; Neale, S | 1 |
| Ergon, MC; Yücesoy, M | 1 |
| Hamidah, A; Jamal, R; Nordiah, AJ; Rizal, AM | 1 |
| Fritsche, TR; Jones, RN; Moet, GJ | 1 |
| Caeiro, JP; Gamez, EA; Garey, KW; Gentry, LO; Gerard, LN; Larocco, MT; Tam, VH; Weston, JS | 1 |
| Johnson, ST | 1 |
| Chow, P; Godambe, S; Maulidi, H | 1 |
| Dowzicky, M; Kuti, JL; Nicolau, DP | 1 |
| Almela, M; Iñurrieta, A; Marco, F; Marcos, M; Martínez, JA; Mensa, J; Soriano, A | 1 |
| Debbia, EA; Gualco, L; Maioli, E; Marchese, A | 1 |
| Aronowitz, P; London, V | 1 |
| Aytac, S; Cengiz, AB; Cetin, M; Ceyhan, M; Secmeer, G; Tuncer, M; Yetgin, S; Yildirim, I | 1 |
| Lodise, TP; McNutt, LA; Patel, N | 1 |
| Klaustermeyer, W; Lam, A; Randhawa, I | 1 |
| Adelman, MH; Cohn, SM; Gilliland-Johnson, KK; Paladino, JA | 1 |
| Arndt, PA; Garratty, G; Leger, RM | 1 |
| Iguchi, A; Kaneda, M; Kobayashi, K; Kobayashi, R; Sato, T; Yasuda, K | 1 |
| Bartolozzi, B; Bosi, A; Fanci, R; Longo, G | 1 |
| Al-Nawas, B; Kinzig-Schippers, M; Shah, PM; Soergel, F | 1 |
| Artini, M; Di Clemente, D; Palma, S; Papa, R; Scoarughi, GL; Selan, L; Veeh, R | 1 |
| Castelletti, S; Chiodi, L; Cirioni, O; Gabrielli, E; Ghiselli, R; Giacometti, A; Mocchegiani, F; Orlando, F; Riva, A; Saba, V; Scalise, G; Silvestri, C | 1 |
| Aldeyab, MA; Bailie, R; Elshibly, SM; Hanley, J; Hughes, CM; Kearney, MP; McDowell, DA; McElnay, JC; McMahon, MA; Scott, MG | 1 |
| Bassi, C; Benini, A; Bertazzoni Minelli, E; Franco, L; Pederzoli, P | 1 |
| Esposito, S; Felaco, FM; Fiore, M; Ianniello, F; Leone, S; Noviello, S; Romagnoli, F; Sarli, E | 1 |
| Cetinkaya, RA; Coşkun, O; Eyigün, CP; Görenek, L; Ide, T; Kiliç, S; Senses, Z | 1 |
| Lantheaume, S; Louerat, C; Riou, R; Rissoan, C | 1 |
| MacDougall, C; Oinonen, M; Pakyz, AL; Polk, RE | 1 |
| Cho, YB; Choi, CH; Jang, CH; Park, H; Park, IY | 1 |
| Patel, DN; Patel, NN | 1 |
| Akinci, E; Balaban, N; Baran, G; Bodur, H; Cevik, MA; Erbay, A; Onguru, P | 1 |
| Iribarren, JL; Jiménez, A; Jiménez, JJ; Lorente, L; Martín, MM; Mora, ML | 1 |
| Simon, A; Wolf, MF | 1 |
| Garcia Gala, JM; Morante Pombo, C; Rodriguez Vicente, P; Vazquez Aller, S | 1 |
| Chang, KT; Ledesma, KR; Quinn, JP; Tam, VH; Wang, TY | 1 |
| Blondel-Hill, E; Dobson, S; Paulus, S; Rassekh, S | 1 |
| Iguchi, A; Kaneda, M; Kobayashi, R; Nakajima, M; Sato, T | 1 |
| Barriere, SL; Goldberg, MR; Kinzig, M; Kitt, MM; Sörgel, F; Wong, SL | 1 |
| Nakwa, F; Velaphi, S; Wadula, J | 1 |
| Hazar, V; Karasu, GT; Ogunc, D; Uygun, V; Yesilipek, A | 1 |
| Hashimoto, Y; Uji, T | 1 |
| Antoine, TL; Blumberg, HM; Desilva, K; Edwards, J; Gaynes, RP; Gould, CV; Jernigan, JA; King, M; Kraman, A; Pack, J; Ribner, B; Seybold, U; Steinberg, J | 1 |
| Aldeyab, MA; Hanley, J; Kearney, MP; McElnay, JC; Scott, MG | 1 |
| Docobo, F; Hernández, JR; López-Cerero, L; Morillo, C; Pachón, J; Pascual, A; Picón, E; Rodríguez-Baño, J | 1 |
| Restrepo, MI | 1 |
| Gensheimer, WG; Greves, C; Mulconry, M; Reddy, SY | 1 |
| Cheatham, SC; Kays, MB; Shea, KM; Smith, DW; Sowinski, KM; Wack, MF | 1 |
| Chong, Y; Kim, CK; Kim, JM; Kim, MS; Kim, S; Lee, K; Roh, KH; Yong, D; Yum, JH | 1 |
| Erdem, E; Gulec, SG; Kebudi, R; Vural, S; Yildirmak, Y | 1 |
| Ichiishi, S; Mikamo, H; Nakao, K; Shibata, T; Tanaka, K; Watanabe, K | 1 |
| Henao-Martinez, A; Jorgensen, J; Owens, A; Woodbury, A | 1 |
| Cortés, C; Giménez, L; Pueyo, A; Ramos, A | 1 |
| Jones, RN; Moet, GJ; Sader, HS; Watters, AA | 1 |
| Jones, RN; Rhomberg, PR; Sader, HS; Stilwell, MG | 1 |
| Bayram, H; Dalay, C; Dalkiran, A; Saltoglu, N; Sert, M; Tasova, Y; Tetiker, T | 1 |
| Bahram, F; Emaneini, M; Fatolahzadeh, B; Feizabadi, MM; Mehdi, FM; Mohammad, E; Morovat, T; Setareh, S; Soroush, S; Taherikalani, M | 1 |
| Drusano, GL; Lodise, TP; Patel, N; Scheetz, MH | 1 |
| Carmeli, Y; Jansen, JP; Kumar, R | 1 |
| Klemencic, S; Patrick, R; Phelan, M; Vahdat, N | 1 |
| Chun, ED; Collins, CD; Malani, PN; Rodgers, PE; Vitale, CA | 1 |
| Doherty, JA; Khan, J; Kollef, MH; Micek, ST; Pervez, M; Reichley, RM; Welch, EC | 1 |
| Bastús, R; Cirera, L; Estany, C; Estrada, C; Garau, J; Gómez, I; Gómez, L; Márquez, M; Martí, JM; Quintana, S | 1 |
| Flamm, R; Friedland, I; Kaniga, K; Lee, M; Redman, R; Tong, SY | 1 |
| Ağkuş, C; Buldu, H; Koç, AN; Metan, G | 1 |
| Cavallo, JD; Chomarat, M; Dubreuil, L; Joly-Guillou, ML; Kempf, M; Maugein, J; Muller-Serieys, C; Roussel-Delvallez, M | 1 |
| Caquelin, C; Glowacki, RC; Grasso, AE; Itokazu, GS; Schwartz, DN; Xamplas, RC | 1 |
| Best, L; Boonlayangoor, S; Hebert, C; Lin, M; Pitrak, D; Tolentino, J; Villaran, R; Weber, SG | 1 |
| Chew, FL; Samsudin, A; Shin, HC; Soong, TK; Visvaraja, S | 1 |
| Akduman, D; Ankarali, H; Aydemir, H; Celebi, G; Engin, H; Gokmen, A; Keskin, AS; Oztoprak, N; Piskin, N | 1 |
| Aquino, VR; Pasqualotto, AC; Severo, LC; Sukiennik, TC; Xavier, MO | 1 |
| Abe, Y; Akashi, K; Harada, N; Iwasaki, H; Kamezaki, K; Miyamoto, T; Mori, Y; Nagasaki, Y; Shimono, N; Takenaka, K; Teshima, T | 1 |
| Hayashi, Y; Lipman, J; Paterson, DL; Roberts, JA | 1 |
| Baloch, K; Hussain, S; Syed, S | 1 |
| Fernández-Torre, JL; Pelayo, AL; Santos-Sánchez, C | 1 |
| Chien, CC; Lee, CH; Li, CC; Liu, JW; Su, LH; Tang, YF | 1 |
| Kang, K; Liu, V; Val, S; Velcek, F | 1 |
| Bellón, T; Bobolea, ID; Cabañas, R; Fiandor-Román, AM; Jurado-Palomo, J; López-Serrano, MC; Prior, N; Quirce, S | 1 |
| Bivas, A; Fraser, A; Leibovici, L; Paul, M; Yahav, D | 1 |
| Ambatipudi, S; Mathai, A; Pathengay, A; Shah, GY | 1 |
| Bauer, SR; Butler, R; Connor, MJ; Fissell, WH; Groszek, J; Hofmann, CL; Rehm, SJ; Salem, C | 1 |
| Di Maggio, T; Fondelli, S; Geminiani, G; Leonildi, A; Mantengoli, E; Menichetti, F; Rossolini, GM; Tagiaferri, E; Tascini, C | 1 |
| Alvarez Tundidor, S; González Rozas, M; Pineda Alonso, M | 1 |
| Appelbaum, PC; Armstrong, ES; Kosowska-Shick, K; Kubo, A; Lin, G; Pankuch, GA | 1 |
| Bansal, D; Gautam, V; Marwaha, N; Marwaha, RK; Oberoi, S; Sharma, RR | 1 |
| Carillo, C; Cassani, C; Cipolloni, AP; Gagliotti, C; Gargiulo, R; Incerti, SS; Moro, ML; Pedna, F; Rossi, MR; Rossolini, GM; Sabia, C; Sarti, M; Testa, G; Venturelli, C | 1 |
| Frei, R; Tschudin-Sutter, S; Widmer, AF | 1 |
| Adam, HJ; DeCorby, M; Hoban, DJ; Karlowsky, JA; Rennie, R; Zhanel, GG | 1 |
| Cabot, G; Juan, C; Mark, BL; Moyá, B; Oliver, A; Reeve, TM; Vocadlo, DJ; Zamorano, L | 1 |
| Barshikar, S; Baylor, AE; Dolman, HS; Glowniak, J; Hong, K; Lavery, T; Nailor, M; Singla, R; Stassinopoulus, J; Tyburski, JG; Wilson, RF; Zimmerman, LH | 1 |
| Cho, YB; Choi, CH; Jang, CH; Jang, SJ; Kim, GH; Kim, JS; Park, H; Yang, HC | 1 |
| Bonnet, R; Delmas, J; Gibold, L; Krebs, M; Mirande, C; Robin, F | 1 |
| Ariga, T; Cho, Y; Ichikawa, M; Iguchi, A; Kaneda, M; Ohshima, J; Suzuki, D | 1 |
| Bosso, JA; Church, EC; Mauldin, PD | 1 |
| Escudero, E; Fernández, A; Gacías, L; Linares, T; Soto, MT | 1 |
| Hawser, SP | 1 |
| Altunsoy, A; Aypak, C; Azap, A; Balık, I; Ergönül, Ö | 1 |
| Cotton, F; De Backer, D; Jacobs, F; Macours, P; Seyler, L; Taccone, FS; Vincent, JL | 1 |
| Emecen, M; Erdem, E; Karaman, S; Kebudi, R; Vural, S; Yildirmak, Y | 1 |
| Clark, NM; Garofalo, J; Grim, SA; Heinrich, LS; Paek, JL; Tokumaru, S | 1 |
| Haber, RM; Peermohamed, S | 1 |
| Chalermsri, C; Sae-Jong, R; Suddhichupaiboon, S; Thamlikitkul, V; Tiengrim, S | 1 |
| Mikamo, H; Miura, Y; Ohki, E; Terada, M; Umemura, T; Yamagishi, Y | 1 |
| Donnell, RW; Hickey, WS; Kaufman, SE | 1 |
| Calogiuri, GF; Di Leo, E; Ferrannini, A; Kounis, NG; Nettis, E; Vacca, A | 1 |
| Alder, J; Arvis, P; Dryden, M; Gyssens, IC; Hampel, B; Kujath, P; Nathwani, D; Reimnitz, P; Schaper, N | 1 |
| Anjum, R; Fahim, Q; Gill, MM; Hassan, A; Kaleem, F; Khalid, A; Usman, J | 1 |
| Landau, Z; Miller, EB; Shichmanter, R; Shtalrid, M | 1 |
| Cappelletty, DM; Yost, RJ | 1 |
| Baykan, M; Demircili, ME; Feyzioğlu, B; Özdemir, M; Pekcan, S; Pirinç, Ş; Taşbent, FE | 1 |
| Amer, MZ; Bandey, M; Bukhari, A; Nemenqani, D | 1 |
| Arakawa, S; Fujisawa, M; Matsumoto, T; Miura, T; Nakano, Y; Shigemura, K; Takahashi, S; Tanaka, K; Tsukamoto, T | 1 |
| Cho, B; Im, SA; Park, GS; Yun, DY | 1 |
| Bonomo, RA; Perez, F | 1 |
| Navarro, MD; Pascual, Á; Picón, E; Retamar, P; Rodríguez-Baño, J | 1 |
| Bulik, CC; Keel, RA; Nicolau, DP; Sutherland, CA; Tessier, PR | 1 |
| Gomi, H; Miura, Y; Morisawa, Y; Sugano, K; Yokota, K | 1 |
| Botha, JF; Fey, P; Florescu, DF; Grant, W; Kalil, AC | 1 |
| Hanson, ND; Kurpiel, PM | 1 |
| Kronenberg, A; Mühlemann, K; Pannatier, A; Plüss-Suard, C; Ruffieux, C; Zanetti, G | 1 |
| Deman, H; Spriet, I; Verhaegen, J; Willems, L | 1 |
| Billon, C; Castaigne, S; Eloy, O; Gerlinger, MP; Rigaudeau, S; Rousselot, P; Touratier, S | 1 |
| Duszynska, W; Hurkacz, M; Kowalska-Krochmal, B; Kübler, A; Switala, M; Taccone, FS | 1 |
| Jawitz, RS; Krach, K; Schapiro, B | 1 |
| Homann, C; Knudsen, JD; Moser, C; Novovic, S; Olsen, H; Semb, S | 1 |
| Hille, DA; Namias, N; Zakrison, TL | 1 |
| Alkhani, AM; Alshaya, WA | 1 |
| Arakawa, S; Fujisawa, M; Matsumoto, M; Miyata, M; Nakano, Y; Shigemura, K; Shirakawa, T; Tanaka, K; Yamashita, M | 1 |
| Lai, L; Lien, YH; Mustafa, E | 1 |
| Chow, I; Ensom, MH; Mabasa, VH; Mah, GT | 1 |
| Bauer, SR; Connor, MJ; Fissell, WH; Groszek, J; Salem, C; Taylor, ME; Tolwani, AJ; Wei, P | 1 |
| Couet, W; Grégoire, N; Marliat, M; Mimoz, O; Nordmann, P; Poirel, L | 1 |
| Bak, N; Holds, JM; Papanicolas, LE | 1 |
| Berthelot, P; Carricajo, A; Lucht, F; Suy, F | 1 |
| Holodniy, M; Lucero, CA; Mercier, RC; Nguyen, N; Oda, G; Ryono, RA; Schirmer, PL | 1 |
| Anderson, DJ; Chen, LF; Davis, ME; Drew, RH; Sharpe, M | 1 |
| Alba, LR; Jia, H; Kubin, CJ; Yoko Furuya, E | 1 |
| Anderson, DJ; Bennett, KM; Dotson, TL; Sarraf-Yazdi, S; Sharpe, M; Vaslef, SN | 1 |
| Cho, H; Ito, K; Kimura, Y; Nakajima, H; Sakai, K; Tetsuka, T; Tsukada, H | 1 |
| Agarwal, A; Bansal, M; Conner, K | 1 |
| Bacigalupo, A; Del Bono, V; Furfaro, E; Mikulska, M; Raiola, AM; Ratto, S; Viscoli, C | 1 |
| Dwivedi, A; Gupta, SK; Pratyush, DD; Rai, M; Singh, SK; Tiwari, S | 1 |
| Hsueh, PR; Lee, YJ; Lin, YC; Liu, HY; Wu, HH | 1 |
| Butterfield, JM; Drusano, GL; Felton, TW; Hope, WW; Kwa, AL; Lodise, TP; Lomaestro, BM | 1 |
| Afridi, FI; Farooqi, BJ | 1 |
| Cox, EG; Kays, MB; Knoderer, CA; Nichols, KR | 1 |
| Lam, JP; Liu, TJ | 1 |
| Farbman, L; Gafter-Gvili, A; Leibovici, L; Paul, M; Peck, A; Raanani, P; Ram, R; Shpilberg, O; Vidal, L; Yeshurun, M | 1 |
| Ay, H; Hatipoglu, M; Mutluoglu, M; Onem, Y; Turhan, V; Uzun, G | 1 |
| Chen, YH; Chen, YS; Chuang, YC; Ho, CM; Hsueh, PR; Huang, CC; Ko, WC; Lee, YL; Liu, CE; Liu, YC; Liu, YM; Lu, PL; Ni, Y; Tang, HJ; Toh, HS; Wang, JH; Xu, Y; Yu, KW | 2 |
| DeDonato, DM; McCool, RA | 1 |
| Bhargava, A; Bheemreddy, S; Chopra, T; Dhar, S; Gudur, UM; Hayakawa, K; Kaye, KS; Lephart, PR; Marchaim, D; Mynatt, RP; Sunkara, B; Zhao, JJ | 1 |
| Faoagali, J; Gallagher, JE; George, N; Gidding, HF; Ginn, AN; Iredell, JR; Lipman, J; O'Driscoll, JS; O'Toole, BI; Partridge, SR; Perri, RA; Wiklendt, AM | 1 |
| Baird, AD; Floyd, MS; Macwilliam, JL; Mistry, R | 1 |
| Rai, M; Rustagi, T; Uy, EM | 1 |
| Baskette, J; Elsayed, S; Hu, AY; Leslie, KA | 1 |
| Fett, N; Kovarik, CL; Wanat, KA | 1 |
| Bolon, MK; Esterly, JS; Patel, J; Postelnick, MJ; Scheetz, MH | 1 |
| Ampofo, K; Sherwin, CM; Spigarelli, MG; Stockmann, C; Waters, CD; Young, DC; Zobell, JT | 1 |
| Danbara, M; Higashihara, M; Horie, R; Ishii, R; Kamata, H; Kimura, H; Miyazaki, K; Okina, S; Osaka, M | 1 |
| Aziz, MN; Desa, MN; Idris, SN; Taib, NM | 1 |
| Ay, H; Önem, Y; Salihoğlu, M; Turhan, V; Ulcay, A; Uzun, G | 1 |
| Bond, CM; Bullard, MJ; Djogovic, D; Meurer, DP; Rowe, BH; Villa-Roel, C | 1 |
| Beumier, M; Cotton, F; De Backer, D; Hites, M; Jacobs, F; Lorent, S; Roisin, S; Seyler, L; Surin, R; Taccone, FS; Vincent, JL; Wolff, F | 1 |
| Bento, L; Estilita, J; Gonçalves-Pereira, J; Gouveia, J; Janeiro, S; Monteiro, C; Oliveira, BS; Paulino, C; Póvoa, P; Salgueiro, A; Vieira, A | 1 |
| Lee, GC; Liou, H; Neldner, K; Quan, CF; Yee, R | 1 |
| Cheatham, SC; Chung, CE; Fleming, MR; Healy, DP; Humphrey, ML; Kays, MB; Shea, KM | 1 |
| Boattini, M; Costa, N; Matos, R; Murinello, N | 1 |
| Blake, P; Brichacek, M; Kao, R | 1 |
| Argento, AC; Heavner, MS; Ruggero, MA; Topal, JE | 1 |
| Marik, PE; Parekh, P | 1 |
| Chu, X; Dong, HL; Mao, JF; Shen, LM; Zhang, CL | 1 |
| Bonten, MJ; Bootsma, MC; Campbell, J; Chau, NV; Farrar, J; Hoa, NT; Hoang, NV; Loan, HT; Nga, TT; Schultsz, C; Thao, le TP; Thuy, TT; Vien, le M; Wit, F; Yen, LM | 1 |
| Francis, L; Jackson, K; Kennedy, GA; May, C; O'Rourke, K | 1 |
| Bloom, BT; Chong, E; Delmore, P; Forur, L; Gordon, P; Reynolds, J; Shaw, J; Uner, H | 1 |
| Kaufmann, M; Lauenstein, M; Persson, GR | 1 |
| Arnold, HM; Hampton, NB; Hoban, A; Hoffmann, J; Hollands, JM; Juang, PH; Kollef, MH; McCormick, S; Micek, ST; Reichley, RM; Skrupky, LP; Smith, JR | 1 |
| Behbehani, S; Tulandi, T | 1 |
| Imamura, Y; Izumikawa, K; Kakeya, H; Kohno, S; Kurihara, S; Miyazaki, T; Morinaga, Y; Nakamura, S; Tsukamoto, M; Yamamoto, Y; Yanagihara, K; Yasuoka, A | 1 |
| Cao, D; Cao, Y; Chen, C; Chen, Y; Li, Q; Li, Z; Shi, W; Wang, Y; Wu, D; Zhu, Y | 1 |
| Akashi, K; Chong, Y; Ito, Y; Kamimura, T; Miyamoto, T; Shimoda, S; Shimono, N; Yakushiji, H | 1 |
| Dholakia, S; Hashimi, Y | 1 |
| Creely, D; Dunne, WM; Gayral, JP; Peyret, M; Shortridge, D; Shubert, C; van Belkum, A; Zambardi, G | 1 |
| Dings, RP; Dunn, DL; Haseman, JR; Leslie, DB; Luong, M; Mayo, KH | 1 |
| Jankar, R; Kalal, C; Khare, S; Rajadhyaksha, A; Sonawale, A | 1 |
| Koyuncu, Ş; Ozan, F | 1 |
| Docobo-Pérez, F; Domínguez-Herrera, J; Egea, P; López-Cerero, L; López-Rojas, R; Pachón, J; Pascual, A; Rodríguez-Baño, J | 1 |
| Flamm, RK; Jones, RN; Sader, HS; Watters, AA | 1 |
| Di Daniele, N; Di Giovamberardino, G; Falcone, C; Ferrannini, M; Niscola, P; Noce, A; Palumbo, R; Pastore, A; Scaramucci, L; Tendas, A | 1 |
| Feizabadi, MM; Ghodousi, A; Haeili, M; Nomanpour, B; Omrani, M | 1 |
| López-Cerero, L; Muniain, MA; Pascual, Á; Retamar, P; Rodríguez-Baño, J | 1 |
| de Andrade, HM; de Carvalho, MA; de Farias, Lde M; dos Santos, KV; dos Santos, SG; Pires, Sda F; Vaz Trindade, MJ; Veloso, Lde C | 1 |
| Abouchahla, W; Courcol, R; Delebarre, M; Delvallée, M; Dessein, R; Kipnis, E; Mazingue, F; Wallet, F | 1 |
| Johnson, PD; Trevillyan, JM | 1 |
| Carlier, M; Carrette, S; De Waele, JJ; Decruyenaere, J; Depuydt, P; Hoste, E; Lipman, J; Roberts, JA; Stove, V; Verstraete, A; Wallis, SC | 1 |
| Fuchita, H; Hamaguchi, S; Honda, T; Hotta, T; Isobe, T; Iwamoto, S; Karino, F; Koba, N; Kuraki, T; Miura, K; Nishikawa, E; Ohe, M; Okimoto, T; Sutani, A; Tada, M; Takeyama, H; Tsubata, Y | 1 |
| Santosa, A; Shek, LP; Teo, BW | 1 |
| Giamarellos-Bourboulis, EJ; Karagianni, V; Liakou, P; Menenakos, E; Sabracos, L; Spyridaki, A; Tsaganos, T; Tsovolou, EC; Tzepi, IM; Zografos, G | 1 |
| Adamson, RT; Amara, S; Huang, X; Lew, I | 1 |
| Chen, F; Clerkin, B; Donahue, TR; Donald, GW; Eibl, G; Hines, OJ; Li, G; Lu, X; Reber, HA; Sunjaya, D; Tomlinson, JS | 1 |
| Kollef, MH | 1 |
| Bhowmick, T; Gross, A; Lam, WJ; Vanschooneveld, TC; Weinstein, MP | 1 |
| Hashiguchi, R; Komatsu, M; Matsuyama, S; Moronaga, Y; Nagahara, C; Oshiro, Y; Sameshima, I; Takeyama, H; Tottori, N; Yaita, K; Yamaguchi, Y | 1 |
| Leung, E; Ly, SC; Scheetz, MH; Venkatesan, N | 1 |
| Balm, M; Carter, J; Humble, M; Moniwa, A; Roohullah, A; Weinkove, R; Wood, C | 1 |
| Huilaja, L; Kallioinen, M; Riekki, R; Soronen, M; Tasanen, K | 1 |
| He, ZF; Wang, YP; Wu, XA | 1 |
| Kumar, A; Shahi, SK; Singh, VK | 1 |
| Allen, N; Fish, DN; Newell, M; Rafferty, KD; Sturm, AW; Toschlog, E; Waibel, B | 1 |
| Beegle, S; Butterfield, JM; Farkas, J; Lodise, TP; Pai, MP; Rosen, J | 1 |
| Browning, R; Darwiche, K; Freitag, L; Kioumis, I; Li, Q; Parrish, S; Petridis, D; Porpodis, K; Ritzoulis, C; Spyratos, D; Turner, JF; Zarogoulidis, K; Zarogoulidis, P | 1 |
| Bandettini, R; Buffa, P; Castagnola, E; Caviglia, I; Ciucci, A; Ginocchio, F; Guida, E; Haupt, R; Loy, A; Masa, DL; Mattioli, G; Perotti, M; Pini Prato, A | 1 |
| Cies, JJ; Kuti, JL; Schlichting, C; Shankar, V | 1 |
| Asín-Prieto, E; Isla, A; Maynar, J; Rodríguez-Gascón, A; Sánchez-Izquierdo, JÁ; Soraluce, A; Trocóniz, IF | 1 |
| Alexander, GJ; Butler, AJ; Dawwas, MF; Ganeshanantham, G; Gerada, J; Sivaprakasam, R; Winterbottom, AP | 1 |
| Antolín, F; Casella, G; Castillo, F; Fernández-Santiago, R; Gómez-Fleitas, M; Herrera, LA; Riaño, M; Rodríguez-Sanjuán, JC | 1 |
| Carrascosa, MF; Gómez-Román, J; Salcines-Caviedes, JR | 1 |
| Felton, TW; Goodwin, J; Gregson, L; Hope, WW; Howard, SJ; Livermore, J; Neely, MN; O'Connor, L; Sharp, A | 1 |
| Biswas, AK; Zanetti, RC | 1 |
| Dong, WL; Lü, Y; Wang, DH; Xia, R; Yan, Z; Yang, Y | 1 |
| Boral, OB; Cağatay, P; Keçeli, SA; Sonmez, N; Tamer, GS; Willke, A | 1 |
| Burke, MJ; Pratt, JA; Stricherz, MK; Verghese, PS | 1 |
| Berhin, C; Bogaerts, P; Glupczynski, Y; Huang, TD; Nordmann, P; Poirel, L | 1 |
| Hung, YP; Ko, WC; Lee, CI; Lee, JC; Lin, HJ; Liu, HC; Tsai, PJ; Wu, YH | 1 |
| Finnegan, PM; Hand, S; Linneman, TW; McDonald, JR; Moenster, RP; Thomas, Z | 1 |
| Fukasawa, C; Hoshino, T; Ishiwada, N; Kutsuna, S; Sato, H; Sawada, K | 1 |
| Chang, SW; Chen, PR; Kuo, HY; Liou, ML; Liu, CC; Pien, CJ; Yeh, HW | 1 |
| Bosnak, VK; Karaoglan, I; Mete, AO; Namiduru, M; Zer, Y | 1 |
| Dilworth, TJ; Dodd, M; Mercier, RC; Ryan, K; Sliwinski, J | 1 |
| Álvarez, JC; Cortés, JA; Cuervo, SI; Díaz, JA; Garzón, JR; Gómez, JC; Sánchez, R; Silva, E | 1 |
| Belghiti, J; Bert, F; Dondero, F; Durand, F; Larroque, B; Moreau, R; Nicolas-Chanoine, MH; Paugam-Burtz, C | 1 |
| Apisarnthanarak, A; Lye, DC; Ng, TM; Teng, CB | 1 |
| Boelens, J; Carlier, M; Carrette, S; Claeys, G; De Waele, JJ; Decruyenaere, J; Depuydt, P; Hoste, E; Leroux-Roels, I; Stove, V; Verstraete, AG | 1 |
| Arda, B; Nazli-Zeka, A; Ozkoren-Calik, S; Pullukcu, H; Sipahi, H; Sipahi, OR; Tasbakan, M; Ulusoy, S; Yamazhan, T | 1 |
| Hamada, Y; Hirayama, T; Kuroyama, M; Sunakawa, K; Takahashi, S | 1 |
| Fortier, LC; Garneau, JR; Valiquette, L | 1 |
| Martínez-Ramos, D; Pérez-Bru, S; Salvador-Sanchís, JL | 1 |
| Arisoy, ES; Corapcioglu, F; Demirsoy, U; Karadogan, M; Karakurt, DG; Oncel, S | 1 |
| Feng, X; He, L; He, Y; Li, C; Liu, H; Liu, X; Ruan, Y; Wu, X; Zhang, Y | 1 |
| Furusawa, H; Inase, N; Kamei, K; Miyazaki, Y; Sonoda, S; Tsuchiya, K; Yaguchi, T | 1 |
| Benjamin, DK; Bloom, BT; Capparelli, EV; Castro, L; Cohen-Wolkowiez, M; Gao, J; Poindexter, B; Smith, PB; Watt, KM; Zhou, C | 1 |
| Kalousis, K; Liodaki, E; Mailänder, P; Schopp, BE; Stang, F | 1 |
| Bruchmann, S; Cabot, G; Haussler, S; Juan, C; Moyà, B; Mulet, X; Oliver, A; Zamorano, L | 1 |
| Burnweit, C; Diana-Zerpa, J; Knight, C; Malvezzi, L; Nazarey, PP; Pasaron, R; Stylianos, S; Stylianos, V; Triana, J; Velis, E | 1 |
| Babores, M; Collum, J; Iyer, S | 1 |
| Doi, Y; Qureshi, ZA | 1 |
| Jain, N; Tewari, VV | 1 |
| Assi, M; Baddley, J; Baden, LR; Caliendo, AM; Chandrasekar, P; Estes, L; Freifeld, A; Hage, CA; Kleiman, M; Kohler, R; Nguyen, H; Norris, S; Razonable, RR; Shields, R; Vergidis, P; Walsh, TJ; Wheat, LJ; Wingard, JR | 1 |
| Ali, N; Baqir, M; Hamid, A; Khurshid, M | 1 |
| Singh, HL; Singh, RM | 1 |
| Ballanti, S; Bocchia, M; Bucaneve, G; Cantaffa, R; Cascavilla, N; Chierichini, A; Cudillo, L; Del Favero, A; Fabbiano, F; Fanci, R; Ferrari, A; Foà, R; Gentile, G; Luppi, M; Manna, A; Martinelli, G; Martino, B; Micozzi, A; Milone, G; Offidani, M; Picardi, M; Primon, V; Quarta, G; Salutari, P; Specchia, G; Zuffa, E | 1 |
| Han, S; Hong, T; Jeon, S; Lee, J; Paek, J; Woo, H; Yim, DS | 1 |
| Birch, A; Della Vecchia, BJ; Dupree, L; Gomes, DM; Jankowski, CA; Kraemer, DF; Smotherman, C | 1 |
| Khardori, N; Shahani, L | 1 |
| Attivi, D; Gibaud, S | 1 |
| Baek, MS; Bristow, J; Chen, F; Cheng, J; Fujimura, K; Lynch, SV; Panzer, AR; Peng, Z; Singh, G; Sorek, R; Srinivasan, R; Tringe, SG; Weng, L; Wiener-Kronish, JP | 1 |
| Boselli, E; Felton, TW; Hope, WW; Lodise, TP; Neely, MN; Roberts, JA; Van Guilder, M | 1 |
| Harada, Y; Hasegawa, H; Izumikawa, K; Kaku, N; Kohno, S; Morinaga, Y; Nakamura, S; Uno, N; Yanagihara, K | 1 |
| Al Omran, Y; Anwuzia-Iwegbu, C; Heaford, A | 1 |
| Burgess, LD; Drew, RH | 1 |
| Ahuja, T; Chen, D; Chen, XJ; Cutro, SR; Dubrovskaya, Y; Holzman, R; Mehta, SA; Papadopoulos, J; Phillips, MS; Scipione, MR | 1 |
| Chu, X; Guo, YY; Liu, QZ; Shen, LM; Wang, J; Zhang, CL | 1 |
| Acipayam, C; Bayram, I; Ozkan, A; Sezgin, G; Tanyeli, A | 1 |
| Wu, H; Xie, W; Ye, Z; Zhang, W; Zhao, C | 1 |
| Badawi, C; Elhalwagy, H; Kumar, S; O'Kane, M | 1 |
| Arakawa, S; Deguchi, T; Fujisawa, M; Hamasuna, R; Ishihara, S; Kobayashi, K; Matsubara, A; Matsumoto, M; Matsumoto, T; Nakane, K; Nakano, Y; Shigemura, K; Sho, T; Tanaka, K; Yamada, Y; Yamamoto, S; Yasuda, M | 1 |
| Bhat Y, R; Lewis, LE; Patra, S; Purakayastha, J; Sivaramaraju, VV | 1 |
| Dilworth, TJ; Leonard, SN; Mercier, RC; Vilay, AM | 1 |
| Garg, A; Goel, A; Nangia, S; Randhawa, VS; Saili, A; Sharma, S | 1 |
| Barretti, P; Bazan, R; Carmello, BL; Freitas, FM; Kojima, CA; Martin, LC; Neves, PD | 1 |
| Chen, PL; Hung, YP; Ko, WC; Lee, JC; Lin, HJ; Liu, HC; Tsai, PJ; Wu, CJ; Wu, YH; Yeh, FH | 1 |
| Chan, MC; Chang, FY; Lee, Y; Lin, JC; Lin, TY; Yang, YS; Yeh, KM | 1 |
| Boutoille, D; Bretonnière, C; Caillon, J; Desessard, C; Guitton, C; Jacqueline, C; Potel, G | 1 |
| Coleman, K; Girard, AM; Lavallade, L; Levasseur, P; Miossec, C; Pace, J | 1 |
| Chen, YH; Chu, FY; Chuang, YC; Hsueh, PR; Huang, CC; Ko, WC; Liao, CH; Sheng, WH; Tang, HJ; Tsai, HY | 1 |
| Piérard, D; Spapen, H; Yusuf, E | 1 |
| Castanheira, M; Farrell, DJ; Jones, RN; Mills, JC | 1 |
| Chan, P; Joo, J; Lo, A; Richman, M; Zhu, JN | 1 |
| Kishimoto, K; Kobayashi, K; Kobayashi, R; Sano, H; Suzuki, D; Yasuda, K | 1 |
| Bergeron, L; Grégoire, JP; Lemieux, P; Thibeault, R | 1 |
| Cies, JJ; Jain, J; Kuti, JL | 1 |
| Agudelo, M; Gonzalez, JM; Rodriguez, CA; Vesga, O; Zuluaga, AF | 1 |
| Chmura, A; Durlik, M; Kawecki, D; Lagiewska, B; Mlynarczyk, G; Pacholczyk, M; Sawicka-Grzelak, A | 1 |
| Bae, EY; Cho, B; Chung, NG; Han, SB; Jeong, DC; Jung, SW; Kang, JH; Kim, HK; Lee, DG; Lee, JW; Park, YJ | 1 |
| Andersen, MH; Arendrup, MC; Bestle, MH; Cozzi-Lepri, A; Drenck, NE; Grarup, J; Hein, L; Helweg-Larsen, J; Jensen, JU; Johansen, ME; Larsen, KM; Lauritsen, AØ; Lundgren, B; Lundgren, JD; Løken, J; Mohr, T; Møller, JK; Olesen, B; Petersen, JA; Reinholdt, K; Strange, D; Søe-Jensen, P; Thormar, K; Tousi, H; Østergaard, C | 1 |
| Carroll, F; Pai, MP; Truong, J; Zheng, H | 1 |
| Lye, DC; Ng, TM; Tan, SH; Teng, CB | 1 |
| Antonucci, E; Beumier, M; Cristallini, S; de Backer, D; Donadello, K; Jacobs, F; Roberts, JA; Rondelet, B; Scolletta, S; Taccone, FS; Vincent, JL | 1 |
| Baek, JY; Chung, DR; Huh, K; Kang, CI; Kim, YS; Ko, KS; Lee, NY; Peck, KR; Sohn, KM; Song, JH | 1 |
| Duffy, A; Gilmore, S; Heil, EL; Nguyen, AD; Patel, NK | 1 |
| Lai, J; Li, S; Liang, L; Peng, B; Wang, Z; Zheng, J | 1 |
| Abu-Seir, H; Gregg, KS; Hough, SM; Marini, BL; Nagel, JL | 1 |
| Avdic, E; Cosgrove, SE; Han, JH; Harris, AD; Hsu, AJ; Lautenbach, E; Rock, C; Tamma, PD | 1 |
| Hamaguchi, S; Ikawa, K; Ishihara, N; Karino, F; Kuraki, T; Miura, K; Morikawa, N; Moriyama, H; Nishimura, N; Sutani, A | 1 |
| Athan, E; Baker, P; Harris, PN; Harris-Brown, T; Ingram, PR; Iredell, J; Lipman, J; McBryde, ES; Miyakis, S; Paterson, DL; Paul, SK; Peleg, AY; Roberts, JA; Rogers, BA; Stewardson, AJ | 1 |
| Han, XY; Li, L; Tarrand, JJ | 1 |
| Hong, MT; Seifert, CF | 1 |
| Hara, T; Horiyama, T; Izawa, M; Kanazawa, S; Maki, H; Sato, T; Tsuji, M; Yamaguchi, T | 1 |
| Joundi, RA; Leis, JA; Wong, BM | 1 |
| Bellón, T; Bobolea, I; Caballero, T; Cabañas, R; Calderon, O; Fiandor, A; Herránz, P; López-Serrano, MC; Prior, N; Quirce, S; Ramirez, E | 1 |
| Pineda, LC; Watt, KM | 1 |
| Arace, P; Ciofi degli Atti, M; Giusti, A; Raponi, M; Raschetti, R; Spiazzi, R; Spila Alegiani, S | 1 |
| Cavanillas, R; Grau, S; Lozano, V; Nocea, G; Valladares, A; Xie, Y | 1 |
| Araya, I; Contreras, S; Fasce, G; Hurtado, V; Núñez, E; Opazo, JL; Quiñones, LA; Saez, E | 1 |
| Cattoir, V; Dargère, S; Daurel, C; de La Blanchardière, A; Guérin, F; Saint-Lorant, G; Verdon, R | 1 |
| Brunetti, L; Cunningham, D; Ding, Y; Lim, J; Nahass, RG; Nguyen, J; Poustchi, S; Toscani, M | 1 |
| Chen, R; Qian, CY; Qian, Q; Sun, MR; Wang, LY; Wang, ML; Zou, SL | 1 |
| Bhattacharya, S; Bhaumik, J; Chandy, M; Goel, G; Mukherjee, S | 1 |
| Diab Cáceres, L; Girón Moreno, RM; Marcos, MC | 1 |
| Awais, M; Rehman, A; Ul-Ain Baloch, N | 1 |
| Gardner, JH; Hahn, U; Lehman, S; Peake, SL; Roberts, JA; Roberts, MS; Sime, FB; Tiong, IS; Warner, MS | 1 |
| Fu, YP; Man, BL | 1 |
| Kaplan, SL; Mao, KR; McNeil, JC; Patel, A; Vallejo, JG | 1 |
| Baines, C; Brown, B; Lewis, I; Smart, D | 1 |
| Azouri, T; Bathina, P; Kandipalli, D; Kaplansky, T; Kaye, KS; Lazarovitch, T; Marchaim, D; Maskit, M; Ofer-Friedman, H; Sharma, S; Shefler, C; Tal-Jasper, R; Tirosh, A; Zaidenstein, R | 1 |
| Baggett, S; Gilbert, S; Heierman, T; Imhof, K; LaFosse, J; McCormick, H; Tomaka, N | 1 |
| Bartoletti, R; Bjerklund Johansen, TE; Brugnolli, A; Cai, T; Eccher, C; Lanzafame, P; Luciani, LG; Malossini, G; Mirone, V; Pickard, R; Tiscione, D; Verze, P; Wagenlehner, FM | 1 |
| Bhambhwani, V; Ghosh, B; Goel, N | 1 |
| Ikawa, K; Kajikawa, K; Kanao, K; Kato, Y; Kobayashi, I; Mitsui, K; Morikawa, N; Nakamura, K; Narushima, M; Nishikawa, G; Sumitomo, M; Tobiume, M; Watanabe, M; Yamada, Y; Yoshizawa, T; Zennami, K | 1 |
| Bagan, P; Couffinhal, JC; Dakhil, B; Gordienco, A; Hernigou, J; Longuet, P | 1 |
| Amornchai, P; Day, NPJ; Langla, S; Limmathurotsakul, D; Peacock, SJ; White, NJ; Wuthiekanun, V | 1 |
| Hirose, Y; Ishikawa, H; Kamata, K; Kanemoto, K; Shiotani, S; Suzuki, H; Suzuki, M; Tokuda, Y | 1 |
| Amyot, J; Awissi, DK; Beauchamp, A; Fagnan, M; Hébert, E; Lavallée, C; Lavigne, V; Leblanc, M; Lebrun, G; Munoz, DL; Pichette, V; Robitaille, R; Savoie, M; Tétreault, N; Varin, F | 1 |
| Cury, JD; Dakkak, M; Siddiqi, F | 1 |
| Akiyama, N; Kanda, Y; Saito, M; Tamura, K | 1 |
| D'Agostino, C; Rhodes, NJ; Roberts, JA; Scheetz, MH; Skoglund, E | 1 |
| Havey, TC; Hull, MW; Leung, V; Romney, MG | 1 |
| Duane, TM; Kikhia, RM; Ober, J; Tessier, JM; Wolfe, LG | 1 |
| Berrazeg, M; Broutin, I; Fournier, D; Jeannot, K; Loeffert, S; Ntsogo Enguéné, VY; Plésiat, P | 1 |
| Ewan, P; Nasser, S; Sellaturay, P | 1 |
| Bose, S; Popovich, MJ; Silver, BJ; Wurm, E | 1 |
| Das, J; Lamb, H; Layton, B; Leahy, BC; Sinnott, N | 1 |
| Emiroğlu, M; Köksal, Y; Köse, D | 1 |
| Alauzet, C; Benayad, H; Bertaux, A; Claudon, M; Lemarié, C; Malikov, S; Mandry, D; Risse, J; Settembre, N; Wahl, D; Zuily, S | 1 |
| El-Zoghby, ZM; Frazee, EN; Larson, SL; Nyberg, SL; Personett, HA | 1 |
| Arah, OA; Chow, AL; Lye, DC | 1 |
| Bruna-Romero, O; da Glória de Souza, D; de Andrade, JP; de Carvalho, MA; de Macêdo Farias, L; dos Santos, KV; Ferreira, JF | 1 |
| Afzelius, P; Bergmann, A; Henriksen, JH | 1 |
| Alicino, C; Di Bella, A; Durando, P; Fontana, S; Gritti, PR; Marchese, A; Orsi, A; Parodi, MC; Ricci, ML; Rota, MC; Scaturro, M; Tinteri, C | 1 |
| Abdul-Aziz, MH; Akova, M; Bassetti, M; De Waele, JJ; Dimopoulos, G; Dulhunty, J; Kaukonen, KM; Koulenti, D; Lipman, J; Martin, C; Montravers, P; Rello, J; Rhodes, A; Roberts, JA; Starr, T; Wallis, SC | 1 |
| Garland, JL; Lewis, JI; Squier, SB | 1 |
| Acosta-García, H; Alfaro-Lara, ER; Bautista-Paloma, FJ; Beltrán-García, M; Cotrina-Luque, J; Gil-Navarro, MV; Luque-Márquez, R | 1 |
| Badal, RE; Cao, B; Chen, S; Chu, Y; Duan, Q; Feng, X; Gui, B; Hu, B; Hu, Z; Huang, W; Kong, H; Liao, K; Luo, Y; Ni, Y; Shao, H; Su, J; Sun, Z; Wang, Y; Wu, A; Xu, Y; Yang, Q; Yu, Y; Zhang, H; Zhang, S | 1 |
| Davies, SW; Dietch, ZC; Efird, JT; Guidry, CA; Sawyer, RG; Shah, PM; Willis, RN | 1 |
| Adelfred, A; Brock, B; Hardlei, TF; Jensen-Fangel, S; Kragh Thomsen, M; Nejatbakhsh, Y; Öbrink-Hansen, K; Petersen, E | 1 |
| Almela, M; Almirante, B; Borrell, N; Cantón, R; Causse, M; Corzo, JE; Delgado-Valverde, M; Farkas, A; Fontecoba-Sánchez, MC; García-Álvarez, L; Gómez-Zorrilla, S; Gurgui, M; Gutiérrez-Gutiérrez, B; Martínez-Martínez, L; Pascual, Á; Praena, J; Roberts, JA; Rodríguez-Baño, J; Torres, E; Valiente-Mendez, A | 1 |
| Hartwich, J; Kurkchubasche, AG; Luks, FI; Muratore, CS; Tracy, TF; Watson-Smith, D; Wills, HE | 1 |
| Buenger, LE; Chung, EK; Crumby, AS; Dees, J; Healy, DP; Kays, MB; Knoderer, CA; Nichols, K | 1 |
| Chan, MTV; Li, Q; Li, Z; Shen, J; Wu, WKK | 1 |
| Bezouška, J; Havel, E; Kaška, M; Malbrain, ML; Martínková, J; Šafránek, P | 1 |
| Cunha, BA | 1 |
| Gholipourmalekabadi, M; Hashemi, A; Mozafari, M; Rostami, A; Sameni, M; Zamani, F | 1 |
| Aamir, M; Abrol, P; Punia, H; Sharma, D | 1 |
| Fowler, RC; Geyer, CN; Hanson, ND; Hawkey, P; Johnson, JR; Johnston, B; Weissman, SJ | 1 |
| Cotton, F; Creteur, J; Gustot, T; Hites, M; Jacobs, F; Lheureux, O; Surin, R; Taccone, FS; Trepo, E; Vincent, JL; Wolff, F | 1 |
| Ambeba, EJ; Cooper, JN; Deans, KJ; Lodwick, DL; Mahida, JB; Minneci, PC; Moss, RL; Nacion, KM; Sulkowski, JP | 1 |
| Brouillette, D; Nguyen, VD; Roy, R; Tourigny, JF | 1 |
| Hung, YP; Ko, WC; Lee, JC; Li, CW; Li, MC; Lin, HJ; Liu, HC; Wu, YH | 1 |
| Huang, W; Jing, Y; Li, J; Wang, Q; Yu, L; Yuan, L; Zhao, X; Zhou, D | 1 |
| El-Ibiary, S; Gorlitsky, B | 1 |
| Castanheira, M; Farrell, DJ; Flamm, RK; Huband, MD; Jones, RN; Sader, HS | 1 |
| Herodes, K; Karjagin, J; Kern, H; Kipper, K; Metsvaht, T; Oselin, K; Starkopf, J; Tamme, K; Tasa, T | 1 |
| Fodero, KE; Horey, AL; Krajewski, MP; Mergenhagen, KA; Ruh, CA; Sellick, JA | 1 |
| Manek, M; O'Donnell, JN; Rhodes, NJ; Scheetz, MH; Venkatesan, N | 1 |
| Iddi, S; Mirambo, M; Moremi, N; Mshana, SE; Mushi, MF; Petro, D; Seni, J | 1 |
| Calvo, G; Fernández, J; Llauradó-Serra, M; Martín-Loeches, I; Pontes, C; Rodríguez, A; Soy, D; Torres, A; Ulldemolins, M; Vaquer, S | 1 |
| Aynioglu, A; Hacihanefioglu, A; Mutlu, B | 1 |
| Gan, WJ; Mu, SM; Ran, XW; Shen, JF; Wang, J; Xian, Y; Xu, ZR; Yan, XD; Yuan, GY; Zhang, BS | 1 |
| Bork, JT; D'Angelo, RG; Heil, EL; Johnson, JK | 1 |
| Cohen, H; Peyko, V; Smalley, S | 1 |
| Hammond, DA; Lusardi, K; Meena, NK; Painter, JT; Smith, MN | 1 |
| Gustinetti, G; Mikulska, M | 1 |
| Boelens, J; Catteeuw, J; Claeys, G; De Bus, L; De Waele, JJ; Decruyenaere, J; Denys, W; Depuydt, PO; Gadeyne, B; Vermeulen, K | 1 |
| Hashimoto, T; Satoh, T; Watanabe, R | 1 |
| Cotta, MO; Lipman, J; Little, PJ; McDonald, C; McWhinney, B; Roberts, JA; Ungerer, JP | 1 |
| Karino, S; Kaye, KS; Koppula, S; Martin, ET; Murray, KP; Mynatt, RP; Navalkele, B; Nishan, B; Pervaiz, A; Pogue, JM; Rybak, MJ; Salim, M; Shaikh, H; Solanki, S; Tashtoush, N | 1 |
| Ariano, R; Iacovides, H; Nash, J; Weber, Z; Zelenitsky, S | 1 |
| Chow, A; De, PP; Harris, PN; Khong, WX; Lye, DC; Ng, TM; Tambyah, PA | 1 |
| Abelleira, M; Castelli, J; Etlin, A; Gerona, S; González, LS; Grecco, G; Harguindeguy, M; Iglesias, C; Leites, A; López, M; Medina, JC; Menéndez, J; Prieto, J; Rando, K; Scalone, P; Valverde, M | 1 |
| Caméléna, F; Hadj, A; Le Monnier, A; Mizrahi, A; Mollo, B; Pilmis, B | 1 |
| Chen, TL; Chuang, MF; Huang, WC; Kuo, SC; Lauderdale, TL; Lee, Y; Tseng, KC; Yang, YS | 1 |
| Ahr, KF; Bhatt, AS; Caballero, S; Calarfiore, M; Devlin, SM; Docampo, MD; Dudakov, JA; Falconer, SB; Gomes, C; Gupta, J; Gyurkocza, B; Hanash, AM; Jay, HV; Jenq, RR; Lieberman, SR; Liu, C; Moss, EL; Murphy, GF; Pamer, EG; Peled, JU; Perobelli, SM; Poeck, H; Porosnicu Rodriguez, KA; Rapaport, F; Shono, Y; Slingerland, AE; Smith, OM; Taur, Y; Tsai, JJ; van den Brink, MRM; Velardi, E; Xu, K; Young, LF | 1 |
| Aduroja, OA; Amde, M; Connor, MJ; Fissell, WH; Gould, ER; Groszek, JJ; Madonia, PN; Nesbitt, R; Salem, C; Shotwell, MS; Taylor, ME; Tolwani, AJ; Wei, P | 1 |
| Bergman, SJ; Metzke, ME; Pointer, S; Schmees, PM; Strader, BD; Valenti, KM | 1 |
| Banerjee, R; Boyce, TG; Cunningham, SA; Hasassri, ME; Jeraldo, PR; Kaye, KS; Norgan, AP; Patel, R; Pogue, JM; Weissman, SJ | 1 |
| Higuchi, H; Horikoshi, Y; Isogai, M; Ito, K; Shoji, T; Suwa, J | 1 |
| Ji, JS; Quan, JJ; Wang, HP; Wang, Y; Wang, YF; Xu, YC; Yu, YS | 1 |
| Hickson, RP; Judd, WR; Mueller, JE; Ratliff, PD; Winstead, EM | 1 |
| Jarrett, D; Khatri, N; Kraleti, S | 1 |
| Ali, M; Naing, AT; Swe, T | 1 |
| Dhillon, S; Kalva, N; Palmer-Hill, S; Patel, J; Walayat, S | 1 |
| Döbbeler, G; Frey, L; Huseyn-Zada, M; Jung, J; Nagel, D; Scharf, C; Vogeser, M; Zander, J; Zoller, M | 1 |
| Dixon, N; Fowler, RC; Geyer, CN; Hanson, ND; Harrison, L; Horiyama, T; Ishii, Y; Moland, ES; Thomson, K; Yoshizumi, A | 1 |
| Chen, J; Kong, C; Zhang, Y; Zhu, L; Zou, X | 1 |
| Benson, S; Davis, A; Hanson, M; Rawlins, M; Robinson, JO | 1 |
| Chen, C; Chen, Y; Dong, M; Li, Q; Li, Z; Lu, J; Wu, D; Zhu, Y | 1 |
| Eliasson, E; Giske, CG; Petersson, J | 1 |
| Boyce, K; Brar, H; Stabler, SN | 1 |
| Cho, H; Eun Kim, D; Hee Park, S; Ho Jang, C; Huang, X; Jeong Yoon, E; Lan Piao, Y; Lee, K; Yeon Lee, S; Zhan, CG | 1 |
| Mikamo, H; Sugimoto, N; Yamagishi, Y | 1 |
| Carroll, K; Romagnoli, M; Simner, PJ; Wang, F; Workneh, M | 1 |
| Bhanot, N; Makadia, J; Min, Z; Rapsinski, GJ | 1 |
| Abraham, MK; Crouter, AJ; Wilkerson, RG | 1 |
| Ahrens, CL; Bauer, SR; Bollinger, JE; Harinstein, LM; Petite, SE | 1 |
| Paul, N | 1 |
| Haruyama, S; Nakamura, M; Nishio, D; Ohmori, S; Okada, E; Omoto, D; Saito-Sasaki, N; Sawada, Y; Yoshioka, M | 1 |
| Foster, CB; Goldfarb, J; Gonzalez, BE; Sabella, C; Saracusa, C; Worley, S; Yusef, D | 1 |
| Mellen, CK; Rindone, JP; Ryba, JE | 1 |
| Bao, H; Lv, Y; Wang, D; Xue, J; Yan, Z | 1 |
| Mayer, B; Meinus, C; Roehmel, JF; Schwarz, C | 1 |
| Monogue, ML; Nicolau, DP | 1 |
| Giuliano, CA; Kale-Pradhan, PB; Patel, CR | 1 |
| Bernatoniene, J; Bielicki, JA; Doerholt, K; Gharbi, M; Goossens, H; Heginbothom, M; Lyall, H; Menson, E; Patel, SV; Paulus, S; Riordan, A; Sharland, M; Vergnano, S; Versporten, A | 1 |
| Frassani, S; Gabrielli, F; Guttadauro, A; Macchini, D; Maternini, M | 1 |
| Goldstein, EJ; Harrell, L; Hecht, DW; Jacobus, NV; Jenkins, SG; McDermott, LA; Newton, D; Patel, R; Snydman, DR | 1 |
| Hori, D; Kishimoto, K; Kobayashi, K; Kobayashi, R; Sano, H; Suzuki, D | 2 |
| Chan, YH; Cheng, WY; Fan, SY; Leung, SM; Shum, HP; Yan, WW | 1 |
| Eng, LC; Kwang, LL; Ng, LS; Rao, S; Tan, TY | 1 |
| Burgess, DR; Burgess, DS; Cox, JN; Martin, CA; Rutter, WC | 1 |
| Beerle, C; Breitenstein, S; Gelpke, H; Staerkle, RF | 1 |
| Betten, DP; Massoll, AF; Powers, SC | 1 |
| Atalay, MA; Demir, K; Demiraslan, H; Doganay, M; Eren, E; Kaynar, L; Koc, AN | 1 |
| Casabar, E; Durkin, MJ; Hays, AJ; Hsueh, K; Jafarzadeh, SR; Krekel, T; Lane, MA; Reyes, M; Ritchie, DJ | 1 |
| Beardsley, J; Johnson, J; Liu, P; Luther, V; Ohl, C; Williamson, J | 1 |
| Evans, R; Hussain, T; Karino, S; Kaye, KS; Koons, J; Koppula, S; Martin, ET; Murray, KP; Mynatt, RP; Navalkele, B; Nishan, B; Perry, W; Pervaiz, A; Pogue, JM; Rybak, MJ; Salim, M; Shaikh, H; Solanki, S; Tashtoush, N | 1 |
| Cai, Y; Haddad, J; Saqi, A | 1 |
| Carvalheira, A; Casquete, R; Silva, J; Teixeira, P | 1 |
| Nicholaus, P; Pallangyo, P | 1 |
| Compain, F; Guerot, E; Jarraud, S; Podglajen, I; Richaud, C; Rossi, B; Rostane, H | 1 |
| Hackel, MA; Hoban, DJ; Karlowsky, JA; Lob, SH; Sahm, DF | 1 |
| Aslanzadeh, J; Brecher, SM; Monogue, ML; Nicolau, DP; Tanner, LK | 1 |
| Gong, R; Huang, X; Li, C; Liu, J; Liu, Y; Xu, H | 1 |
| Beaudoin, ME; Cavalcanti, NC; Derendorf, H; Grunwitz, C; Kircher, P; Nichols, WW; Pieper, S; Schuck, VJ; Sy, SK; Tabosa, MA; Zhuang, L | 1 |
| Dubrovskaya, Y; Louie, E; Mousavi, M; Papadopoulos, J; Scipione, MR; Zapolskaya, T | 1 |
| Adler, NR; Aung, AK; Goh, MS; McLean, CA | 1 |
| Compain, F; Grohs, P; Kaibi, I; Lavollay, M; Mainardi, JL; Morand, P; Podglajen, I; Taieb, G | 1 |
| Lipsky, BA; Mutluoglu, M | 1 |
| Gentry, CA; Williams, RJ | 1 |
| Chaudhury, A; Kalawat, U; Rani, AS; Sumant, S; Venkataramana, B; Verma, A | 1 |
| Deis, AS; Simpson, SQ; Whiles, BB | 1 |
| Burgess, DR; Burgess, DS; Rutter, WC; Talbert, JC | 1 |
| Baumer, T; Fry, C; Gunawardena, H; Luppe, S; Sieradzan, K | 1 |
| Merino Rodríguez, E; Miquel Plaza, J; Rebolledo Olmedo, S | 1 |
| Breilh, D; Jaber, S; Jean-Pierre, H; Jung, B; Legeron, R; Mahul, M; Molinari, N; Signe, J; Uhlemann, AC | 1 |
| Burgess, DS; Rutter, WC | 1 |
| Aslanzadeh, J; Kuti, JL; Nicolau, DP; Stainton, SM; Thabit, AK | 1 |
| Anupurba, S; Banerjee, T | 1 |
| Kim, JH; Kim, MJ; Sohn, JW; Yang, KS; Yoon, YK | 1 |
| Gao, L; Li, Y; Lyu, Y | 1 |
| Rodriguez-Bano, J; Tamma, PD | 1 |
| Li, B; Li, L; Peters, BM; Shirtliff, ME; Xie, J; Xu, Z; Yu, G | 1 |
| Jensen, BH; Justesen, US; Krogfelt, KA; Petersen, AM; Sydenham, TV | 1 |
| Carlier, M; De Cock, PAJG; de Jaeger, A; De Paepe, P; Delanghe, JR; Della Pasqua, OE; Robays, H; van Dijkman, SC; Vande Walle, J; Verstraete, AG; Willems, J | 1 |
| Clark, R; Cohen-Wolkowiez, M; Gonzalez, D; Hornik, CP; Kelly, MS; Ku, LC; Salerno, S; Smith, PB | 1 |
| LeCleir, LK; Pettit, RS | 1 |
| Bleasdale, SC; Gross, AE; Gupta, V; Johannes, RS; Srinivasan, A; Tabak, YP | 1 |
| Krishnan, U; Lopez, RN; Ooi, CY | 1 |
| Basu, A; Borse, RH; Gaultney, J; Kauf, TL; Medic, G; Miller, B; Prabhu, VS; Sen, SS | 1 |
| Avedissian, SN; Miglis, C; Postelnick, M; Rhodes, NJ; Scheetz, MH; Sutton, SH; Wunderink, RG; Zembower, TR | 1 |
| Farber, JL; Filippone, EJ; Kraft, WK | 1 |
| Chan, JD; Dellit, TH; Lynch, JB | 1 |
| Aardema, H; Alffenaar, JW; Dieperink, W; Kosterink, JGW; Nannan Panday, P; van Hateren, K; Wessels, M; Zijlstra, JG | 1 |
| Bremer-Streck, S; Hochhaus, A; Kiehntopf, M; Lindig, U; Rachow, T; Schlattmann, P; Schlüter, V; Scholl, S; von Lilienfeld-Toal, M | 1 |
| Hincapie Castillo, J; Jeon, N; Klinker, KP; Staley, B; Winterstein, AG | 1 |
| Ahir, H; Foo, J; Merchant, S; Prabhu, V; Sarpong, E | 1 |
| Cassisa, V; Coron, N; Eveillard, M; Godefroy, A; Joly-Guillou, ML; Kempf, M; Marion, E; Marsollier, L; Pailhoriès, H; Pavlickova, S | 1 |
| Falagas, ME; Kofteridis, DP; Maraki, S; Mavromanolaki, VE; Perdikis, D; Samonis, G; Vardakas, KZ | 1 |
| Alós, JI; Fernández, S; Grados, M; Lara, N | 1 |
| Başaran, S; Bingöl, Z; Çağatay, A; Eraksoy, H; Karabıçak, N; Kılıçaslan, Z; Özsüt, H; Şafak, S; Sarıbuğa, A; Şimşek Yavuz, S; Sutton, DA; Wiederhold, NP | 1 |
| Kim, HS; Kim, HY; Kim, YK; Lee, J; Lee, JA; Lee, SS; Seo, YB; Song, W; Uh, Y | 1 |
| Allerberger, F; Jesumirhewe, C; Lepuschitz, S; Ruppitsch, W; Springer, B | 1 |
| Borgatta, B; Gattarello, S; Imbiscuso, AT; Larrosa, MN; Lujàn, M; Mazo, CA; Rello, J | 1 |
| Ang, BS; Ling, LM; Lye, DC; Ng, TM; Phang, VY; Tan, MW; Tan, SH; Tay, HL; Teng, CB; Young, B | 1 |
| Hayashi, Y; Katayama, M; Suzuki, D; Takimoto, K; Wang, Q | 1 |
| Huang, YC; Lin, YT; Wang, FD | 1 |
| Arnaud, E; Larcher, R; Lavigne, JP; Pantel, A; Sotto, A | 1 |
| Cotta, MO; Lefrant, JY; Lipman, J; Muller, L; Roberts, JA; Roger, C; Wallis, SC | 1 |
| Ikawa, K; Kajihara, T; Morikawa, N; Murakami, Y; Murao, N; Ohge, H; Shigemoto, N; Shimada, N; Sueda, T; Uegami, S; Uemura, K; Watadani, Y; Yano, R | 1 |
| Cahan, A; Cohen, MJ; Kleinhendler, E; Moses, AE; Paltiel, O; Strahilevitz, J | 1 |
| Darmalingam, M; Salciccioli, JD; Woodcock, H | 1 |
| Cho, B; Chung, NG; Han, SB; Jeong, DC; Kang, JH; Kim, HS; Kim, SK; Lee, DG; Lee, JW; Park, BK | 1 |
| Beri, K; Shariff, M | 1 |
| Lam, M; Yong, CH | 1 |
| Effraim, P; Li, L; Tham, SW; Waxman, S | 1 |
| García Carretero, R; Lopez-Lomba, M; Rodriguez-Maya, B; Vazquez-Gomez, O | 1 |
| Cohen-Wolkowiez, M; Greenberg, RG; Rivera-Chaparro, ND | 1 |
| Burgess, DR; Burgess, DS; Cotner, SE; Martin, CA; Rutter, WC; Wallace, KL | 1 |
| Ashraf, T; Darwish, D; Ghazawi, A; Mohsin, J; Pál, T; Petersen, JE; Sonnevend, A | 1 |
| Anderson, KT; Kao, LS; Lally, KP; Mueck, KM; Putnam, LR; Tsao, K | 1 |
| Hahn, U; Lipman, J; Peake, SL; Roberts, JA; Roberts, MS; Sime, FB; Tiong, IS; Warner, MS | 1 |
| Morimoto, T; Morimoto, Y; Nagashima, H; Tokuyama, S | 1 |
| Autmizguine, J; Kassir, N; Litalien, C; Théorêt, Y; Thibault, C; Varin, F | 1 |
| Anderson, CW; Cazares, KS; Denunzio, TM; Lustik, MB; Patel, SM | 1 |
| Fusco, NM; Hassinger, AB; Holsen, MR; Meaney, CJ | 1 |
| Goodlet, KJ; Nailor, MD; Nicolau, DP | 1 |
| Awdishu, L | 1 |
| Isami, K; Kawamata, Y; Kozono, A; Miyoshi, T; Sasaki, E; Senba, M; Tsumagari, K; Tsuruta, M; Yamashina, T; Yamashita, K | 1 |
| Heather, CS; Maley, M | 1 |
| Bryan, M; Cowden, C; Downes, KJ; Fisher, BT; Goldstein, SL; Gong, W; Huang, YS; Laskin, BL; Zaoutis, TE | 1 |
| Hindler, JA; Humphries, RM; Miller, SA; Wong-Beringer, A | 1 |
| Deresinski, S; Watkins, RR | 1 |
| Kempker, RR; Kumar, S; Mgbemena, O; Serota, DP; Weiss, DS; Wozniak, JE | 1 |
| Castanheira, M; Flamm, RK; Pfaller, MA; Shortridge, D | 1 |
| Logan, J; Mellor, TE; Mitchell, N | 1 |
| Álvarez-Marín, R; Aznar, J; Lepe, JA; Ortiz de la Rosa, JM; Pachón, J; Rodríguez-Villodres, Á; Smani, Y | 1 |
| Bathoorn, E; Beerthuizen, GIJM; Friedrich, AW; Kooistra-Smid, AMD; Nieuwenhuis, MK; Pirii, LE; Rossen, JWA; Vogels, W | 1 |
| Guerra Valero, YC; Lipman, J; Naicker, S; Ordenez Meija, JL; Parker, SL; Roberts, JA; Wallis, SC | 1 |
| Caffrey, AR; Dosa, D; LaPlante, KL; Lodise, TP; Luther, MK; Timbrook, TT | 1 |
| Demetriou, M; Maltezos, E; Panagopoulos, P; Panopoulou, M; Papanas, N | 1 |
| Grupper, M; Kuti, JL; Nicolau, DP; Thabit, AK | 1 |
| Choi, JK; Joo, EJ; Ko, JH; Lee, NR; Moon, SY; Park, DA; Peck, KR | 1 |
| Abouelkheir, M; Alsubaie, S | 1 |
| Dolff, B; Harder, S; Hogardt, M; Keiner, N; Kempf, VAJ; Kessel, J; Reinheimer, C; Stephan, C; Wichelhaus, T; Wieters, I | 1 |
| Branski, LK; Cambiaso-Daniel, J; Capek, KD; De Crescenzo, A; Finnerty, CC; Herndon, DN; Hundeshagen, G; Killion, EA; Kinsky, MP; Mlcak, RP; Norbury, WB; Sljivich, M; Voigt, CD | 1 |
| Hatti, M; Odenholt, I; Resman, F; Solomonidi, N; Tham, J | 1 |
| Bergen, PJ; Bulitta, JB; Kirkpatrick, CMJ; Landersdorfer, CB; Lipman, J; McGregor, MJ; Millen, N; Paterson, DL; Roberts, JA; Sime, FB | 1 |
| Adondakis, MG; Brown, EM; Oliver, MR; Skedros, JG | 1 |
| Kato, M; Matsuoka, T; Mori, T; Ohashi, K; Shinoda, Y; Tachi, T; Teramachi, H; Yoshida, S; Yoshimura, T | 1 |
| Jaffer, ZN; Nicholson, C | 1 |
| Jafri, SM; Nemakayala, DR; Rai, MP; Rayamajhi, S | 1 |
| Alexander, EL; Bhowmick, T; Bidair, M; Bleasdale, SC; Chorvat, E; Dragoescu, PO; Dudley, MN; Fedosiuk, E; Fusaro, K; Giamarellos-Bourboulis, EJ; Griffith, D; Horcajada, JP; Kaye, KS; Lomovskaya, O; Loutit, J; Metallidis, S; Morgan, E; Murta, C; Sagan, OS; Sarychev, Y; Stoev, V; Stus, V; Vazquez, J; Zaitsev, V | 1 |
| Acuña, M; Benadof, D; Veas, A; Vega, JR | 1 |
| Lagan, KM; McArdle, CD; McDowell, DA | 1 |
| Borders, C; Bower, M; Groysman, L; Schnure, A; Tran, MH | 1 |
| Colby, J; Fissell, WH; Groszek, JJ; Patel, P; Seegmiller, A; Shotwell, M; Verhoven, SM; Verstraete, A | 1 |
| Oda, K; Ota, K; Sakamoto, N; So, M; Suzuki, T | 1 |
| Arıcı, M; Balcı, C; Hayran, SA; Ünal, S; Uzun, Ö; Yüce, D | 1 |
| Ashhurst-Smith, C; Ferguson, JK; Hughes, C | 1 |
| Arnaud, A; Costet, N; Donnio, PY; Engrand, C; Habonimana, E; Nardi, N; Taleb, M; Tattevin, P; Wodey, E | 1 |
| Alobaid, A; Hiremath, S; Kanji, S; Patel, R; Porteous, R; Roberts, JA; Watpool, I; Xie, J; Zelenitsky, S; Zhang, G | 1 |
| Gopalakrishnan, M; John, JF; Manappallil, RG; Nambiar, H | 1 |
| Castanheira, M; Duncan, LR; Flamm, RK; Sader, HS | 1 |
| Imaizumi, M; Kitaoka, S; Kumaki, S; Metoki, T; Miyabayashi, H; Noguchi, R; Onuma, R; Sato, A; Sato, T; Tazawa, Y; Watanabe, Y | 1 |
| Abdel Warith, A; Alhamad, F; Alrumaih, I; Alzahrani, M | 1 |
| Andukuri, VG; Iguidbashian, JP; Kukrety, S; Parekh, JD | 1 |
| Fung, MA; Gorouhi, F; Konia, T; Kornmehl, H; Tartar, DM | 1 |
| Caccese, E; Marinai, C; Messori, A; Trippoli, S; Tulli, G | 1 |
| Hao, D; Hu, Z; Liu, X; Sun, T; Tian, H; Wang, T; Wang, X | 1 |
| Farkas, A; Heil, EL; Nicolau, DP; Roberts, JA; Thom, KA | 1 |
| Bando, S; Egawa, S; Kasai, K; Kimura, T; Kira, S; Kiyota, H; Koide, H; Murakami, M; Yamada, H | 1 |
| Al Khamis, M; Alenazi, TH; Arabi, Y; Athan, E; Baker, P; Bassetti, M; Beatson, SA; Bhally, H; Boyles, TH; Crowe, A; Daneman, N; Falcone, M; Griffin, P; Harris, PNA; Harris-Brown, T; Ingram, P; Iredell, J; Kanj, S; Lee, TH; Looke, D; Lorenc, P; Lye, DC; Mendelson, M; Miyakis, S; Mo, Y; Paterson, DL; Peleg, AY; Righi, E; Roberts, L; Rogers, BA; Tambyah, PA; Walls, G; Yilmaz, M; Zikri, A | 1 |
| Beaulieu, C; Kurczewski, L; Yajnik, V | 1 |
| Bernard, S; Lee, K; Pakyz, A; Stevens, M; Vaughan, D | 1 |
| Albanèse, J; Bornet, C; Curti, C; Fersing, C; Guinard, B; Lamy, E; Mathias, F; Primas, N; Souab, HK; Vanelle, P | 1 |
| Cabri, W; Cerisoli, L; Ferrazzano, L; Martelli, G; Ricci, A; Tolomelli, A; Viola, A | 1 |
| Bandettini, R; Barco, S; Cangemi, G; Castagnola, E; Mesini, A; Saffioti, C | 1 |
| Brock, B; Friberg, LE; Kristoffersson, AN; Maarbjerg, SF; Nielsen, EI; Schrøder, H; Thorsted, A; Wang, M | 1 |
| Juang, P; Kollef, MH; Micek, ST | 1 |
| Damen, C; De Waele, JJ; Dhaese, S; Stove, V; Verstraete, AG | 1 |
| Autmizguine, J; Kassir, N; Lavigne, J; Litalien, C; Théorêt, Y; Thibault, C | 1 |
| Cho, M; Kobayashi, D; Shimbo, T; Yokota, K | 1 |
| Avedissian, SN; Chalkias, A; d'Aloja, E; Downes, KJ; Fitzgerald, JC; Gilchrist, A; Hiner, D; Liu, J; Locci, E; Lodise, TP; Pais, GM; Prozialeck, WC; Rhodes, NJ; Scheetz, MH; Xanthos, T; Zuppa, AF | 1 |
| Lai, CC; Wang, JH | 1 |
| Campanon, MV; Davila, I; de Arriba, S; Gallardo, A; Gracia-Bara, MT; Laffond, E; Macias, EM; Martin, C; Moreno, EM; Muñoz-Bellido, FJ; Sobrino, M | 2 |
| Agic, A; Milicic, D; Pasalic, M; Samardzic, J; Skoric, B | 1 |
| Becker, A; Braun, E; Chaudier, P; Chidiac, C; Corbin, K; Dupieux, C; Ferry, T; Fessy, MH; Goutelle, S; Gunst, S; Laurent, F; Lustig, S; Mabrut, E; Triffault-Fillit, C; Valour, F | 1 |
| Hector, E; Hussein, Z; Lipman, S; Reisfeld, S; Stein, M; Tannous, E; Tonna, A | 1 |
| Chen, H; Yu, Z | 1 |
| DeMott, JM; Hammond, DA; Peksa, GD; Traversa, A | 1 |
| Cottrell, K; Harris, PNA; Heffernan, AJ; Islam, K; Lipman, J; Naicker, S; Roberts, JA; Sime, FB; Sumi, CD; Wallis, SC | 1 |
| Izquierdo C, G; Navea M, D; Torres T, JP; Valverde G, C; Zylbersztajn, B | 1 |
| Brüggemann, RJ; de Wildt, SN; Kolwijck, E; Kramers, C; Schouten, JA; Workum, JD | 1 |
| Ali, FR; Fernandes, B; Madrigal-Burgaleta, R; Shafi, N; Watson, D | 1 |
| Du, H; Duan, W; Heng, L; Liu, L; Ren, J; Wang, S; Yang, Q; Zhang, Z; Zheng, Y | 1 |
| Azzini, AM; Bassi, C; Bazaj, A; Cascio, GL; De Pastena, M; Filippini, C; Maruccio, M; Mazzariol, A; Montagnini, G; Paiella, S; Romeo, F; Salvia, R; Scarlini, L; Secchettin, E; Zaffagnini, A | 1 |
| Lin, FJ; Shao, CH; Tai, CH; Wang, CC; Wang, JT; Wu, CC | 1 |
| Academia, EC; Jenrette, JE; McLaughlin, JM; Mueller, SW | 1 |
| Egge, JA; Heintz, BH; Lee, JD; Livorsi, DJ; Lund, BC; Mosher, HJ | 1 |
| Kubíčková, V; Urbánek, K | 1 |
| He, A; He, L; Qian, Y | 1 |
| Lv, J; Su, X; Wu, G; Zhang, F | 1 |
| Canouï, E; Chouchana, L; Contejean, A; Kerneis, S; Tisseyre, M; Treluyer, JM | 1 |
| Bowler, S; Gerhardy, B | 1 |
| Conde, IR; de la Fuente Aguado, J; Ferreiro, JLL; García, JP; González, LG; Otero, JÁ; Rivo, AS; Soneira, MF | 1 |
| Burdette, SD; Elliott, BP; Madden, JA; Markert, RJ; Pleiman, CM; Speelmon, EC; Tang, MM | 1 |
| Chua, NG; Hoo, GSR; Kwa, AL; Lee, L; Ling, LM; Ng, TM | 1 |
| Copaescu, A; Trubiano, JA | 1 |
| Asai, N; Hagihara, M; Kato, H; Koizumi, Y; Mikamo, H; Ohashi, W; Sakanashi, D; Shibata, Y; Shiota, A; Suematsu, H; Watanabe, H; Yamagishi, Y | 1 |
| Peyko, V | 1 |
| Imai, T; Kakeya, H; Kawaguchi, H; Nagayama, K; Nakamura, Y; Oshima, K; Sakurai, N; Shibata, W; Yamada, K; Yamashita, Y; Yano, T | 1 |
| Duong, L; Harriott, NG; Ives, AL; Pan-Chen, S; Rungkitwattanakul, D | 1 |
| Dote, S; Horiuchi, N; Inose, R; Kobayashi, Y; Muraki, Y; Sazanami, K; Yagi, T | 1 |
| Dong, YN; Fang, ZY; Hao, GX; Hou, SS; Huang, X; Li, X; Shi, HY; Tang, BH; Van Den Anker, J; Wu, YE; Yao, BF; Yu, YH; Zhao, W; Zheng, Y | 1 |
| Dupont, H; Eloy, P; Esposito-Farèse, M; Grall, N; Lasocki, S; Montravers, P; Seguin, P; Veber, B; Weiss, E | 1 |
| Li, T; Liu, K; Mao, H; Ni, J; Wu, B; Xing, C; Xu, X; Zhang, Y | 1 |
| Aizawa, F; Azuma, M; Chuma, M; Goda, M; Hamano, H; Ishizawa, K; Izumi, Y; Nakamoto, A; Okada, N; Yagi, K; Zamami, Y | 1 |
| Iwazawa, H; Kanenishi, K; Kosaka, S; Motoki, T; Suzuki, K; Takahashi, K; Tanaka, H; Tatsumichi, T; Yamaguchi, K | 1 |
| Agarwal, SK; Buckley, MS; D'Alessio, PA; Kane-Gill, SL; Kobic, E; Komerdelj, IA; Martinez, BK; Rangan, P; Tinta, NC; Yerondopoulos, MJ; Ziadat, DS | 1 |
| Albertsen, BK; Friberg, LE; Maarbjerg, SF; Nielsen, EI; Schrøder, H; Thorsted, A; Wang, M | 1 |
| Al-Jebawi, Y; Karalic, K; Mhanna, MJ; Shekhawat, P | 1 |
| Chua, NG; Cove, M; Hee, DKH; Hoo, GSR; Kwa, AL; Lee, LS; Lee, W; Lim, TP; Ling, LM; Loo, L; Ng, TM; Ong, JCL; Soong, JL; Tang, SSL; Zhou, YP | 1 |
| Annecke, T; Bach, F; Bauer, M; Bracht, H; Brenner, T; Brinkmann, A; Frey, O; Hagel, S; Hohn, A; Jarczak, D; Kiehntopf, M; Kluge, S; König, C; Lehmann, T; Michels, G; Müller, C; Neugebauer, S; Nierhaus, A; Pletz, MW; Roberts, JA; Weigand, M; Weismann, D; Witzke, D | 1 |
| Imai, S; Kadomura, S; Kashiwagi, H; Miyai, T; Sato, Y; Sugawara, M; Takekuma, Y | 1 |
| Dhamija, P; Goyal, T; Gupta, P; Trikha, V; Vardhan, G | 1 |
| Almind, SR; Andreasen, MR; Frimodt-Møller, N; Hansen, KH; Hertz, FB; Jelsbak, L; Nielsen, KL; Schønning, K | 1 |
| Taito, S; Yoshihiro, S | 1 |
| Alrashed, MA; Borgstrom, MC; Kang, N; Perona, SJ; Torabi, MR | 1 |
| Kim, HI; Kim, HS; Kim, YK; Lee, DH; Lee, SH; Park, S | 1 |
| Hagel, S; Lehmann, T; Pletz, MW | 1 |
| Debaveye, Y; Dreesen, E; Gijsen, M; Spriet, I; Wauters, J | 1 |
| Akers, KS; Chung, KK; DeLuca, JP; Livezey, JR; Nadeau, RJ; Por, ED; Pruskowski, KA; Selig, DJ | 1 |
| Butragueño-Laiseca, L; Campillo, N; Fernández, SN; García, X; Grau, S; Marco-Ariño, N; Padilla, B; Santiago, MJ; Slöcker, M; Troconiz, IF | 1 |
| Braun-Feldweg, J; Germer, CT; Lock, JF; Meyer-Sautter, P; Rüsch, J; Surat, G | 1 |
| Alexandre, K; Giry, M; Lamoureux, F; Pestel-Caron, M; Sarfati, S; Wils, J | 1 |
| Ardebili, A; Bagheri, H; Goharrizi, MASB; Hjimohammadi, A; Izanloo, A; Jamali, A; Shahri, FN | 1 |
| Bauer, MJ; Flora, MS; Forde, BM; Habib, ZH; Harris, P; Islam, K; Roberts, JA; Shirin, T; Sime, FB; Wallis, SC | 1 |
| Bazan, NS; Elmazar, MM; Naiim, CM; Sabri, NA | 1 |
| Bian, L; He, K; Liang, W; Lv, J; Wu, Z; Yue, H | 1 |
| Baczek, SM; Cohen, JA; Hodge, LA; Ingemi, AI; Kaplan, MC; Kiley, PS; Pearston, AP; Shaeffer, ZA; Soriano, KM; Stanley, JS; Talt, IE; Wilson, TJ; Yao, A | 1 |
| Chen, CH; Chen, CM; Chen, WC; Fang, WF; Fu, PK; Ku, SC; Kuo, LK; Lai, CC; Tu, CY; Wang, CY; Wang, YT | 1 |
| François, T; Luc, A; Novy, E; Pape, E; Scala-Bertola, J | 1 |
| Gillani, SW; Hussain, MW; Mahmood, RK; Rathore, HA; Saeed, MW; Vippadapu, P | 1 |
| Alosaimy, S; Amaya, L; Biagi, M; Chandler, E; Cubillos, A; Davis, SL; Finch, N; Hobbs, ALV; Holger, D; Jorgensen, SCJ; Kufel, WD; Kunz Coyne, AJ; Lagnf, AM; Li, D; Molina, KC; Moore, WJ; Morrisette, T; Mubarez, M; Patch, M; Polisetty, RS; Rebold, N; Rico, M; Rybak, MJ; Sakoulas, G; Simon, SP; Smith, IMK; Tran, NN; Truong, J; Venugopalan, V; Veve, MP; Witucki, P; Wrin, J; Yost, C | 1 |
| Ankravs, MJ; Bellomo, R; Deane, AM; Rechnitzer, T; Roberts, JA; Sharrock, L; Wallis, SC | 1 |
| Aardema, H; Colin, P; De Corte, T; De Waele, JJ; Dhaese, SAM; Ongenae, F; Stove, V; Van Hoecke, S; Vander Mijnsbrugge, D; Verhaeghe, J; Verstraete, AG; Zijlstra, JG | 1 |
| Cottrell, K; Harris, PNA; Heffernan, AJ; Lipman, J; Naicker, S; Roberts, JA; Sime, FB; Sumi, CD; Wallis, SC | 1 |
| Al Jalali, V; Ballarini, N; Bauer, M; Bergmann, F; Jorda, A; König, F; Lackner, E; Nussbaumer-Pröll, A; Oesterreicher, Z; Reiter, B; Stimpfl, T; Wölfl-Duchek, M; Wulkersdorfer, B; Zeitlinger, M | 1 |
| Côté, JM; Kane-Gill, SL; Murray, PT | 1 |
| Ben-Zvi, H; Fanous, E; Herscovici, T; Kaplan, E; Livni, G; Mor, M; Schiller, O; Vardi, Y | 1 |
| Carta, N; Décaudin, B; Degand, F; Gaudy, R; Genay, S; Lebuffe, G; Martin Mena, A; Maury, É; Négrier, L; Odou, P; Thibaut, M | 1 |
| Laramie, KE; Miller, MA; Mueller, SW; Roper, SE; Torian, SC; Wiktor, AJ | 1 |
| Jang, SM; Lewis, SJ; Rhie, SJ | 1 |
| Benaboud, S; Béranger, A; Berthaud, R; Bille, E; Bouazza, N; Foissac, F; Gana, I; Lesage, F; Oualha, M; Renolleau, S; Thy, M; Toubiana, J; Tréluyer, JM; Urien, S | 1 |
| Cai, Q; Cao, Y; Chen, C; Gao, P; Hou, FF; Hu, Y; Johnson, DW; Kong, Y; Li, G; Li, H; Liu, B; Liu, H; Liu, X; Lu, F; Nie, S; Shen, J; Shi, Y; Su, G; Tang, Y; Wan, Q; Weng, J; Xiao, C; Xie, D; Xu, G; Xu, H; Xu, X; Yang, Q; Zha, Y; Zhou, Y | 1 |
| Lee, JS; Lee, SH; Oh, J; Park, SY | 1 |
| El-Haffaf, I; Guilhaumou, R; Marsot, A; Velly, L | 1 |
| Caldwell, JT; Dong, S; Fei, L; Goldstein, SL; Hasson, D; Kaplan, J; Slagle, C; Tang Girdwood, S; Tang, P; Vinks, AA | 1 |
| Gill, CM; Nicolau, DP | 1 |
| Engdahl, S; Pettit, RS; Riggsbee, D | 1 |
| Harris, PNA; Humphries, RM; Mathers, AJ; Tamma, PD; Wenzler, E | 1 |
| An, G; Balevic, SJ; Chan, AW; Cohen-Wolkowiez, M; Conrad, T; Gu, K; Hemmersbach-Miller, M; Kirkpatrick, CMJ; Landersdorfer, CB; Schmader, KE; Swamy, GK; Walter, EB; Winokur, PL | 1 |
| Bauer, SR; Campbell, MJ; Dettmer, MR; Erickson, RM; Fertel, BS; Sacha, GL; Wesolek, JL | 1 |
| Andereck, J; Casey, JD; Dear, ML; Dennis, B; Lloyd, BD; Nelson, G; Qian, ET; Rice, TW; Seitz, K; Self, WH; Semler, MW; Siemann, J; Siew, ED; Stollings, J; Wang, L; Wrenn, J; Wright, A; Wright, P | 1 |
| Chang, Q; Ding, L; He, X; Huang, W; Li, X; Wan, X | 1 |
| Bercot, B; Bernier, J; Bleibtreu, A; Chaibi, K; Contejean, A; Cuzon, G; Delory, T; El Alaoui, F; Escaut, L; Joseph, A; Lafaurie, M; Maillard, A; Molina, JM; Paccoud, O; Poupet, H; Robert, J; Surgers, L; Tankovic, J; Villa, A | 1 |
| Armengol de la Hoz, MÁ; Becker, CD; Calvachi-Prieto, P; Celi, LA; Chen, AY; Chen, C; Dagan, A; Deng, CY; Johnson, AEW; Khazi-Syed, A; Scurlock, C | 1 |
| Babicky, ML; Behrman, SW; Bentrem, DJ; Bertens, KA; Brajcich, BC; Celinski, SA; Chan, CHF; Cohen, ME; D'Angelica, MI; Dillhoff, M; Dixon, MEB; Ellis, RJ; Fernandez-Del Castillo, C; Gholami, S; Gönen, M; House, MG; Karanicolas, PJ; Ko, CY; Lavu, H; Liu, JB; Maithel, SK; McAuliffe, JC; Ott, MJ; Pitt, HA; Reames, BN; Sanford, DE; Sarpel, U; Scaife, CL; Seo, SK; Serrano, PE; Smith, T; Snyder, RA; Talamonti, MS; Thompson, VM; Weber, SM; Yopp, AC; Zabor, EC | 1 |
| Cao, SS; Cui, B; Cui, F; Cui, J; Fan, BY; Fan, TT; Guan, Y; Ji, B; Li, MY; Li, SR; Wang, JW; Wang, L; Yan, CY; Zhang, W | 1 |
| Furuya, K; Ito, K; Makio, S; Shimada, T; Sugiyama, K | 1 |
| Guo, G; Liu, Y; Wu, Y; Zeng, J | 1 |
| Cotta, MO; Elhadi, M; Farkas, A; Imani, S; Kanji, S; Luque-Pardos, S; Roberts, JA; Sanches, C; Sandaradura, I; Scheetz, MH; Schellack, N; Tabah, A; Timsit, JF; Wilks, K; Williams, PG; Xie, J | 1 |
| Barreto, EF; Chang, J; Lesnicki, E; Marianski, S; Pais, GM; Scheetz, MH; Valdez, K | 1 |
| Chen, CH; Chen, CM; Chen, WC; Cheng, WC; Fang, WF; Fu, PK; Ku, SC; Kuo, LK; Lai, CC; Tu, CY; Wang, YT | 1 |
| Bahrs, C; Bartonickova, L; Burgmann, H; Hagel, S; Paulussen, E; Pletz, MW; Schneider, L; Starzengruber, P; Tobudic, S | 1 |
| Aral, M; Ates, S; Doganer, A; Nazik, S; Orak, F; Yalcinkaya, KT | 1 |
| Colman, R; De Cock, PA; De Paepe, P; Devreese, M; Dhont, E; Hermans, E; Vande Walle, J; Verougstraete, N; Zeitlinger, M | 1 |
| Cullen, S; Duncan, E; Patel, JB | 1 |
| Diekema, DJ; McAdam, AJ | 1 |
| Andereck, JW; Casey, JD; Dear, ML; Dennis, BM; Han, JH; Lloyd, BD; Marvi, TK; Nelson, GE; Qian, ET; Rice, TW; Seitz, KP; Self, WH; Semler, MW; Shotwell, MS; Siemann, JK; Siew, ED; Stollings, JL; Wang, L; Wrenn, JO; Wright, A; Wright, PW | 1 |
52 review(s) available for piperacillin and piperacillin, tazobactam drug combination
| Article | Year |
|---|---|
Piperacillin/tazobactam: a new beta-lactam/beta-lactamase inhibitor combination.
Topics: Bacterial Infections; beta-Lactamase Inhibitors; Child; Child, Preschool; Clinical Trials as Topic; Drug Therapy, Combination; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Infant; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam | 1995 |
[A combined dosage form of piperacillin and tazobactam--tazocin].
Topics: Bacterial Infections; Drug Therapy, Combination; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Molecular Structure; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 1997 |
Rahnella aquatilis bacteremia in a patient with relapsed acute lymphoblastic leukemia.
Topics: Bacteremia; Bone Marrow Transplantation; Burkitt Lymphoma; Drug Therapy, Combination; Gram-Negative Bacterial Infections; Humans; Immunocompromised Host; Immunosuppressive Agents; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Rahnella | 2001 |
Piperacillin/tazobactam: a pharmacoeconomic review of its use in moderate to severe bacterial infections.
Topics: Bacterial Infections; Cost-Benefit Analysis; Cross Infection; Drug Therapy, Combination; Drug Tolerance; Economics, Pharmaceutical; Hospitalization; Humans; Microbial Sensitivity Tests; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2001 |
Mycotic aneurysm of the descending thoracic aorta caused by Pseudomonas aeruginosa in a solid organ transplant recipient: case report and review.
Topics: Adult; Aneurysm, Infected; Aortic Aneurysm, Thoracic; Aztreonam; Blood Vessel Prosthesis Implantation; Debridement; Drug Therapy, Combination; Humans; Infusions, Parenteral; Male; Organ Transplantation; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas Infections; Secondary Prevention; Treatment Outcome; Vancomycin | 2002 |
The role of beta-lactam antimicrobials as single agents in treatment of intra-abdominal infection.
Topics: Abdomen; Abdominal Abscess; Ampicillin; Anti-Bacterial Agents; Bacterial Infections; beta-Lactamase Inhibitors; Carbapenems; Cephalosporins; Clavulanic Acids; Drug Resistance, Bacterial; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sulbactam; Surgical Wound Infection; Ticarcillin | 2000 |
Safety and tolerability of ertapenem.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacteria, Aerobic; Bacteria, Anaerobic; Bacterial Infections; beta-Lactams; Ceftriaxone; Clinical Trials as Topic; Community-Acquired Infections; Ertapenem; Female; Humans; Lactams; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Randomized Controlled Trials as Topic | 2004 |
The clinical and economic benefits of administering piperacillin-tazobactam by continuous infusion.
Topics: Anti-Bacterial Agents; Clinical Nursing Research; Cost-Benefit Analysis; Drug Administration Schedule; Drug Costs; Drug Monitoring; Economics, Pharmaceutical; Hospital Costs; Humans; Infusions, Intravenous; Nursing Administration Research; Nursing Staff, Hospital; Patient Selection; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Time and Motion Studies; Treatment Outcome; Workload | 2005 |
[Treatment of febrile neutropenia episodes in children, with a piperacillin-tazobactam and netilmicin combination].
Topics: Adolescent; Anti-Bacterial Agents; Antineoplastic Agents; Bacterial Infections; Child; Child, Preschool; Clinical Trials as Topic; Drug Combinations; Drug Evaluation; Escherichia coli Infections; Female; Fever; Fever of Unknown Origin; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Infant; Male; Neoplasms; Netilmicin; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Postoperative Complications; Retrospective Studies; Treatment Outcome; Urinary Tract Infections | 2005 |
A 37-year-old with vomiting and severe, left-sided abdominal pain 3 years after gastric bypass surgery.
Topics: Abdominal Pain; Adult; Analgesics; Anti-Bacterial Agents; Diagnosis, Differential; Emergency Nursing; Emergency Treatment; Female; Fluid Therapy; Gastric Bypass; Humans; Intussusception; Jejunal Diseases; Pain Measurement; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Risk Factors; Tomography, X-Ray Computed; Vomiting | 2006 |
Piperacillin-tazobactam-induced drug hypersensitivity syndrome.
Topics: Adult; Anti-Bacterial Agents; Drug Hypersensitivity; Education, Medical, Continuing; Female; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2006 |
Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Clinical Trials as Topic; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Randomized Controlled Trials as Topic; Soft Tissue Infections | 2007 |
Antibiotic policy and prescribing strategies for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae: the role of piperacillin-tazobactam.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; Enterobacteriaceae; Enterobacteriaceae Infections; Escherichia coli; Klebsiella; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Practice Patterns, Physicians'; Treatment Outcome | 2008 |
[Boerhaave syndrome and pregnancy. A case report and review of the literature].
Topics: Adult; Anti-Bacterial Agents; Chest Pain; Esophageal Perforation; Female; Humans; Parenteral Nutrition; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pregnancy; Pregnancy Complications; Subcutaneous Emphysema; Vomiting | 2009 |
The use of piperacillin-tazobactam in neonatal and paediatric patients.
Topics: Anti-Bacterial Agents; Child; Clinical Trials as Topic; Cross Infection; Humans; Infant, Newborn; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2009 |
[Pharmacological properties and clinical efficacies of tazobactam/piperacillin (Zosyn 2.25, Zosyn 4.5), an injectable antibiotic combined with beta-lactamase inhibitor].
Topics: Adult; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Child; Clinical Trials as Topic; Drug Resistance, Bacterial; Humans; Injections, Intravenous; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2009 |
Pharmacokinetic evaluation of piperacillin-tazobactam.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Drug Administration Schedule; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Treatment Outcome | 2010 |
Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams.
Topics: Anti-Bacterial Agents; beta-Lactams; Cefepime; Ceftazidime; Cephalosporins; Fever; Humans; Imipenem; Meropenem; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Randomized Controlled Trials as Topic; Thienamycins | 2010 |
Acute generalized exanthematous pustulosis simulating toxic epidermal necrolysis: a case report and review of the literature.
Topics: Acute Generalized Exanthematous Pustulosis; Adult; Anti-Bacterial Agents; Anti-Inflammatory Agents; Biopsy; Diagnosis, Differential; Humans; Hydrocortisone; Immunoglobulins, Intravenous; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prognosis; Stevens-Johnson Syndrome; Treatment Outcome | 2011 |
Rationale and evidence for extended infusion of piperacillin-tazobactam.
Topics: Animals; Anti-Bacterial Agents; Humans; Infusions, Intravenous; Length of Stay; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Time Factors | 2011 |
Evaluating outcomes associated with alternative dosing strategies for piperacillin/tazobactam: a qualitative systematic review.
Topics: Anti-Bacterial Agents; Drug Administration Schedule; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Treatment Outcome | 2012 |
Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. cephalosporins and penicillins.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Cefepime; Ceftazidime; Cephalosporins; Clavulanic Acids; Cystic Fibrosis; Disease Progression; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Ticarcillin | 2013 |
Molecular Adsorbent Recirculating System (MARS(®)) removal of piperacillin/tazobactam in a patient with acetaminophen-induced acute liver failure.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Anti-Bacterial Agents; Dose-Response Relationship, Drug; Drug Overdose; Female; Humans; Inactivation, Metabolic; Liver Failure, Acute; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam | 2013 |
Using higher doses to compensate for tubing residuals in extended-infusion piperacillin-tazobactam.
Topics: Animals; Anti-Bacterial Agents; Dose-Response Relationship, Drug; Humans; Infusion Pumps; Infusions, Intravenous; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Time Factors | 2013 |
Liver abscess caused by multidrug-resistant Pseudomonas aeruginosa treated with colistin; a case report and review of the literature.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; Cephalosporins; Cholangitis; Colistin; Drug Resistance, Multiple, Bacterial; Humans; Kidney; Liver Abscess, Pyogenic; Male; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections | 2013 |
Escherichia coli sequence type 131: epidemiology and challenges in treatment.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cephalosporins; Cystitis; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sepsis; United States | 2014 |
Continuous infusion of piperacillin/tazobactam in patients with severe infections: A possible pharmacokinetic optimisation?
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactamase Inhibitors; Drug Costs; Drug Stability; Humans; Infusions, Intravenous; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2014 |
Prolonged vs intermittent infusion of piperacillin/tazobactam in critically ill patients: a narrative and systematic review.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Critical Illness; Female; Humans; Infusions, Intravenous; Length of Stay; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Randomized Controlled Trials as Topic; Retrospective Studies | 2014 |
New antibiotic dosing in infants.
Topics: Ampicillin; Anti-Bacterial Agents; Bacterial Infections; Clindamycin; Humans; Infant; Infant, Newborn; Infant, Premature; Intensive Care Units, Neonatal; Meropenem; Metronidazole; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Practice Guidelines as Topic; Thienamycins | 2015 |
Severe ovarian hyperstimulation syndrome complicated by Stenotrophomonas maltophilia peritonitis: a case report and literature review.
Topics: Adult; Anti-Bacterial Agents; Ceftazidime; Female; Gram-Negative Bacterial Infections; Humans; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Penicillanic Acid; Peritonitis; Piperacillin; Piperacillin, Tazobactam Drug Combination; Stenotrophomonas maltophilia; Treatment Outcome | 2015 |
Multidrug-resistant Pseudomonas aeruginosa endophthalmitis in a silicone oil-filled eye treated with piperacillin/tazobactam: report of a case and review of literature.
Topics: Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Endophthalmitis; Humans; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Postoperative Complications; Pseudomonas aeruginosa; Pseudomonas Infections; Retinal Detachment; Retinal Perforations; Silicone Oils; Visual Acuity; Vitrectomy; Young Adult | 2015 |
Treatment options for extended-spectrum beta-lactamase (ESBL) and AmpC-producing bacteria.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Cefepime; Cephalosporins; Drug Resistance, Bacterial; Drug Therapy, Combination; Enterobacteriaceae; Enterobacteriaceae Infections; Gram-Negative Aerobic Bacteria; Gram-Negative Bacterial Infections; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2016 |
Bloodstream infections in neutropenic cancer patients: A practical update.
Topics: Anti-Bacterial Agents; Bacteremia; Cefepime; Cephalosporins; Disease Management; Drug Resistance, Bacterial; Febrile Neutropenia; Fluoroquinolones; Gram-Negative Bacteria; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pre-Exposure Prophylaxis; Risk Factors | 2016 |
Infections caused by Tissierella praeacuta: A report of two cases and literature review.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacteremia; Bacterial Typing Techniques; Femoral Neck Fractures; Femur; Firmicutes; Humans; Liver Abscess; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Polymerase Chain Reaction; Pseudarthrosis; Pyonephrosis; RNA, Ribosomal, 16S; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Thienamycins; Treatment Outcome | 2016 |
Bile cast nephropathy: A case report and review of the literature.
Topics: Acute Kidney Injury; Adrenal Cortex Hormones; Anion Exchange Resins; Anti-Bacterial Agents; Biopsy; Chemical and Drug Induced Liver Injury, Chronic; Cholagogues and Choleretics; Cholestyramine Resin; Humans; Hyperbilirubinemia; Jaundice, Obstructive; Male; Middle Aged; Osteomyelitis; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Plasmapheresis; Renal Dialysis; Renal Insufficiency, Chronic; Ursodeoxycholic Acid | 2016 |
A possible role of IL-23-producing cells in a patient with psoriasiform drug eruption due to tazobactam and piperacillin hydrate: a case study and literature review.
Topics: Anti-Bacterial Agents; Drug Eruptions; Humans; Interleukin-17; Interleukin-23; Male; Middle Aged; Parakeratosis; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2017 |
Does Piperacillin-Tazobactam Increase the Risk of Nephrotoxicity when Used with Vancomycin: A Meta-Analysis of Observational Trials.
Topics: Anti-Bacterial Agents; Drug Therapy, Combination; Humans; Kidney Diseases; Observational Studies as Topic; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Retrospective Studies; Vancomycin | 2017 |
Is the Combination of Piperacillin-Tazobactam and Vancomycin Associated with Development of Acute Kidney Injury? A Meta-analysis.
Topics: Acute Kidney Injury; Adult; Anti-Bacterial Agents; Drug Therapy, Combination; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Vancomycin | 2016 |
The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; Cefepime; Cephalosporins; Cephamycins; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Treatment Outcome | 2017 |
The Nephrotoxicity of Vancomycin.
Topics: Acute Kidney Injury; Animals; Anti-Bacterial Agents; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Risk Factors; Vancomycin | 2017 |
Clinical efficacy of piperacillin/tazobactam in the treatment of complicated skin and soft tissue infections.
Topics: Anti-Bacterial Agents; Drug Therapy, Combination; Fluoroquinolones; Humans; Moxifloxacin; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Randomized Controlled Trials as Topic; Skin Diseases, Bacterial; Soft Tissue Infections; Treatment Outcome | 2017 |
Drug-induced kidney disease in the ICU: mechanisms, susceptibility, diagnosis and management strategies.
Topics: Acute Kidney Injury; Critical Illness; Disease Susceptibility; Drug Therapy, Combination; Humans; Intensive Care Units; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Practice Guidelines as Topic; Renal Replacement Therapy; Risk Factors; Vancomycin | 2017 |
Lemierre's syndrome variant of the gut.
Topics: Abdominal Pain; Anti-Bacterial Agents; Anticoagulants; beta-Lactams; Endoscopy, Gastrointestinal; Ertapenem; Fever; Fusobacterium Infections; Fusobacterium necrophorum; Heparin; Humans; Lemierre Syndrome; Male; Penicillanic Acid; Phlebitis; Piperacillin; Piperacillin, Tazobactam Drug Combination; Portal Vein; Treatment Outcome | 2017 |
Vancomycin Plus Piperacillin-Tazobactam and Acute Kidney Injury in Adults: A Systematic Review and Meta-Analysis.
Topics: Acute Kidney Injury; Adult; Critical Care; Drug Therapy, Combination; Humans; Observational Studies as Topic; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Randomized Controlled Trials as Topic; Vancomycin | 2018 |
Rapid onset severe thrombocytopenia following reexposure to piperacillin-tazobactam: report of two cases and review of the literature.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Humans; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Thrombocytopenia | 2018 |
Generalized fixed drug eruption to piperacillin/tazobactam and review of literature.
Topics: Adult; Anti-Bacterial Agents; Anti-Inflammatory Agents; Drug Eruptions; Humans; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Triamcinolone | 2018 |
Antibiotic-induced black hairy tongue: two case reports and a review of the literature.
Topics: Adolescent; Aged; Anti-Bacterial Agents; Female; Humans; Linezolid; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tongue, Hairy | 2020 |
Comparative Prevalence of Acute Kidney Injury in Chinese Patients Receiving Vancomycin with Concurrent β-Lactam Antibiotics: A Retrospective Cohort Study.
Topics: Acute Kidney Injury; Adult; Anti-Bacterial Agents; Bayes Theorem; Cohort Studies; Drug Therapy, Combination; Humans; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prevalence; Retrospective Studies; Vancomycin | 2021 |
Pharmacokinetics of piperacillin and tazobactam in critically Ill patients treated with continuous kidney replacement therapy: A mini-review and population pharmacokinetic analysis.
Topics: Anti-Bacterial Agents; Critical Illness; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Renal Replacement Therapy; Tazobactam | 2022 |
Comparison of Duration and Empiric Antibiotic Choice of Post-Operative Treatment in Abdominal Sepsis.
Topics: Anti-Bacterial Agents; Carbapenems; Humans; Intraabdominal Infections; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Sepsis | 2022 |
A Meta-Analysis on Clinical Outcomes of Ceftolozane versus Piperacillin in Combination with Tazobactam in Patients with Complicated Urinary Tract Infections.
Topics: Anti-Bacterial Agents; Cephalosporins; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pyelonephritis; Tazobactam; Urinary Tract Infections | 2022 |
Piperacillin-tazobactam induced immune hemolytic anemia led to increased renal impairment and eventual death from multiple organ failure in a patient with hypertensive nephropathy: case report and literature review.
Topics: Aged; Anemia, Hemolytic; Humans; Male; Multiple Organ Failure; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2023 |
109 trial(s) available for piperacillin and piperacillin, tazobactam drug combination
| Article | Year |
|---|---|
Piperacillin/tazobactam in comparison with clindamycin plus gentamicin in the treatment of intra-abdominal infections.
Topics: Abdomen; Bacterial Infections; Clindamycin; Drug Therapy, Combination; Female; Gentamicins; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 1995 |
Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment
Topics: Adolescent; Adult; Aged; Agranulocytosis; Amikacin; Ceftazidime; Child; Child, Preschool; Drug Therapy, Combination; Female; Fever; Humans; Infant; Male; Middle Aged; Neoplasms; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies | 1995 |
Piperacillin/tazobactam in the treatment of lower respiratory tract infections: an open non-comparative and multicentered trial. Latin American Clinical Research Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Drug Therapy, Combination; Female; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Respiratory Tract Infections | 1994 |
[Piperacillin/tazobactam in the treatment of abdominal sepsis in patients with peritonitis].
Topics: Abdominal Abscess; Adult; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Penicillanic Acid; Peritonitis; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sepsis | 1997 |
[Clinico-laboratory study of piperacillin/tazobactam in the treatment of patients with would infection].
Topics: Adolescent; Adult; Aged; beta-Lactamase Inhibitors; Drug Therapy, Combination; Female; Humans; Laboratories; Male; Microbial Sensitivity Tests; Middle Aged; Necrosis; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Recurrence; Soft Tissue Infections; Wound Infection | 1997 |
[Use of piperacillin/tazobactam as empirical monotherapy in the treatment of bacterial infections in a resuscitation department].
Topics: Adult; Bacterial Infections; Drug Therapy, Combination; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Hospital Departments; Humans; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Resuscitation; Treatment Outcome | 1997 |
[Effect of piperacillin/tazobactam on the anti-infection resistance in patients with infections in the peritoneal cavity].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Drug Therapy, Combination; Humans; Immunity, Innate; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Peritoneal Diseases; Piperacillin; Piperacillin, Tazobactam Drug Combination | 1997 |
Piperacillin-tazobactam as empiric monotherapy in febrile neutropenic patients with haematological malignancies.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; beta-Lactamase Inhibitors; Drug Combinations; Drug Therapy, Combination; Enzyme Inhibitors; Female; Fever; Gram-Negative Bacteria; Gram-Positive Bacteria; Hematologic Neoplasms; Humans; Male; Middle Aged; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Treatment Outcome | 1997 |
Treatment of ventilator-associated pneumonia with piperacillin-tazobactam/amikacin versus ceftazidime/amikacin: a multicenter, randomized controlled trial. VAP Study Group.
Topics: Amikacin; Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Consumer Product Safety; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Population; Treatment Failure; Ventilators, Mechanical | 1998 |
[Clinical studies of tazobactam/piperacillin (TAZ/PIPC) in pediatric patients].
Topics: Adolescent; Bacteria; Bacterial Infections; Child; Child, Preschool; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Humans; Infant; Infant, Newborn; Infusions, Intravenous; Injections, Intravenous; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 1998 |
[Clinical studies on tazobactam/piperacillin (YP-14) in the pediatric field].
Topics: Acute Disease; Bacteria; Child; Child, Preschool; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Humans; Infant; Infusions, Intravenous; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia; Pyelonephritis; Tonsillitis | 1998 |
[Pharmacokinetic and clinical evaluation of tazobactam/piperacillin in the pediatric field].
Topics: Bacteria; Bacterial Infections; Child; Child, Preschool; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Humans; Infant; Infusions, Intravenous; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 1998 |
[Pharmacokinetic, bacteriological and clinical evaluation of tazobactam/piperacillin in pediatrics].
Topics: Bacterial Infections; Child; Child, Preschool; Drug Therapy, Combination; Female; Humans; Infant; Infusions, Intravenous; Injections, Intravenous; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 1998 |
Efficacy, safety, and tolerance of piperacillin/tazobactam compared to co-amoxiclav plus an aminoglycoside in the treatment of severe pneumonia.
Topics: Aged; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Community-Acquired Infections; Cross Infection; Drug Therapy, Combination; Female; Gentamicins; Humans; Male; Middle Aged; Netilmicin; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Treatment Outcome | 1998 |
[Laboratory and clinical studies on tazobactam/piperacillin in the field of pediatrics].
Topics: Bacterial Infections; beta-Lactamase Inhibitors; Child, Preschool; Drug Therapy, Combination; Escherichia coli; Female; Haemophilus; Haemophilus influenzae; Humans; Infant; Male; Penicillanic Acid; Penicillin Resistance; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Staphylococcus aureus; Streptococcus pneumoniae; Urinary Tract Infections | 1998 |
[Fundamental and clinical studies on tazobactam/piperacillin in the pediatric field].
Topics: Bacterial Infections; beta-Lactamase Inhibitors; Child; Drug Therapy, Combination; Female; Humans; Infant; Male; Penicillanic Acid; Pharyngitis; Piperacillin; Piperacillin, Tazobactam Drug Combination; Respiratory Tract Infections; Staphylococcus aureus; Tonsillitis; Whooping Cough | 1998 |
[Basic and clinical studies on tazobactam/piperacillin in pediatric field].
Topics: Acute Disease; Bacterial Infections; beta-Lactamase Inhibitors; Bordetella pertussis; Bronchitis; Child; Child, Preschool; Drug Therapy, Combination; Female; Haemophilus influenzae; Humans; Infant; Lymphadenitis; Male; Otitis Media, Suppurative; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Staphylococcus aureus; Streptococcus agalactiae; Streptococcus pneumoniae; Streptococcus pyogenes; Urinary Tract Infections; Whooping Cough | 1998 |
Comparison of intravenous/oral ciprofloxacin plus metronidazole versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections.
Topics: Abdomen; Abdominal Abscess; Administration, Oral; Anti-Infective Agents; Appendicitis; Bacterial Infections; Ciprofloxacin; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Injections, Intravenous; Male; Metronidazole; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies | 2000 |
Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial.
Topics: Aged; Amikacin; Ceftazidime; Cephalosporins; Critical Care; Cross Infection; Drug Therapy, Combination; Female; Hospital Mortality; Hospitals, Teaching; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Proportional Hazards Models; Prospective Studies; Spain; Survival Analysis; Treatment Outcome | 2001 |
[Comparative study of piperacillin/tazobactam versus imipenem/cilastatin in febrile neutropenia (1994-1996)].
Topics: Adolescent; Adult; Aged; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Drug Therapy, Combination; Female; Fever; Humans; Imipenem; Male; Middle Aged; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2001 |
Pharmacokinetic and pharmacodynamic profile of high dose extended interval piperacillin-tazobactam.
Topics: Adult; Area Under Curve; Cross-Over Studies; Drug Therapy, Combination; Female; Humans; Male; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2001 |
A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia.
Topics: Adolescent; Adult; Aged; Amikacin; Anti-Bacterial Agents; Bacterial Infections; Double-Blind Method; Drug Therapy, Combination; Female; Fever; Humans; Male; Middle Aged; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Treatment Outcome | 2001 |
[Comparison of 2 administration protocols (continuous or discontinuous) of a time-dependent antibiotic, Tazocin].
Topics: Adolescent; Adult; Aged; Area Under Curve; Bacteria, Anaerobic; Bacterial Infections; Drug Administration Schedule; Drug Therapy, Combination; Enterobacteriaceae Infections; Female; Gram-Positive Bacterial Infections; Humans; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2001 |
Clinafloxacin versus piperacillin/tazobactam in the treatment of severe skin and soft-tissue infections in adults at a Veterans Affairs medical center.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Dermatitis, Phototoxic; Double-Blind Method; Drug Therapy, Combination; Female; Fluoroquinolones; Hospitals, Veterans; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Skin Diseases, Infectious; Soft Tissue Infections; United States | 2002 |
Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital.
Topics: Aged; Aged, 80 and over; Bacterial Infections; Chi-Square Distribution; Drug Therapy, Combination; Female; Hospitals, Community; Hospitals, Teaching; Humans; Infusions, Intravenous; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Statistics, Nonparametric | 2002 |
Comparative pharmacokinetic and pharmacodynamic profile of piperacillin/tazobactam 3.375G Q4H and 4.5G Q6H.
Topics: Adult; Area Under Curve; Chromatography, High Pressure Liquid; Cross-Over Studies; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections | 2002 |
Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial.
Topics: Abdominal Abscess; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Digestive System Surgical Procedures; Double-Blind Method; Drug Therapy, Combination; Ertapenem; Female; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Hospitalization; Humans; Lactams; Male; Middle Aged; Penicillanic Acid; Peritonitis; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Research Design; Treatment Outcome | 2003 |
Ertapenem versus piperacillin-tazobactam for treatment of mixed anaerobic complicated intra-abdominal, complicated skin and skin structure, and acute pelvic infections.
Topics: Abdomen; Adult; Aged; Anti-Bacterial Agents; Bacteria, Anaerobic; Bacterial Infections; beta-Lactams; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ertapenem; Female; Humans; Lactams; Male; Middle Aged; Pelvic Infection; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Skin Diseases, Bacterial; Surgical Wound Infection | 2002 |
Surgical infections with enterococcus: outcome in patients treated with ertapenem versus piperacillin-tazobactam.
Topics: Abdomen; Adolescent; Adult; Aged; Anti-Bacterial Agents; beta-Lactams; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Enterococcus; Ertapenem; Female; Gram-Positive Bacterial Infections; Humans; Lactams; Male; Middle Aged; Pelvic Infection; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Skin Diseases, Bacterial; Surgical Wound Infection; Treatment Outcome | 2002 |
Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Double-Blind Method; Fever; Humans; Middle Aged; Neoplasms; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Treatment Outcome; Vancomycin | 2003 |
Piperacillin-tazobactam versus ciprofloxacin plus amoxicillin in the treatment of infective episodes after liver transplantation.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Double-Blind Method; Drug Therapy, Combination; Enterobacteriaceae; Female; Fever; Humans; Liver Transplantation; Male; Metronidazole; Middle Aged; Penicillanic Acid; Penicillins; Piperacillin; Piperacillin, Tazobactam Drug Combination; Postoperative Complications; Prospective Studies; Staphylococcus aureus | 2003 |
[Randomized, prospective and comparative clinical trial of piperacillin/tazobactam versus ceftriaxone plus ornidazole in the treatment of biliary tract infections].
Topics: Aged; Anti-Bacterial Agents; Bile Duct Diseases; Ceftriaxone; Female; Humans; Infections; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies | 2003 |
Management of complicated appendicitis and comparison of outcome with other primary sites of intra-abdominal infection: results of a trial comparing ertapenem and piperacillin-tazobactam.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anti-Bacterial Agents; Appendicitis; Bacterial Infections; beta-Lactams; Colonic Diseases; Demography; Double-Blind Method; Ertapenem; Female; Humans; Lactams; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Risk Factors; Severity of Illness Index | 2004 |
Treatment of polymicrobial infections: post hoc analysis of three trials comparing ertapenem and piperacillin-tazobactam.
Topics: Abdomen; Adolescent; Adult; Anti-Bacterial Agents; Bacteria, Aerobic; Bacteria, Anaerobic; Bacterial Infections; beta-Lactams; Double-Blind Method; Ertapenem; Female; Humans; Lactams; Male; Pelvic Infection; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Skin Diseases, Bacterial; Treatment Outcome | 2004 |
Efficacy of ertapenem against methicillin-susceptible Staphylococcus aureus in complicated skin/skin structure infections: results of a double-blind clinical trial versus piperacillin-tazobactam.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Double-Blind Method; Ertapenem; Female; Humans; Lactams; Male; Methicillin Resistance; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Skin Diseases, Bacterial; Staphylococcal Infections; Staphylococcus aureus | 2004 |
Efficacy of piperacillin-tazobactam in the treatment of surgical wound infection after clean-contaminated head and neck oncologic surgery.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Female; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Head and Neck Neoplasms; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Surgical Wound Infection; Treatment Outcome | 2004 |
Randomized comparison of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of patients with intra-abdominal infection.
Topics: Abdominal Abscess; Adult; Anti-Bacterial Agents; Cilastatin; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Imipenem; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam | 2004 |
A randomized clinical trial of ceftriaxone and amikacin versus piperacillin tazobactam and amikacin in febrile patients with hematological neoplasia and severe neutropenia.
Topics: Adult; Aged; Amikacin; Anti-Bacterial Agents; Ceftriaxone; Drug Therapy, Combination; Female; Fever; Hematologic Neoplasms; Humans; Male; Middle Aged; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Treatment Outcome | 2005 |
Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion.
Topics: Adult; Aged; Anti-Bacterial Agents; Cholangitis; Community-Acquired Infections; Cross Infection; Drug Administration Schedule; Female; Fever of Unknown Origin; Hospitalization; Humans; Infections; Infusions, Intravenous; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia; Prospective Studies; Treatment Outcome; Urinary Tract Infections | 2005 |
An open-label, randomized study comparing efficacy and safety of intravenous piperacillin/tazobactam and ampicillin/sulbactam for infected diabetic foot ulcers.
Topics: Ampicillin; Anti-Bacterial Agents; Bacterial Infections; Diabetic Foot; Female; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Sulbactam; Time Factors; Vancomycin; Wound Infection | 2005 |
Piperacillin-sulbactam versus piperacillin-tazobactam: a multicentre, randomised, single-blind, controlled clinical trial.
Topics: Adult; Anti-Bacterial Agents; Drug Combinations; Female; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Respiratory Tract Infections; Single-Blind Method; Sulbactam; Urinary Tract Infections | 2005 |
Prophylaxis of early bacterial infections after autologous peripheral blood stem cell transplantation (PBSCT): a matched-pair study comparing oral fluoroquinolones and intravenous piperacillin-tazobactam.
Topics: Adolescent; Adult; Aged; Amphotericin B; Bacteremia; Bacterial Infections; Female; Fever; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Male; Matched-Pair Analysis; Middle Aged; Neutropenia; Penicillanic Acid; Peripheral Blood Stem Cell Transplantation; Piperacillin; Piperacillin, Tazobactam Drug Combination; Premedication; Transplantation, Autologous | 2005 |
Bowel colonization with resistant gram-negative bacilli after antimicrobial therapy of intra-abdominal infections: observations from two randomized comparative clinical trials of ertapenem therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Carrier State; Ceftriaxone; Digestive System Surgical Procedures; Drug Resistance, Bacterial; Drug Therapy, Combination; Ertapenem; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Intestines; Lactams; Male; Metronidazole; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2005 |
Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intraabdominal infections.
Topics: Abdominal Abscess; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Double-Blind Method; Drug Resistance, Bacterial; Drug Therapy, Combination; Enterobacteriaceae; Ertapenem; Female; Humans; Lactams; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Rectum; Treatment Outcome | 2005 |
Sequential intravenous/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Aza Compounds; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Tolerance; Female; Fluoroquinolones; Humans; Injections, Intravenous; Male; Middle Aged; Moxifloxacin; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Quinolines; Safety; Skin Diseases, Bacterial | 2005 |
Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial.
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactams; Diabetic Foot; Double-Blind Method; Drug Administration Schedule; Ertapenem; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Severity of Illness Index; Treatment Outcome | 2005 |
Management of diabetic foot in a Jordanian hospital.
Topics: Amikacin; Amputation, Surgical; Anti-Bacterial Agents; Ceftazidime; Chemotherapy, Adjuvant; Debridement; Diabetic Foot; Drug Combinations; Drug Monitoring; Humans; Imipenem; Kidney Diseases; Length of Stay; Lincomycin; Metronidazole; Patient Selection; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sepsis; Severity of Illness Index; Treatment Outcome; Wound Healing; Wound Infection | 2005 |
Efficacy and safety of ertapenem versus piperacillin-tazobactam for the treatment of intra-abdominal infections requiring surgical intervention.
Topics: Abdomen; Abscess; Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Anti-Bacterial Agents; Bacterial Infections; Bacteroides fragilis; Bacteroides Infections; beta-Lactams; Diarrhea; Ertapenem; Escherichia coli Infections; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Penicillanic Acid; Peritonitis; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Treatment Outcome | 2006 |
[Controlled, open, parallel-group study of the clinical and microbiological efficacy of piperacillin-tazobactam versus metronidazole + gentamicin in urgent colorectal surgery].
Topics: Acute Disease; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Appendicitis; Drug Administration Schedule; Drug Therapy, Combination; Emergency Treatment; Female; Humans; Male; Metronidazole; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Surgical Wound Infection | 2006 |
A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cefepime; Cephalosporins; Female; Fever; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Male; Middle Aged; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Treatment Outcome | 2006 |
Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections.
Topics: Abdominal Abscess; Administration, Oral; Adult; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Appendicitis; Aza Compounds; Bacterial Infections; Cross Infection; Double-Blind Method; Female; Fluoroquinolones; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Injections, Intravenous; Intestinal Perforation; Male; Middle Aged; Moxifloxacin; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Quinolines; Safety; Stomach Rupture; Treatment Outcome | 2006 |
Antibiotic prophylaxis in hernia repair and breast surgery: a prospective randomized study comparing piperacillin/tazobactam versus placebo.
Topics: Age Factors; Anti-Bacterial Agents; Antibiotic Prophylaxis; Breast Neoplasms; Double-Blind Method; Drainage; Female; Herniorrhaphy; Humans; In Vitro Techniques; Lymph Node Excision; Male; Mastectomy; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Sex Factors; Surgical Wound Infection; Time Factors | 2006 |
Early discharge of hospitalised patients with community-acquired urosepsis when treated with levofloxacin in sequential therapy.
Topics: Anti-Bacterial Agents; Anti-Infective Agents, Urinary; Community-Acquired Infections; Drug Administration Schedule; Female; Hospitalization; Humans; Length of Stay; Levofloxacin; Male; Middle Aged; Ofloxacin; Patient Discharge; Penicillanic Acid; Pilot Projects; Piperacillin; Piperacillin, Tazobactam Drug Combination; Urinary Tract Infections | 2006 |
Randomized, multicenter, double-blind study of efficacy, safety, and tolerability of intravenous ertapenem versus piperacillin/tazobactam in treatment of complicated intra-abdominal infections in hospitalized adults.
Topics: Abdominal Abscess; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; APACHE; Bacterial Infections; Bacteroides; beta-Lactams; Double-Blind Method; Ertapenem; Escherichia coli; Female; Humans; Male; Middle Aged; Penicillanic Acid; Peritonitis; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2007 |
Piperacillin-tazobactam plus amikacin as an initial empirical therapy of febrile neutropenia in paediatric cancer patients.
Topics: Adolescent; Adult; Amikacin; Anti-Bacterial Agents; Bacterial Infections; Child; Child, Preschool; Drug Therapy, Combination; Female; Humans; Infant; Male; Neoplasms; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2008 |
Piperacillin/tazobactam plus amikacin versus carbapenem monotherapy as empirical treatment of febrile neutropenia in childhood hematological malignancies.
Topics: Adolescent; Amikacin; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Carbapenems; Child; Child, Preschool; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Leukemia, Myeloid, Acute; Male; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2008 |
Pharmacoeconomics of ciprofloxacin plus metronidazole vs. piperacillin-tazobactam for complicated intra-abdominal infections.
Topics: Abdominal Abscess; Adult; Aged; Anti-Bacterial Agents; Appendicitis; Ciprofloxacin; Cost-Benefit Analysis; Double-Blind Method; Drug Therapy, Combination; Economics, Pharmaceutical; Female; Humans; Male; Metronidazole; Middle Aged; Penicillanic Acid; Peritonitis; Piperacillin; Piperacillin, Tazobactam Drug Combination; Treatment Outcome | 2008 |
A prospective, randomized study comparing cefozopran with piperacillin-tazobactam plus ceftazidime as empirical therapy for febrile neutropenia in children with hematological disorders.
Topics: Adolescent; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cefozopran; Ceftazidime; Cephalosporins; Child; Child, Preschool; Drug Therapy, Combination; Female; Hematologic Neoplasms; Humans; Infant; Infant, Newborn; Male; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prognosis; Prospective Studies; Survival Rate | 2008 |
Clinical cure of ventilator-associated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion.
Topics: Aged; Anti-Bacterial Agents; Bacteria; Cohort Studies; Female; Humans; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Treatment Outcome | 2009 |
Piperacillin/tazobactam plus ceftazidime versus sulbactam/ampicillin plus aztreonam as empirical therapy for fever in severely neutropenic pediatric patients.
Topics: Adolescent; Ampicillin; Anti-Bacterial Agents; Aztreonam; beta-Lactams; Ceftazidime; Child; Child, Preschool; Drug Therapy, Combination; Female; Fever; Humans; Infant; Infant, Newborn; Male; Neoplasms; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Severity of Illness Index; Sulbactam | 2009 |
Lack of pharmacokinetic drug interactions following concomitant administration of telavancin with aztreonam or piperacillin/tazobactam in healthy participants.
Topics: Adolescent; Adult; Aminoglycosides; Anti-Bacterial Agents; Aztreonam; Drug Interactions; Drug Therapy, Combination; Dysgeusia; Female; Humans; Lipoglycopeptides; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2009 |
Piperacillin/tazobactam versus cefepime for the empirical treatment of pediatric cancer patients with neutropenia and fever: a randomized and open-label study.
Topics: Adolescent; Anti-Bacterial Agents; Cefepime; Cephalosporins; Child; Child, Preschool; Female; Fever; Humans; Infant; Male; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies | 2009 |
Imipenem-cilastatin versus piperacillin-tazobactam as monotherapy in febrile neutropenia.
Topics: Adolescent; Anti-Bacterial Agents; Bacterial Infections; Child; Child, Preschool; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Female; Fever; Humans; Imipenem; Male; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies | 2010 |
Piperacillin/tazobactam versus imipenem/cilastatin for severe diabetic foot infections: a prospective, randomized clinical trial in a university hospital.
Topics: Adult; Aged; Aged, 80 and over; Amputation, Surgical; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Cilastatin; Cilastatin, Imipenem Drug Combination; Diabetic Foot; Drug Combinations; Female; Hospitals, University; Humans; Imipenem; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Recurrence; Time Factors; Treatment Outcome | 2010 |
Low-dose beta-lactam plus amikacin in febrile neutropenia: cefepime vs. piperacillin/tazobactam, a randomized trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Cefepime; Cephalosporins; Female; Fever of Unknown Origin; Humans; Incidence; Male; Middle Aged; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Poisoning; Prospective Studies; Treatment Outcome; Young Adult | 2010 |
Piperacillin-tazobactam versus carbapenem therapy with and without amikacin as empirical treatment of febrile neutropenia in cancer patients: results of an open randomized trial at a university hospital.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Antineoplastic Agents; Bacterial Infections; Carbapenems; Drug Eruptions; Drug Therapy, Combination; Female; Fever; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasms; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Survival Rate; Young Adult | 2010 |
Piperacillin/tazobactam versus cefozopran for the empirical treatment of pediatric cancer patients with febrile neutropenia.
Topics: Adolescent; Anti-Bacterial Agents; Bacterial Infections; Cefozopran; Cephalosporins; Child; Child, Preschool; Female; Fever; Humans; Male; Neoplasms; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2011 |
Comparison of piperacillin tazobactam and cefoperazone sulbactam monotherapy in treatment of febrile neutropenia.
Topics: Adolescent; Anti-Bacterial Agents; Cefoperazone; Child; Child, Preschool; Female; Fever; Humans; Infant; Male; Neoplasms; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sulbactam; Time Factors | 2012 |
Microbiological equivalence of bacteriostatic and bactericidal activities of the sera from healthy volunteers receiving generic piperacillin/tazobactam (Pipertaz) and original piperacillin/tazobactam (Tazocin).
Topics: Adolescent; Adult; Anti-Bacterial Agents; Bacteria; Cross-Over Studies; Drug Therapy, Combination; Drugs, Generic; Female; Humans; Inhibitory Concentration 50; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Serum Bactericidal Test; Thailand; Therapeutic Equivalency; Young Adult | 2011 |
A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Aza Compounds; Double-Blind Method; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Quinolines; Skin; Skin Diseases, Bacterial | 2011 |
[Efficacy and safety of piperacillin-tazobactam for febrile neutropenic patients in Japan].
Topics: Anti-Bacterial Agents; Female; Fever; Hematologic Neoplasms; Humans; Japan; Male; Middle Aged; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Treatment Outcome | 2012 |
Clinical and microbiological results following nonsurgical periodontal therapy with or without local administration of piperacillin/tazobactam.
Topics: Anti-Bacterial Agents; Chronic Periodontitis; Combined Modality Therapy; Debridement; Female; Gingival Hemorrhage; Humans; Male; Middle Aged; Penicillanic Acid; Periodontal Pocket; Piperacillin; Piperacillin, Tazobactam Drug Combination; Treatment Outcome | 2013 |
Prolonged infusion antibiotics for suspected gram-negative infections in the ICU: a before-after study.
Topics: Aged; Anti-Bacterial Agents; beta-Lactams; Cefepime; Cephalosporins; Cohort Studies; Cross Infection; Drug Administration Schedule; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitals, Teaching; Hospitals, Urban; Humans; Infusions, Intravenous; Intensive Care Units; Length of Stay; Male; Meropenem; Middle Aged; Missouri; Penicillanic Acid; Pilot Projects; Piperacillin; Piperacillin, Tazobactam Drug Combination; Thienamycins | 2013 |
Prospective randomized comparison study of piperacillin/tazobactam and meropenem for healthcare-associated pneumonia in Japan.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Cross Infection; Female; Humans; Japan; Male; Meropenem; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Prospective Studies; Statistics, Nonparametric; Thienamycins; Treatment Outcome | 2013 |
Population pharmacokinetics of piperacillin/tazobactam in neonates and young infants.
Topics: Age Factors; Anti-Bacterial Agents; Body Weight; China; Computer Simulation; Drug Dosage Calculations; Drug Monitoring; Female; Humans; Infant; Infant, Newborn; Intensive Care Units, Neonatal; Male; Models, Biological; Nonlinear Dynamics; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2013 |
Antibiotic rotation for febrile neutropenic patients with hematological malignancies: clinical significance of antibiotic heterogeneity.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactam Resistance; Cefepime; Cephalosporins; Ciprofloxacin; Drug Administration Schedule; Female; Fever; Gram-Negative Bacterial Infections; Hematologic Neoplasms; Humans; Male; Meropenem; Middle Aged; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Thienamycins | 2013 |
Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations.
Topics: Adult; Anti-Bacterial Agents; Cystic Fibrosis; Female; Humans; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Serum; Time Factors; Treatment Outcome; Young Adult | 2014 |
Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Critical Illness; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Renal Replacement Therapy; Serum; Young Adult | 2014 |
[Treatment study of hospital acquired pneumonia by optimizing dosing regimen of piperacillin/tazobactam:prolonged vs. regular infusion].
Topics: Aged; Anti-Bacterial Agents; Cross Infection; Drug Administration Schedule; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Prospective Studies | 2013 |
Temocillin and piperacillin/tazobactam resistance by disc diffusion as antimicrobial surrogate markers for the detection of carbapenemase-producing Enterobacteriaceae in geographical areas with a high prevalence of OXA-48 producers.
Topics: Bacterial Proteins; Belgium; beta-Lactamases; Biomarkers; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; France; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prevalence | 2014 |
Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial.
Topics: beta-Lactamase Inhibitors; Creatine; Critical Illness; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Male; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Thienamycins | 2014 |
Do proinflammatory cytokine levels predict serious complication risk of infection in pediatric cancer patients?
Topics: Adolescent; Anti-Bacterial Agents; Bacterial Infections; Child; Child, Preschool; Cytokines; Female; Fever; Humans; Infant; Inflammation Mediators; Male; Neoplasms; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Predictive Value of Tests; Risk Factors | 2014 |
Prophylactic first-line antibiotics reduce infectious fever and shorten hospital stay during chemotherapy-induced agranulocytosis in childhood acute myeloid leukemia.
Topics: Adolescent; Agranulocytosis; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Cefepime; Cephalosporins; Child; Child, Preschool; Female; Fever; Humans; Infection Control; Length of Stay; Leukemia, Myeloid, Acute; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Vancomycin | 2014 |
Monotherapy with amikacin or piperacillin-tazobactum empirically in neonates at risk for early-onset sepsis: a randomized controlled trial.
Topics: Amikacin; Anti-Bacterial Agents; Bacterial Infections; Drug Therapy, Combination; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; India; Infant, Newborn; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Risk Factors; Sepsis; Treatment Outcome | 2014 |
Febrile neutropenia: median door-to-needle time - results of an initial audit.
Topics: Adolescent; Adult; Aged; Amikacin; Anti-Bacterial Agents; Chemotherapy-Induced Febrile Neutropenia; Female; Hematologic Neoplasms; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Young Adult | 2015 |
Results of a multicenter, controlled, randomized clinical trial evaluating the combination of piperacillin/tazobactam and tigecycline in high-risk hematologic patients with cancer with febrile neutropenia.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antineoplastic Agents; Bacteremia; Chemotherapy-Induced Febrile Neutropenia; Drug Combinations; Female; Hematologic Neoplasms; Humans; Male; Middle Aged; Minocycline; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Risk Factors; Tigecycline; Young Adult | 2014 |
Role of prophylactic antibiotics in neonates born through meconium-stained amniotic fluid (MSAF)--a randomized controlled trial.
Topics: Amikacin; Amniotic Fluid; Anti-Bacterial Agents; Antibiotic Prophylaxis; Double-Blind Method; Female; Humans; Infant, Newborn; Infusions, Intravenous; Male; Meconium; Meconium Aspiration Syndrome; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pregnancy; Prospective Studies; Sepsis | 2015 |
Comparison between piperacillin/tazobactam and cefepime monotherapies as an empirical therapy for febrile neutropenia in children with hematological and malignant disorders: A prospective, randomized study.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Bacterial Infections; Cefepime; Cephalosporins; Child; Child, Preschool; Febrile Neutropenia; Female; Hematologic Neoplasms; Humans; Infant; Infant, Newborn; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Young Adult | 2015 |
Population pharmacokinetics of the piperacillin component of piperacillin/tazobactam in pediatric oncology patients with fever and neutropenia.
Topics: Anti-Bacterial Agents; Child; Child, Preschool; Female; Fever; Humans; Male; Models, Biological; Neoplasms; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections | 2015 |
Invasive Candida infections and the harm from antibacterial drugs in critically ill patients: data from a randomized, controlled trial to determine the role of ciprofloxacin, piperacillin-tazobactam, meropenem, and cefuroxime.
Topics: Age Factors; Aged; Anti-Bacterial Agents; APACHE; Candidiasis, Invasive; Cefuroxime; Ciprofloxacin; Critical Illness; Denmark; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Intensive Care Units; Male; Meropenem; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Single-Blind Method; Thienamycins | 2015 |
Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial.
Topics: Adult; Anti-Bacterial Agents; Bacteremia; Ceftriaxone; Clinical Protocols; Drug Resistance, Microbial; Escherichia coli Infections; Humans; Klebsiella Infections; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sample Size; Thienamycins | 2015 |
Can therapeutic drug monitoring optimize exposure to piperacillin in febrile neutropenic patients with haematological malignancies? A randomized controlled trial.
Topics: Anti-Bacterial Agents; Drug Monitoring; Female; Fever of Unknown Origin; Hematologic Neoplasms; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Neutropenia; New Zealand; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Time Factors; Treatment Outcome | 2015 |
Continuous versus intermittent piperacillin/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Load; Cross Infection; Double-Blind Method; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Remission Induction; Spain; Time Factors; Treatment Outcome; Young Adult | 2016 |
A clinical evaluation of efficacy and safety of cefepime monotherapy versus piperacillin-tazobactam in patients of paediatric age group with febrile neutropenia in a tertiary care centre of north India.
Topics: Adolescent; Anti-Bacterial Agents; Bacterial Infections; Cefepime; Cephalosporins; Child; Child, Preschool; Drug Therapy, Combination; Febrile Neutropenia; Female; Fever; Humans; India; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Tertiary Care Centers; Treatment Outcome | 2016 |
Piperacillin-tazobactam vs. imipenem-cilastatin as empirical therapy in hematopoietic stem cell transplantation recipients with febrile neutropenia.
Topics: Adult; Anti-Bacterial Agents; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Febrile Neutropenia; Female; Follow-Up Studies; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Imipenem; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prognosis; Risk Factors | 2016 |
A comparison of the efficacy of piperacillin-tazobactam and cefoperazone-sulbactam therapies in the empirical treatment of patients with febrile neutropenia.
Topics: Adult; Aged; Antineoplastic Agents; Cefoperazone; Drug Combinations; Drug Eruptions; Febrile Neutropenia; Female; Hematologic Neoplasms; Humans; Leukocyte Count; Male; Middle Aged; Neutrophils; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Sulbactam; Treatment Outcome; Young Adult | 2016 |
Ertapenem versus piperacillin/tazobactam for diabetic foot infections in China: a Phase 3, multicentre, randomized, double-blind, active-controlled, non-inferiority trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; beta-Lactamase Inhibitors; beta-Lactams; China; Diabetic Foot; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Ertapenem; Female; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Treatment Outcome; Young Adult | 2016 |
Clinical outcomes of extended versus intermittent administration of piperacillin/tazobactam for the treatment of hospital-acquired pneumonia: a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamase Inhibitors; China; Chromatography, High Pressure Liquid; Costs and Cost Analysis; Critical Illness; Cross Infection; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Plasma; Pneumonia, Bacterial; Treatment Outcome; Young Adult | 2017 |
A prospective randomized trial comparing piperacillin/tazobactam with meropenem as empirical antibiotic treatment of febrile neutropenic children and adolescents with hematologic and malignant disorders.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Chemotherapy-Induced Febrile Neutropenia; Child; Child, Preschool; Female; Hematologic Neoplasms; Humans; Infant; Infant, Newborn; Male; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Thienamycins | 2017 |
Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Cefepime; Cephalosporins; Cross Infection; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Genotype; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Republic of Korea; Tazobactam; Urinary Tract Infections | 2017 |
Meropenem versus piperacillin/tazobactam with or without immunoglobulin as second-line therapy for febrile neutropenia in pediatric patients.
Topics: Adolescent; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Child; Child, Preschool; Febrile Neutropenia; Female; Humans; Immunoglobulins, Intravenous; Infant; Infant, Newborn; Male; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Thienamycins; Treatment Outcome; Young Adult | 2018 |
Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial.
Topics: Acute Disease; Adult; Aged; Anti-Bacterial Agents; Boronic Acids; Drug Combinations; Female; Humans; Intention to Treat Analysis; Male; Meropenem; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Practice Guidelines as Topic; Pyelonephritis; Thienamycins; Urinary Tract Infections; Urine | 2018 |
Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacteremia; Cause of Death; Ceftriaxone; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Meropenem; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Thienamycins | 2018 |
Antibiotic Prophylaxis with Piperacillin-Tazobactam Reduces Post-Operative Infectious Complication after Pancreatic Surgery: An Interventional, Non-Randomized Study.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Enterobacteriaceae; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies | 2021 |
Risk factors for therapeutic failure in the management of post-operative peritonitis: a post hoc analysis of the DURAPOP trial.
Topics: Anti-Bacterial Agents; Humans; Penicillanic Acid; Peritonitis; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Risk Factors | 2021 |
Effect of therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial.
Topics: Adult; Anti-Bacterial Agents; Drug Monitoring; Female; Humans; Multiple Organ Failure; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sepsis | 2022 |
Extended infusion of piperacillin-tazobactam versus intermittent infusion in critically ill egyptian patients: a cost-effectiveness study.
Topics: Anti-Bacterial Agents; Cost-Benefit Analysis; Critical Illness; Egypt; Gram-Negative Bacterial Infections; Humans; Infusions, Intravenous; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies | 2022 |
Comparison of pharmacokinetics and stability of generics of cefepime, linezolid and piperacillin/tazobactam with their respective originator drugs: an intravenous bioequivalence study in healthy volunteers.
Topics: Anti-Bacterial Agents; Cefepime; Drugs, Generic; Healthy Volunteers; Humans; Linezolid; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam; Therapeutic Equivalency | 2022 |
Protocol and statistical analysis plan for the Antibiotic Choice On ReNal outcomes (ACORN) randomised clinical trial.
Topics: Acute Kidney Injury; Adult; Anti-Bacterial Agents; Cefepime; Cephalosporins; Humans; Kidney; Penicillins; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies | 2023 |
706 other study(ies) available for piperacillin and piperacillin, tazobactam drug combination
| Article | Year |
|---|---|
National survey of the in vitro spectrum of piperacillin-tazobactam tested against more than 40,000 aerobic clinical isolates from 236 medical centers.
Topics: Bacteria; beta-Lactamase Inhibitors; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 1995 |
Comparative antimicrobial activity of piperacillin-tazobactam tested against more than 5000 recent clinical isolates from five medical centers. A reevaluation after five years.
Topics: Bacteria; Drug Resistance, Microbial; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Time Factors | 1995 |
Comparative in-vitro activity of piperacillin-tazobactam against recent clinical isolates, a Dutch national multicentre study.
Topics: Bacteria; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 1994 |
Pharmacokinetics of tazobactam M1 metabolite after administration of piperacillin/tazobactam in subjects with renal impairment.
Topics: Adult; Aged; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Penicillanic Acid; Peritoneal Dialysis, Continuous Ambulatory; Piperacillin; Piperacillin, Tazobactam Drug Combination; Renal Dialysis; Renal Insufficiency; Tazobactam | 1994 |
In vitro susceptibility of Acinetobacter baumannii to biapenem, piperacillin/tazobactam and thirteen other antimicrobial agents.
Topics: Acinetobacter; Anti-Bacterial Agents; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Thienamycins | 1994 |
A reminder: piperacillin/tazobactam is not for Pseudomonas.
Topics: Adult; Drug Therapy, Combination; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas Infections | 1994 |
Susceptibility of beta-lactamase-producing enterococci to piperacillin with tazobactam.
Topics: beta-Lactamase Inhibitors; Culture Media; Drug Synergism; Drug Therapy, Combination; Enterococcus faecalis; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Penicillin Resistance; Piperacillin; Piperacillin, Tazobactam Drug Combination; Streptomycin; Tazobactam | 1993 |
Piperacillin-tazobactam combination approved by FDA.
Topics: Drug Approval; Drug Therapy, Combination; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; United States; United States Food and Drug Administration | 1994 |
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Topics: Drug Incompatibility; Drug Therapy, Combination; Injections, Intravenous; Nephelometry and Turbidimetry; Particle Size; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Solutions; Spectrometry, Fluorescence | 1994 |
Piperacillin/tazobactam.
Topics: Bacterial Infections; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 1994 |
Use of beta-lactam/beta-lactamase-inhibitor combinations as antimycobacterial agents.
Topics: Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Ampicillin; Animals; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Clavulanic Acids; Drug Therapy, Combination; Mice; Microbial Sensitivity Tests; Mycobacterium; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sulbactam | 1993 |
Molecular genetics of resistance to both ceftazidime and beta-lactam-beta-lactamase inhibitor combinations in Klebsiella pneumoniae and in vivo response to beta-lactam therapy.
Topics: Abdominal Abscess; Amino Acid Sequence; Ampicillin; Animals; Base Sequence; beta-Lactamase Inhibitors; beta-Lactamases; Ceftazidime; Cephalosporin Resistance; Cephalosporins; DNA, Bacterial; Drug Therapy, Combination; Escherichia coli; Klebsiella Infections; Klebsiella pneumoniae; Molecular Biology; Molecular Sequence Data; Penicillanic Acid; Penicillin Resistance; Piperacillin; Piperacillin, Tazobactam Drug Combination; R Factors; Rats; Sulbactam | 1996 |
Piperacillin/tazobactam in the treatment of hospitalized patients with urinary tract infections: an open non-comparative and multicentered trial.
Topics: Adult; Aged; Aged, 80 and over; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Treatment Outcome; Urinary Tract Infections | 1996 |
An open, multicenter clinical trial of piperacillin/tazobactam in the treatment of pediatric patients with intra-abdominal infections.
Topics: Bacteria, Aerobic; Child; Child, Preschool; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Humans; Infant; Male; Penicillanic Acid; Peritonitis; Piperacillin; Piperacillin, Tazobactam Drug Combination | 1996 |
Comment: piperacillin/tazobactam: a new beta-lactam/beta-lactamase inhibitor combination.
Topics: Drug Therapy, Combination; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Renal Dialysis | 1995 |
[Effectiveness of piperacillin/tazobactam in the treatment of fever of unknown etiology in patients with granulocytopenia].
Topics: Adolescent; Agranulocytosis; Child; Child, Preschool; Drug Therapy, Combination; Fever of Unknown Origin; Hematologic Diseases; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Treatment Outcome | 1997 |
Quality control guidelines for amoxicillin, amoxicillin-clavulanate, azithromycin, piperacillin-tazobactam, roxithromycin, ticarcillin, ticarcillin-clavulanate, trovafloxacin (CP 99,219), U-100592, and U-100766 for various National Committee for Clinical
Topics: Acetamides; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Azithromycin; Clavulanic Acids; Fluoroquinolones; Humans; Linezolid; Microbial Sensitivity Tests; Naphthyridines; Oxazoles; Oxazolidinones; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Quality Control; Roxithromycin; Ticarcillin | 1996 |
Effect of pH on in vitro antimicrobial susceptibility of the Bacteroides fragilis group.
Topics: Ampicillin; Anti-Bacterial Agents; Anti-Infective Agents; Bacteroides fragilis; Ciprofloxacin; Clindamycin; Drug Therapy, Combination; Fluoroquinolones; Hydrogen-Ion Concentration; Imipenem; Meropenem; Microbial Sensitivity Tests; Naphthyridines; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sulbactam; Thienamycins | 1997 |
Reappraisal of the antimicrobial susceptibilities of Chryseobacterium and Flavobacterium species and methods for reliable susceptibility testing.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Drug Therapy, Combination; Flavobacterium; Fluoroquinolones; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Reproducibility of Results; Vancomycin | 1997 |
Influence of pregnancy on the pharmacokinetic behaviour and the transplacental transfer of the piperacillin-tazobactam combination.
Topics: Adult; Amniotic Fluid; beta-Lactamase Inhibitors; Drug Therapy, Combination; Female; Fetal Blood; Fetus; Humans; Kinetics; Maternal-Fetal Exchange; Penicillanic Acid; Penicillins; Piperacillin; Piperacillin, Tazobactam Drug Combination; Placenta; Pregnancy | 1998 |
In vitro activity of piperacillin/tazobactam versus other broad-spectrum antibiotics against nosocomial gram-negative pathogens isolated from burn patients.
Topics: Burns; Cross Infection; Drug Therapy, Combination; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 1998 |
[Transferability of tazobactam/piperacillin (TAZ/PIPC) to cerebrospinal fluid of rabbit with meningitis caused by Staphylococcus aureus].
Topics: Animals; beta-Lactamase Inhibitors; Drug Therapy, Combination; Enzyme Inhibitors; Meningitis, Bacterial; Penicillanic Acid; Penicillins; Piperacillin; Piperacillin, Tazobactam Drug Combination; Rabbits; Staphylococcal Infections; Tazobactam; Time Factors | 1998 |
[Evaluation of in vitro susceptibility of hospital bacterial isolates to piperacillin and tazocin (piperacillin/tazobactam].
Topics: beta-Lactamase Inhibitors; Body Fluids; Cross Infection; Drug Resistance, Microbial; Drug Therapy, Combination; Enterobacteriaceae; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Piperacillin, Tazobactam Drug Combination; Species Specificity; Tazobactam | 1998 |
[Susceptibility of clinical strains of gram-positive bacteria to selected beta-lactam antibiotics].
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Clavulanic Acids; Cross Infection; Drug Resistance, Microbial; Drug Therapy, Combination; Gram-Positive Bacteria; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Species Specificity; Thienamycins; Ticarcillin | 1998 |
Resistance patterns of Pseudomonas aeruginosa to carbapenems and piperacillin/tazobactam.
Topics: Carbapenems; Cross Infection; Drug Resistance, Multiple; Drug Therapy, Combination; Humans; Incidence; Microbial Sensitivity Tests; Penicillanic Acid; Penicillin Resistance; Penicillins; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Pseudomonas aeruginosa; Risk Factors | 1999 |
Treatment of experimental pneumonia in rats caused by a PER-1 extended-spectrum beta-lactamase-producing strain of Pseudomonas aeruginosa.
Topics: Amikacin; Animals; Anti-Bacterial Agents; beta-Lactamases; Cefepime; Cephalosporins; Colony Count, Microbial; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Imipenem; Lung; Male; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Rats; Rats, Wistar | 1999 |
[In vitro activity of piperacillin-tazobactam against Klebsiella pneumoniae clinical isolates, producers or not of extended spectrum beta-lactamases].
Topics: beta-Lactamases; Drug Therapy, Combination; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 1999 |
[Severe pneumonia caused by Bordetella bronchiseptica].
Topics: Bordetella bronchiseptica; Bordetella Infections; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial | 1999 |
In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactams.
Topics: Bacteria; Bacterial Infections; beta-Lactams; Brazil; Cross Infection; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; Hospitals, University; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2000 |
Cost efficacy of tazobactam/piperacillin versus imipenem/cilastatin in the treatment of intra-abdominal infection.
Topics: Abdomen; Adult; Bacterial Infections; Cilastatin; Cilastatin, Imipenem Drug Combination; Cost-Benefit Analysis; Decision Trees; Drug Combinations; Drug Costs; Drug Therapy, Combination; Health Care Costs; Humans; Imipenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Protease Inhibitors; Randomized Controlled Trials as Topic; Retrospective Studies; Thienamycins | 2001 |
Renal abscess: recovery without hospitalization and drainage.
Topics: Abscess; Adolescent; Anti-Bacterial Agents; Ceftriaxone; Child; Drainage; Female; Hospitalization; Humans; Kidney; Kidney Diseases; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Radiography; Staphylococcal Infections; Ultrasonography | 2001 |
Effect of piperacillin-tazobactam on clinical capillary zone electrophoresis of serum proteins.
Topics: Drug Therapy, Combination; Electrophoresis, Capillary; Humans; Infusions, Intravenous; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Spectrophotometry, Ultraviolet | 2002 |
Penetration of piperacillin/tazobactam (4 g/500 mg) into synovial tissue.
Topics: Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Drug Therapy, Combination; Humans; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Synovial Membrane | 2002 |
Pharmacokinetics of piperacillin-tazobactam in anuric intensive care patients during continuous venovenous hemodialysis.
Topics: Adult; Aged; Anuria; Drug Therapy, Combination; Humans; Intensive Care Units; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Renal Dialysis | 2002 |
Potency and antimicrobial spectrum update for piperacillin/tazobactam (2000): emphasis on its activity against resistant organism populations and generally untested species causing community-acquired respiratory tract infections.
Topics: Community-Acquired Infections; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Europe; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Latin America; Microbial Sensitivity Tests; North America; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Respiratory Tract Infections; Sentinel Surveillance; Time Factors | 2002 |
Development and optimization of a reversed-phase high-performance liquid chromatographic method for the determination of piperacillin and tazobactam in tazocin injectable powder.
Topics: Chromatography, High Pressure Liquid; Hydrogen-Ion Concentration; Particle Size; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Powders; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Tazobactam | 2002 |
Jet-black eschar.
Topics: Anti-Bacterial Agents; Diagnosis, Differential; Drug Therapy, Combination; Ecthyma; Female; Gentamicins; Humans; Infant; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections | 2002 |
Lemierre's disease caused by co-infection of Arcanobacterium haemolyticum and Fusobacterium necrophorum: a case report.
Topics: Actinomycetales; Actinomycetales Infections; Adult; Anti-Bacterial Agents; Drug Therapy, Combination; Fusobacterium Infections; Humans; Jugular Veins; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sepsis; Thrombophlebitis; Vancomycin | 2002 |
Selection of oxacillin resistance in oxacillin-sensitive Staphylococcus aureus through exposure to ciprofloxacin but not piperacillin/tazobactam.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Microbial Sensitivity Tests; Oxacillin; Penicillanic Acid; Penicillins; Piperacillin; Piperacillin, Tazobactam Drug Combination; Selection, Genetic; Staphylococcus aureus | 2002 |
The effect of antibiotic rotation on colonization with antibiotic-resistant bacilli in a neonatal intensive care unit.
Topics: Anti-Bacterial Agents; Ceftazidime; Cross Infection; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Gentamicins; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Infant, Newborn; Intensive Care Units, Neonatal; Microbial Sensitivity Tests; Penicillanic Acid; Pharynx; Piperacillin; Piperacillin, Tazobactam Drug Combination; Rectum | 2002 |
[Piperacillin-tazobactam also at home].
Topics: Ambulatory Care; Drug Therapy, Combination; Home Care Services; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2002 |
In vitro activity of ertapenem against common clinical isolates in relation to human pharmacokinetics.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Ceftriaxone; Community-Acquired Infections; Drug Resistance, Microbial; Drug Therapy, Combination; Enterobacteriaceae; Ertapenem; Haemophilus influenzae; Humans; Lactams; Microbial Sensitivity Tests; Moraxella catarrhalis; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Staphylococcus aureus; Streptococcus agalactiae; Streptococcus pyogenes | 2002 |
[Second multicenter study of the in vitro susceptibility to piperacillin-tazobactam].
Topics: Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2002 |
Variable susceptibility to piperacillin/tazobactam amongst Klebsiella spp. with extended-spectrum beta-lactamases.
Topics: Bacterial Outer Membrane Proteins; beta-Lactamases; Drug Resistance, Multiple, Bacterial; Humans; Klebsiella; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2003 |
Antibiotic therapy of ventilator-associated pneumonia: in search of the magic bullet.
Topics: Cross Infection; Drug Therapy, Combination; Humans; Intensive Care Units; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia; Respiration, Artificial; Treatment Outcome | 2003 |
Variability in antibiotic prescribing patterns and outcomes in patients with clinically suspected ventilator-associated pneumonia.
Topics: Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; California; Cross Infection; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Intensive Care Units; Male; Middle Aged; Multivariate Analysis; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia; Proportional Hazards Models; Prospective Studies; Respiration, Artificial; Survival Rate; Treatment Outcome | 2003 |
Bacterial susceptibilities to piperacillin/tazobactam in a tertiary care hospital: 5-year review.
Topics: Anti-Bacterial Agents; Drug Resistance, Microbial; Drug Therapy, Combination; Hospitals; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Practice Patterns, Physicians'; Pseudomonas aeruginosa; Retrospective Studies | 2003 |
Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: report from the ARREST program.
Topics: beta-Lactamases; Cefepime; Cephalosporins; Drug Therapy, Combination; Escherichia coli; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Probability | 2003 |
[Outpatient parenteral antibiotic therapy (OPAT) of diabetic foot infections with piperacillin/tazobactam].
Topics: Adult; Aged; Ambulatory Care; Anti-Bacterial Agents; Bacterial Infections; Diabetic Foot; Female; Humans; Injections; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies | 2002 |
Treatment with a broad-spectrum cephalosporin versus piperacillin-tazobactam and the risk for isolation of broad-spectrum cephalosporin-resistant Enterobacter species.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Ceftazidime; Ceftriaxone; Cohort Studies; Drug Therapy, Combination; Enterobacter; Enterobacteriaceae Infections; Female; Humans; Male; Middle Aged; Multivariate Analysis; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Proportional Hazards Models; Retrospective Studies; Risk Factors | 2003 |
In vitro activity of piperacillin/tazobactam and other broad-spectrum antibiotics against bacteria from hospitalised patients in the British Isles.
Topics: Bacteria; Bacterial Infections; Cephalosporins; Drug Resistance, Bacterial; Drug Therapy, Combination; Enterobacteriaceae; Gram-Negative Bacteria; Humans; In Vitro Techniques; Ireland; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Time Factors; United Kingdom | 2003 |
Comparison of four antimicrobial susceptibility testing methods to determine the in vitro activities of piperacillin and piperacillin-tazobactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa.
Topics: Drug Resistance, Bacterial; Drug Therapy, Combination; Enterobacteriaceae; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Piperacillin, Tazobactam Drug Combination; Population Surveillance; Pseudomonas aeruginosa | 2003 |
Association of antibiotic utilization measures and reduced incidence of infections with extended-spectrum beta-lactamase-producing organisms.
Topics: Anti-Bacterial Agents; beta-Lactamases; Ceftazidime; Cephalosporin Resistance; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Taiwan | 2003 |
Incidence of neutropenia during treatment of bone-related infections with piperacillin-tazobactam.
Topics: Age Factors; Aged; Drug Therapy, Combination; Female; Fever; Humans; Incidence; Male; Middle Aged; Neutropenia; Osteomyelitis; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2003 |
Comparative in vitro activity of piperacillin, piperacillin-sulbactam and piperacillin-tazobactam against nosocomial pathogens isolated from intensive care patients.
Topics: Anti-Bacterial Agents; Cross Infection; Drug Therapy, Combination; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sulbactam | 2003 |
Reduction in multiresistant nosocomial infections in neonates following substitution of ceftazidime with piperacillin/tazobactam in empiric antibiotic therapy.
Topics: Anti-Bacterial Agents; Ceftazidime; Cross Infection; Drug Resistance, Multiple, Bacterial; Humans; Infant, Newborn; Infection Control; Israel; Klebsiella Infections; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2003 |
Cost analysis of continuous versus intermittent infusion of piperacillin-tazobactam: a time-motion study.
Topics: Costs and Cost Analysis; Drug Therapy, Combination; Economics, Pharmaceutical; Humans; Infusions, Intravenous; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Time Factors | 2003 |
In vitro activity of combination therapy with cefepime, piperacillin-tazobactam, or meropenem with ciprofloxacin against multidrug-resistant Pseudomonas aeruginosa strains.
Topics: Anti-Bacterial Agents; Cefepime; Cephalosporins; Drug Interactions; Drug Resistance, Multiple; Drug Therapy, Combination; Humans; Lactams; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2003 |
Replacement of broad-spectrum cephalosporins by piperacillin-tazobactam: impact on sustained high rates of bacterial resistance.
Topics: Anti-Bacterial Agents; Argentina; Cephalosporin Resistance; Cephalosporins; Cross Infection; Drug Prescriptions; Drug Utilization; Humans; Infection Control; Klebsiella Infections; Klebsiella pneumoniae; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2004 |
False-positive galactomannan platelia Aspergillus test results for patients receiving piperacillin-tazobactam.
Topics: Anti-Bacterial Agents; Antigens, Fungal; Aspergillus; False Positive Reactions; Galactose; Humans; Mannans; Microbiological Techniques; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sensitivity and Specificity | 2004 |
Treatment with piperacillin-tazobactam and false-positive Aspergillus galactomannan antigen test results for patients with hematological malignancies.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antigens, Fungal; Aspergillus; Case-Control Studies; False Positive Reactions; Female; Galactose; Hematologic Neoplasms; Humans; Male; Mannans; Microbiological Techniques; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sensitivity and Specificity | 2004 |
Monotherapy versus multi-drug therapy for the treatment of perforated appendicitis in children.
Topics: Ampicillin; Appendectomy; Appendicitis; Child; Clindamycin; Drug Combinations; Drug Therapy, Combination; Female; Gentamicins; Humans; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Postoperative Complications; Retrospective Studies | 2003 |
Steady-state plasma and intrapulmonary concentrations of piperacillin/tazobactam 4 g/0.5 g administered to critically ill patients with severe nosocomial pneumonia.
Topics: Cross Infection; Epithelial Cells; Female; Humans; Intensive Care Units; Lung; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Prospective Studies; Respiration, Artificial | 2004 |
Rash associated with piperacillin/tazobactam administration in infectious mononucleosis.
Topics: Adult; Anti-Bacterial Agents; Drug Combinations; Drug Eruptions; Humans; Infectious Mononucleosis; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2004 |
Double-disk synergy test positivity in Stenotrophomonas maltophilia clinical strains.
Topics: Amoxicillin-Potassium Clavulanate Combination; Ampicillin; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactams; Drug Resistance, Bacterial; Drug Synergism; Enzyme Inhibitors; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Stenotrophomonas maltophilia; Sulbactam | 2004 |
Long-term surveillance of cefotaxime and piperacillin-tazobactam prescribing and incidence of Clostridium difficile diarrhoea.
Topics: Aged; Anti-Bacterial Agents; Cefotaxime; Cephalosporins; Clostridioides difficile; Diarrhea; Drug Prescriptions; Drug Resistance; Drug Utilization; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Public Policy; Retrospective Studies; United Kingdom | 2004 |
[Self-limited thrombotic microangiopathy associated with perianal abscess].
Topics: Abscess; Acute Kidney Injury; Adult; Amoxicillin-Potassium Clavulanate Combination; Anal Canal; Debridement; Drug Therapy, Combination; Female; Hemolytic-Uremic Syndrome; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Plasma; Plasmapheresis; Staphylococcal Infections; Thrombocytopenia | 2004 |
Bilateral parotid abscesses in an HIV-infected child caused by Streptococcus pneumoniae.
Topics: Abscess; Anti-Bacterial Agents; Child, Preschool; Drainage; Female; HIV Infections; Humans; Lymph Nodes; Parotid Diseases; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumococcal Infections; Streptococcus pneumoniae; Treatment Outcome | 2004 |
False-positive Aspergillus galactomannan antigen test results.
Topics: Adult; Amoxicillin-Potassium Clavulanate Combination; Antigens, Fungal; Aspergillus; False Positive Reactions; Galactose; Humans; Male; Mannans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2004 |
Detection of galactomannan antigenemia in patients receiving piperacillin-tazobactam and correlations between in vitro, in vivo, and clinical properties of the drug-antigen interaction.
Topics: Animals; Anti-Bacterial Agents; Antigens, Fungal; Aspergillosis; Enzyme-Linked Immunosorbent Assay; False Positive Reactions; Female; Galactose; Humans; Mannans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Rabbits | 2004 |
Lack of evidence that false-positive Aspergillus galactomannan antigen test results are due to treatment with piperacillin-tazobactam.
Topics: Adult; Aged; Aspergillus; False Positive Reactions; Galactose; Humans; Mannans; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Reagent Kits, Diagnostic | 2004 |
Burkholderia cenocepacia vaginal infection in patient with smoldering myeloma and chronic hepatitis C.
Topics: Aged; Anti-Bacterial Agents; Burkholderia cepacia complex; Burkholderia Infections; Drug Resistance, Multiple, Bacterial; Female; Hepatitis C, Chronic; Humans; Multiple Myeloma; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Vaginosis, Bacterial | 2004 |
In vitro antienterococcal activity explains associations between exposures to antimicrobial agents and risk of colonization by multiresistant enterococci.
Topics: Animals; Anti-Bacterial Agents; Carrier State; Ceftriaxone; Colony Count, Microbial; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Bacterial; Enterococcus faecium; Feces; Female; Gastrointestinal Tract; Gram-Positive Bacterial Infections; Mice; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2004 |
Impact of a formulary switch from ticarcillin-clavulanate to piperacillin-tazobactam on colonization with vancomycin-resistant enterococci.
Topics: Anti-Bacterial Agents; Carrier State; Clavulanic Acids; Cross Infection; Enterococcus faecium; Female; Formularies, Hospital as Topic; Gastrointestinal Tract; Humans; Intensive Care Units; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Risk Factors; Ticarcillin; Time Factors; Vancomycin Resistance | 2004 |
Amebic liver abscess with bacterial superinfection in a patient with no epidemiologic risk factors.
Topics: Animals; Anti-Infective Agents; Entamoeba histolytica; Epidemiologic Factors; Humans; Liver; Liver Abscess, Amebic; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Risk Factors; Spain; Superinfection; Tomography, X-Ray Computed; Treatment Outcome | 2004 |
[Investigation of the in-vitro effectiveness of ertapenem against Pseudomonas aeruginosa strains isolated from intensive care unit patients].
Topics: Anti-Bacterial Agents; beta-Lactams; Drug Resistance, Multiple, Bacterial; Ertapenem; Humans; Imipenem; Intensive Care Units; Lactams; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2004 |
Effect of bovine lactoferrin on the MICs of ampicillin/sulbactam (UNASYN), amoxicillin/clavulanic acid (Augmentin), ticarcillin clavulanate (Timentin), and piperacillin-tazobactam (ZOSYN), against clinical and environmental isolates of motile Aeromonas.
Topics: Aeromonas; Amoxicillin-Potassium Clavulanate Combination; Ampicillin; Animals; Anti-Bacterial Agents; Cattle; Clavulanic Acids; Lactoferrin; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sulbactam; Ticarcillin | 2005 |
Stable antimicrobial susceptibility rates for clinical isolates of Pseudomonas aeruginosa from the 2001-2003 tracking resistance in the United States today surveillance studies.
Topics: beta-Lactams; Ceftazidime; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gatifloxacin; Gentamicins; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; United States | 2005 |
Predictors of outcome for children with perforated appendicitis initially treated with non-operative management.
Topics: Abdominal Abscess; Adolescent; Anti-Bacterial Agents; Appendectomy; Appendicitis; Cellulitis; Child; Drainage; Female; Humans; Male; Outcome Assessment, Health Care; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Predictive Value of Tests; Prognosis; Retrospective Studies; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2004 |
Acute generalized exanthematous pustulosis caused by piperacillin/tazobactam.
Topics: Acute Disease; Aged; Anti-Bacterial Agents; Drug Eruptions; Exanthema; Female; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Skin Diseases, Vesiculobullous | 2005 |
Cervical spondylodiscitis from an ingested pin: a case report.
Topics: Accidents; Adolescent; Amoxicillin-Potassium Clavulanate Combination; Antibiotic Prophylaxis; Bone Plates; Ceftriaxone; Cervical Vertebrae; Clindamycin; Combined Modality Therapy; Deglutition Disorders; Discitis; Diskectomy; Emergencies; Equipment Contamination; Follow-Up Studies; Foreign Bodies; Humans; Laryngoscopy; Larynx; Male; Neck Pain; Oxacillin; Paresthesia; Penicillanic Acid; Pharynx; Piperacillin; Piperacillin, Tazobactam Drug Combination; Radiography; Recurrence; Retropharyngeal Abscess; Spinal Fusion; Vancomycin; Wounds, Penetrating | 2005 |
Chryseobacterium indologenes non-catheter-related bacteremia in a patient with a solid tumor.
Topics: Anti-Bacterial Agents; Bacteremia; Carcinoma, Squamous Cell; Chryseobacterium; Drug Therapy, Combination; Flavobacteriaceae Infections; Humans; Lymphatic Metastasis; Male; Middle Aged; Nose Neoplasms; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2005 |
Continuous infusion beta-lactams for intensive care unit pulmonary infections.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactams; Cefepime; Ceftazidime; Cephalosporins; Computer Simulation; Drug Combinations; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Infusions, Intravenous; Intensive Care Units; Microbial Sensitivity Tests; Monte Carlo Method; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; United States | 2005 |
Antimicrobial susceptibility of aerobic microorganisms isolated from intraabdominal infections in pediatric patients in Poland.
Topics: Abdomen; Adolescent; Bacteria, Aerobic; Bacterial Infections; beta-Lactamases; Child; Child, Preschool; Drug Resistance, Bacterial; Enterobacteriaceae; Escherichia coli; Humans; Infant; Infant, Newborn; Klebsiella; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Poland; Pseudomonas aeruginosa | 2005 |
Reproducibility assessment of tigecycline MIC results by broth microdilution methods using commercially prepared dry-form panels.
Topics: Anti-Bacterial Agents; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Minocycline; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Reagent Kits, Diagnostic; Reproducibility of Results; Tigecycline | 2005 |
Pharmacodynamics of intermittent and continuous infusion piperacillin/tazobactam and cefepime against extended-spectrum beta-lactamase-producing organisms.
Topics: beta-Lactam Resistance; beta-Lactamases; Cefepime; Cephalosporins; Drug Therapy, Combination; Escherichia coli; Infusion Pumps; Klebsiella pneumoniae; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2005 |
Galactomannan in piperacillin-tazobactam: how much and to what extent?
Topics: Anti-Bacterial Agents; Aspergillosis; Drug Contamination; Galactose; Humans; Mannans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2005 |
Comparative in vitro antimicrobial activity of a novel quinolone, garenoxacin, against aerobic and anaerobic microbial isolates recovered from general, vascular, cardiothoracic and otolaryngologic surgical patients.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteria, Aerobic; Bacteria, Anaerobic; Bacterial Infections; Fluoroquinolones; Humans; Imipenem; Metronidazole; Microbial Sensitivity Tests; Moxifloxacin; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Quinolines | 2005 |
Pharmacodynamic modeling of beta-lactam antibiotics for the empiric treatment of secondary peritonitis: a report from the OPTAMA program.
Topics: Anti-Bacterial Agents; beta-Lactams; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Models, Biological; Monte Carlo Method; Penicillanic Acid; Peritonitis; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2005 |
Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program.
Topics: Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Ciprofloxacin; Cross Infection; Dose-Response Relationship, Drug; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Monte Carlo Method; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Thienamycins | 2005 |
[Clinical effects of piperacillin and tazobactam/piperacillin on Haemophilus influenzae lower respiratory tract infection in pediatric patients].
Topics: Anti-Bacterial Agents; Child; Child, Preschool; Haemophilus Infections; Haemophilus influenzae; Humans; Infant; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Respiratory Tract Infections | 2005 |
Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study.
Topics: Anti-Infective Agents; Candida glabrata; Candidiasis; Case-Control Studies; Cross Infection; Female; Fluconazole; Fungemia; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Risk Factors; Vancomycin | 2005 |
Failure of levofloxacin treatment in community-acquired pneumococcal pneumonia.
Topics: Aged; Anti-Bacterial Agents; Bacterial Proteins; Community-Acquired Infections; DNA Topoisomerases, Type II; Drug Resistance, Multiple, Bacterial; Humans; Levofloxacin; Ofloxacin; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Pneumococcal; Streptococcus pneumoniae; Streptolysins; Treatment Failure | 2005 |
The use of piperacillin/tazobactam (in association with amikacin) in neonatal sepsis: efficacy and safety data.
Topics: Amikacin; Anti-Bacterial Agents; Drug Resistance, Bacterial; Drug Therapy, Combination; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Infant, Newborn; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Sepsis | 2006 |
Comparative study of antibiotic-containing polymethylmetacrylate capsules and beads.
Topics: Amikacin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Capsules; Clindamycin; Microspheres; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Polymethyl Methacrylate | 2006 |
[Postoperative pneumonia: nosocomial, predictable, iatrogenic, preventable or not?].
Topics: Alcoholism; Amoxicillin-Potassium Clavulanate Combination; Antibiotic Prophylaxis; Carcinoma, Squamous Cell; Ciprofloxacin; Cross Infection; Disease Susceptibility; Fatal Outcome; Humans; Iatrogenic Disease; Immunocompromised Host; Liver Cirrhosis, Alcoholic; Male; Malnutrition; Malpractice; Middle Aged; Mouth; Neck Dissection; Neoplasm Recurrence, Local; Oxygen; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia; Postoperative Complications; Pulmonary Disease, Chronic Obstructive; Risk Factors; Smoking; Tongue Neoplasms | 2006 |
Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program.
Topics: Anti-Bacterial Agents; Bacterial Infections; Cilastatin; Cilastatin, Imipenem Drug Combination; Dose-Response Relationship, Drug; Drug Combinations; Gram-Negative Bacteria; Gram-Positive Cocci; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Models, Biological; Monte Carlo Method; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Population Surveillance; Prevalence; Soft Tissue Infections; Thienamycins | 2005 |
Comparative in vitro activity of beta-lactam/beta-lactamase inhibitor combinations against gram negative bacteria.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; Cefoperazone; Clavulanic Acids; Cross Infection; Gram-Negative Bacteria; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sulbactam; Ticarcillin | 2005 |
Impact of a piperacillin-tazobactam shortage on antimicrobial prescribing and the rate of vancomycin-resistant enterococci and Clostridium difficile infections.
Topics: Anti-Bacterial Agents; California; Clostridioides difficile; Cross Infection; Drug Prescriptions; Drug Utilization; Enterococcus; Enterocolitis, Pseudomembranous; Gram-Positive Bacterial Infections; Humans; Length of Stay; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; United States; Vancomycin Resistance | 2006 |
Examination of a novel, specified local antibiotic therapy through polymethylmethacrylate capsules in a rabbit osteomyelitis model.
Topics: Animals; Anti-Bacterial Agents; Capsules; Chronic Disease; Delayed-Action Preparations; Disease Models, Animal; Drug Implants; Male; Osteomyelitis; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Polymethyl Methacrylate; Rabbits; Staphylococcal Infections; Staphylococcus aureus; Tibia | 2006 |
Conservative treatment of an early aortic graft infection due to Acinetobacter baumanii.
Topics: Acinetobacter baumannii; Aged; Anti-Bacterial Agents; Aortic Aneurysm, Abdominal; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Combined Modality Therapy; Debridement; Female; Gentamicins; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prosthesis-Related Infections; Rifampin; Treatment Outcome | 2006 |
Piperacillin/tazobactam-induced paresthesiae.
Topics: Adult; Anti-Bacterial Agents; Bacteremia; Humans; Hypersensitivity, Delayed; Lung Abscess; Male; Methicillin Resistance; Paresthesia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Staphylococcus aureus | 2006 |
[Interstitial nephritis attributed to treatment with piperacillin-tazobactam and with ciprofloxacin].
Topics: Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Humans; Male; Nephritis, Interstitial; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2006 |
Prospective drug utilization evaluation of three broad-spectrum antimicrobials: cefepime, piperacillin-tazobactam and meropenem.
Topics: Anti-Bacterial Agents; Cefepime; Cephalosporins; Drug Utilization Review; Humans; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Thienamycins | 2006 |
Isolation and 16S ribosomal RNA gene sequence-based identification of Clostridium scindens from an intra-abdominal abscess.
Topics: Abdominal Abscess; Adolescent; Anti-Bacterial Agents; Clostridium; Clostridium Infections; Crohn Disease; Female; Gentamicins; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Penicillanic Acid; Phylogeny; Piperacillin; Piperacillin, Tazobactam Drug Combination; Postoperative Complications; RNA, Ribosomal, 16S; Tomography, X-Ray Computed | 2006 |
Pharmacokinetic interaction between methotrexate and piperacillin/tazobactam resulting in prolonged toxic concentrations of methotrexate.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Drug Interactions; Female; Humans; Methotrexate; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2006 |
Mutant prevention concentrations of levofloxacin alone and in combination with azithromycin, ceftazidime, colistin (Polymyxin E), meropenem, piperacillin-tazobactam, and tobramycin against Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Azithromycin; Ceftazidime; Colistin; Dose-Response Relationship, Drug; Drug Synergism; In Vitro Techniques; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Mutation; Ofloxacin; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Thienamycins; Tobramycin | 2006 |
Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; beta-Lactamase Inhibitors; Escherichia coli; Female; Humans; Klebsiella oxytoca; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Time Factors; Treatment Outcome; Urinary Tract Infections | 2006 |
Central line-related bacteraemia due to Roseomonas mucosa in a neutropenic patient with acute myeloid leukaemia in Piraeus, Greece.
Topics: Acute Disease; Adult; Amikacin; Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bacteremia; Base Sequence; Catheterization, Central Venous; Cytarabine; Humans; Leukemia, Myeloid; Male; Methylobacteriaceae; Molecular Sequence Data; Neutropenia; Penicillanic Acid; Phylogeny; Piperacillin; Piperacillin, Tazobactam Drug Combination; RNA, Bacterial; RNA, Ribosomal, 16S; Vidarabine | 2006 |
Risk factors for isolation of low-level mupirocin-resistant versus -susceptible methicillin-resistant Staphylococcus aureus from patients in intensive care units.
Topics: Adult; Aged; Anti-Bacterial Agents; Case-Control Studies; Cephalosporins; Drug Resistance, Bacterial; Female; Humans; Intensive Care Units; Male; Methicillin Resistance; Microbial Sensitivity Tests; Middle Aged; Mupirocin; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Quinolones; Risk Factors; Staphylococcal Infections; Staphylococcus aureus | 2007 |
Antibiotic-induced enterococcal expansion in the mouse intestine occurs throughout the small bowel and correlates poorly with suppression of competing flora.
Topics: Animals; Anti-Bacterial Agents; Cephalosporins; Clavulanic Acids; Clindamycin; Drug Resistance, Multiple, Bacterial; Enterococcus faecium; Escherichia coli; Green Fluorescent Proteins; Intestine, Small; Metronidazole; Mice; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Ticarcillin | 2006 |
Endocarditis caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: emergence of resistance to ciprofloxacin and piperacillin-tazobactam during treatment despite initial susceptibility.
Topics: beta-Lactamases; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Endocarditis, Bacterial; Female; Heart Valve Prosthesis; Humans; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prosthesis-Related Infections; Thienamycins | 2006 |
Kinetics of galactomannan in surgical patients receiving perioperative piperacillin/tazobactam prophylaxis.
Topics: Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Colon; False Positive Reactions; Female; Galactose; Gastrectomy; Humans; Kinetics; Male; Mannans; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Rectum | 2006 |
Evaluating broad-spectrum antimicrobials.
Topics: Animals; Anti-Bacterial Agents; Cefepime; Cephalosporins; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Thienamycins | 2006 |
Influence of culture site-specific MIC distributions on the pharmacokinetic and pharmacodynamic properties of piperacillin/tazobactam and piperacillin: a data analysis.
Topics: Anti-Bacterial Agents; Bacterial Infections; Data Interpretation, Statistical; Enzyme Inhibitors; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Monte Carlo Method; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam | 2006 |
Bactericidal activity of ertapenem against major intra-abdominal pathogens.
Topics: Abdomen; Anti-Bacterial Agents; Bacterial Infections; Bacteroides fragilis; beta-Lactams; Ceftazidime; Ceftriaxone; Digestive System Diseases; Enterobacter cloacae; Enterococcus faecalis; Ertapenem; Escherichia coli; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Klebsiella; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Proteus mirabilis; Staphylococcus aureus; Time Factors | 2006 |
Restricted use of glycopeptides in paediatric cancer patients with fever and neutropenia.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Bacterial Infections; Child; Child, Preschool; Drug Therapy, Combination; Female; Fever; Fever of Unknown Origin; Fosfomycin; Glycopeptides; Humans; Infant; Length of Stay; Male; Neoplasms; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Teicoplanin; Treatment Outcome | 2006 |
Knowledge, attitudes, and behaviors regarding piperacillin-tazobactam prescribing practices: results from a multicenter study.
Topics: Anti-Bacterial Agents; Drug Utilization; Focus Groups; Health Knowledge, Attitudes, Practice; Hospitals, University; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Practice Guidelines as Topic; Practice Patterns, Physicians'; Skin Diseases, Infectious; Soft Tissue Infections | 2006 |
Bacteremia due to extended-spectrum beta -lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Cephalosporins; Cohort Studies; Community-Acquired Infections; Cross Infection; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Fluoroquinolones; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2006 |
Comparative activities of cefepime and piperacillin/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotype.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cefepime; Cephalosporins; Drug Resistance, Multiple, Bacterial; Escherichia coli; Humans; Klebsiella; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2007 |
Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; APACHE; beta-Lactams; Cohort Studies; Critical Illness; Cross Infection; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Models, Biological; Monte Carlo Method; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas Infections; Retrospective Studies | 2007 |
Lost in transcription.
Topics: Anti-Bacterial Agents; Humans; Immunosuppressive Agents; Medication Errors; Methotrexate; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2007 |
Susceptibilities of ESBL-producing Enterobacteriaceae to ertapenem, meropenem and piperacillin-tazobactam with and without clavulanic acid.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Clavulanic Acid; Drug Interactions; Ertapenem; Escherichia coli; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Thienamycins | 2007 |
Clinical predictors of treatment failure for diabetic foot infections: data from a prospective trial.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Diabetic Foot; Ertapenem; Female; Humans; Leukocyte Count; Male; Middle Aged; Multivariate Analysis; Outcome Assessment, Health Care; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Randomized Controlled Trials as Topic; Risk Factors; Severity of Illness Index; Treatment Failure | 2007 |
Epidemiology of bacteremia and factors associated with multi-drug-resistant gram-negative bacteremia in hematopoietic stem cell transplant recipients.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacteremia; Brazil; Carbapenems; Cephalosporins; Child; Child, Preschool; Drug Resistance, Multiple; Female; Gram-Negative Bacterial Infections; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Infant; Male; Middle Aged; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Predictive Value of Tests; Prospective Studies; Risk Factors | 2007 |
Consensus statement on antimicrobial therapy of intra-abdominal infections in Asia.
Topics: Abdomen; Anti-Infective Agents; Asia; Bacterial Infections; beta-Lactamase Inhibitors; Consensus; Drug Resistance, Bacterial; Drug Therapy, Combination; Enterobacteriaceae; Enterobacteriaceae Infections; Fluoroquinolones; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Practice Guidelines as Topic | 2007 |
Comparative costs of ertapenem and piperacillin-tazobactam in the treatment of diabetic foot infections.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Diabetic Foot; Drug Administration Schedule; Drug Combinations; Ertapenem; Female; Health Care Costs; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2007 |
Piperacillin/tazobactam-induced seizure rapidly reversed by high flux hemodialysis in a patient on peritoneal dialysis.
Topics: Anti-Bacterial Agents; Brain; Bronchiectasis; Cefazolin; Cefepime; Cephalosporins; Electroencephalography; Epilepsies, Myoclonic; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Molecular Structure; Penicillanic Acid; Penicillin G; Peritoneal Dialysis, Continuous Ambulatory; Piperacillin; Piperacillin, Tazobactam Drug Combination; Renal Dialysis; Tomography, X-Ray Computed | 2007 |
In vitro activity of piperacillin/tazobactam and ertapenem against Bacteroides fragilis and Escherichia coli in pure and mixed cultures.
Topics: Anti-Bacterial Agents; Bacteroides fragilis; beta-Lactams; Colony Count, Microbial; Ertapenem; Escherichia coli; Microbial Sensitivity Tests; Microbial Viability; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Time Factors | 2007 |
Use of cefepime for the treatment of infections caused by extended spectrum: beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cefepime; Cephalosporins; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Hospitals, Urban; Humans; India; Intensive Care Units; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sepsis; Thienamycins | 2007 |
Effects of imipenem-cilastatin, ertapenem, piperacillin-tazobactam, and ceftriaxone treatments on persistence of intestinal colonization by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae strains in mice.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamases; Ceftriaxone; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Humans; Imipenem; Intestines; Klebsiella Infections; Klebsiella pneumoniae; Mice; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2007 |
Diffuse disseminated candidiasis in a patient with Felty's syndrome: a case report.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Blood Transfusion; Candidiasis; Felty Syndrome; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prednisone; Recombinant Proteins; Spleen; Splenectomy; Treatment Outcome | 2007 |
False positive galactomannan results in adult hematological patients treated with piperacillin-tazobactam.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Artifacts; Aspergillosis; Biomarkers; Combined Modality Therapy; Enzyme-Linked Immunosorbent Assay; False Positive Reactions; Female; Fungemia; Galactose; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Mannans; Middle Aged; Mucositis; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Predictive Value of Tests; Prospective Studies; Sensitivity and Specificity | 2007 |
Anaphylaxis to piperacillin-tazobactam despite a negative penicillin skin test.
Topics: Adult; Anaphylaxis; Anti-Allergic Agents; Anti-Bacterial Agents; Anti-Inflammatory Agents; Blood Pressure; Bronchodilator Agents; Crohn Disease; Dexamethasone; Diphenhydramine; Epinephrine; Female; Heart Rate; Humans; Intestinal Fistula; Penicillanic Acid; Penicillins; Piperacillin; Piperacillin, Tazobactam Drug Combination; Predictive Value of Tests; Radioallergosorbent Test; Skin Tests | 2007 |
Cefepime restriction improves gram-negative overall resistance patterns in neonatal intensive care unit.
Topics: Anti-Bacterial Agents; Cefepime; Cephalosporins; Cohort Studies; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacterial Infections; Humans; Infant, Newborn; Infant, Premature; Intensive Care Units, Neonatal; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Thienamycins; Time Factors | 2007 |
Optimising piperacillin/tazobactam dosing in paediatrics.
Topics: Age Factors; Anti-Bacterial Agents; Body Weight; Child; Child, Preschool; Computer Simulation; Demography; Drug Labeling; Humans; Infant; Metabolic Clearance Rate; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Regression Analysis; Tissue Distribution | 2007 |
Piperacillin-tazobactam in pediatric cancer patients younger than 25 months: a retrospective multicenter survey.
Topics: Bacterial Infections; Fever of Unknown Origin; Humans; Hypersensitivity; Infant; Infant, Newborn; Neoplasms; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Treatment Outcome; Withholding Treatment | 2007 |
[The frequency of PER-1 type extended spectrum beta-lactamases in nosocomial isolates of Pseudomonas aeruginosa].
Topics: Anti-Bacterial Agents; beta-Lactamases; Cross Infection; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Humans; Imipenem; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Polymerase Chain Reaction; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins; Tobramycin | 2007 |
Molecular epidemiology of clinical Pseudomonas aeruginosa isolates carrying IMP-1 metallo-beta-lactamase gene in a University Hospital in Turkey.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactamases; Drug Resistance, Multiple, Bacterial; Genes, Bacterial; Hospitals, University; Humans; Imipenem; Integrons; Microbial Sensitivity Tests; Molecular Epidemiology; Molecular Sequence Data; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Plasmids; Polymerase Chain Reaction; Pseudomonas aeruginosa; Pseudomonas Infections; Turkey | 2007 |
Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion?
Topics: Anti-Bacterial Agents; Computer Simulation; Drug Administration Schedule; Drug Resistance, Bacterial; Hospitals; Humans; Infusions, Intravenous; Microbial Sensitivity Tests; Monte Carlo Method; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Time Factors | 2007 |
Amoxicillin-associated hemorrhagic colitis in the presence of Klebsiella oxytoca.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Enterocolitis, Pseudomembranous; Humans; Klebsiella Infections; Klebsiella oxytoca; Male; Metronidazole; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sinusitis | 2007 |
Comparative activity of ertapenem and piperacillin tazobactam in a murine systemic infection model with Bacteroides fragilis and Escherichia coli.
Topics: Animals; Anti-Bacterial Agents; Ascitic Fluid; Bacteroides fragilis; Bacteroides Infections; beta-Lactams; Blood; Colony Count, Microbial; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Mice; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sepsis | 2007 |
Sternal tuberculosis.
Topics: Abscess; Adult; Anti-Bacterial Agents; Antitubercular Agents; Drug Therapy, Combination; Humans; Male; Mycobacterium Infections; Mycobacterium tuberculosis; Ofloxacin; Osteomyelitis; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sternum; Thorax; Tomography, X-Ray Computed; Tuberculosis; Vancomycin | 2009 |
Impact of antibiotic restriction on broad spectrum antibiotic usage in the ICU of a developing country.
Topics: Anti-Bacterial Agents; Cefepime; Cephalosporins; Developing Countries; Drug Prescriptions; Drug Resistance, Microbial; Drug Utilization Review; Humans; Imipenem; Intensive Care Units; Medical Order Entry Systems; Organizational Policy; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Polymyxin B; Program Development; Vancomycin | 2007 |
The antimicrobial peptide tachyplesin III coated alone and in combination with intraperitoneal piperacillin-tazobactam prevents ureteral stent Pseudomonas infection in a rat subcutaneous pouch model.
Topics: Animals; Anti-Bacterial Agents; Antimicrobial Cationic Peptides; Bacterial Adhesion; Biofilms; Colony Count, Microbial; Disease Models, Animal; DNA-Binding Proteins; Drug-Eluting Stents; In Vitro Techniques; Male; Penicillanic Acid; Peptides, Cyclic; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Rats; Rats, Wistar; Ureteral Diseases | 2007 |
Acquisition of rectal colonization by vancomycin-resistant Enterococcus among intensive care unit patients treated with piperacillin-tazobactam versus those receiving cefepime-containing antibiotic regimens.
Topics: Aged; Anti-Bacterial Agents; Cefepime; Cephalosporins; Culture Media; Enterococcus; Female; Gram-Positive Bacterial Infections; Humans; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Rectum; Vancomycin Resistance | 2008 |
[Replacement of third-generation cephalosporins by piperacillin-tazobactam decreases colonization of extended-spectrum beta-lactamases-producing intestinal Escherichia coli].
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Cephalosporins; Escherichia coli; Escherichia coli Infections; Female; Humans; Intestines; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies | 2007 |
Drug monitoring and toxicology (DMT).
Topics: Acidosis; Aged; Anti-Bacterial Agents; Drug Monitoring; Gas Chromatography-Mass Spectrometry; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2008 |
[Investigation of Aspergillus galactomannan levels in antimicrobial agents].
Topics: Ampicillin; Anti-Bacterial Agents; Antigens, Fungal; Aspergillosis; Aspergillus; Cross Reactions; Drug Contamination; False Positive Reactions; Galactose; Humans; Immunoenzyme Techniques; Mannans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2007 |
In vitro potency evaluations of various piperacillin/tazobactam generic products compared with the contemporary branded (Zosyn, Wyeth) formulation.
Topics: Anti-Bacterial Agents; Bacteria; Drugs, Generic; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2008 |
Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Cohort Studies; Drug Resistance, Bacterial; Female; Hospital Mortality; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Treatment Outcome | 2008 |
Warm autoantibody or drug dependent antibody? That is the question!
Topics: Anemia, Hemolytic, Autoimmune; Antibody Specificity; Antigen-Antibody Reactions; Autoantibodies; Female; Hemoglobins; Hot Temperature; Humans; Isoantibodies; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Transfusion Reaction | 2007 |
Suspected drug reaction with piperacillin/tazobactam, in a premature infant.
Topics: Anti-Bacterial Agents; Exanthema; Humans; Infant, Newborn; Infant, Premature; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sepsis; Tazobactam | 2008 |
A pharmacodynamic simulation to assess tigecycline efficacy for hospital-acquired pneumonia compared with other common intravenous antibiotics.
Topics: Anti-Bacterial Agents; Cross Infection; Humans; Imipenem; Levofloxacin; Microbial Sensitivity Tests; Minocycline; Models, Biological; Monte Carlo Method; Ofloxacin; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia; Tigecycline | 2008 |
Effect of antimicrobial therapy on mortality in 377 episodes of Enterobacter spp. bacteraemia.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacteremia; beta-Lactam Resistance; Enterobacter; Enterobacteriaceae Infections; Female; Humans; Male; Middle Aged; Multivariate Analysis; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prevalence; Risk Factors; Treatment Outcome | 2008 |
In vitro interaction between mecillinam and piperacillin-tazobactam in the presence of azithromycin against members of the Enterobacteriaceae family and Pseudomonas aeruginosa.
Topics: Amdinocillin; Anti-Bacterial Agents; Azithromycin; Drug Interactions; Drug Synergism; Drug Therapy, Combination; Enterobacteriaceae; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa | 2008 |
Purpuric rash of meningococcemia.
Topics: Anti-Infective Agents; Anti-Inflammatory Agents; Bacteremia; Ceftriaxone; Humans; Hydrocortisone; Male; Meningococcal Infections; Middle Aged; Neisseria meningitidis; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Protein C; Purpura; Recombinant Proteins; Vancomycin | 2008 |
Relationship between various definitions of prior antibiotic exposure and piperacillin-tazobactam resistance among patients with respiratory tract infections caused by Pseudomonas aeruginosa.
Topics: Aged; Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Retrospective Studies; Risk Factors | 2008 |
Cephalosporin induced toxic epidermal necrolysis and subsequent penicillin drug exanthem.
Topics: Aged, 80 and over; Cephalosporins; Drug Hypersensitivity; Exanthema; Humans; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Stevens-Johnson Syndrome | 2008 |
Serological studies of piperacillin antibodies.
Topics: Adsorption; Anemia, Hemolytic; Antibodies; Antibody Specificity; beta-Lactamase Inhibitors; Blood Donors; Coombs Test; Drug Hypersensitivity; Erythrocyte Membrane; Humans; Penicillanic Acid; Penicillin G; Piperacillin; Piperacillin, Tazobactam Drug Combination; Plasma; Tazobactam | 2008 |
A prospective, open-label noncomparative study with piperacillin-tazobactam monotherapy as management of fever in patients with acute leukemia.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Female; Fever; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Young Adult | 2008 |
Concentrations of piperacillin-tazobactam in human jaw and hip bone.
Topics: Adolescent; Adult; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Drug Combinations; Female; Humans; Jaw; Male; Middle Aged; Pelvic Bones; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tissue Distribution; Young Adult | 2008 |
Phosphorylcholine impairs susceptibility to biofilm formation of hydrogel contact lenses.
Topics: Anti-Bacterial Agents; Bacterial Adhesion; Biofilms; Coated Materials, Biocompatible; Contact Lenses, Hydrophilic; Gentamicins; Hydrogel, Polyethylene Glycol Dimethacrylate; Imipenem; Microbial Sensitivity Tests; Microscopy, Confocal; Penicillanic Acid; Phosphorylcholine; Piperacillin; Piperacillin, Tazobactam Drug Combination; Polyhydroxyethyl Methacrylate; Pseudomonas aeruginosa; Silicon; Staphylococcus epidermidis | 2009 |
Protective effects of the combination of alpha-helical antimicrobial peptides and rifampicin in three rat models of Pseudomonas aeruginosa infection.
Topics: Animals; Anti-Bacterial Agents; Antimicrobial Cationic Peptides; Blood; Drug Synergism; Drug Therapy, Combination; Endotoxins; Injections, Intravenous; Magainins; Microbial Sensitivity Tests; Penicillanic Acid; Peritoneum; Piperacillin; Piperacillin, Tazobactam Drug Combination; Plasma; Pseudomonas aeruginosa; Pseudomonas Infections; Rats; Rats, Wistar; Rifampin; Survival Analysis; Treatment Outcome; Tumor Necrosis Factor-alpha; Xenopus Proteins | 2008 |
Comparison of the effect of ciprofloxacin and Tazocin on the incidence of meticillin-resistant Staphylococcus aureus (MRSA) in an Intensive Care Unit.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Ciprofloxacin; Cross Infection; Data Interpretation, Statistical; Drug Combinations; Electrophoresis, Gel, Pulsed-Field; Hand Disinfection; Hygiene; Intensive Care Units; Methicillin-Resistant Staphylococcus aureus; Penicillanic Acid; Personnel, Hospital; Piperacillin; Piperacillin, Tazobactam Drug Combination; Staphylococcal Infections; Tazobactam | 2008 |
Piperacillin-tazobactam penetration into human pancreatic juice.
Topics: Aged; Ampulla of Vater; Anti-Bacterial Agents; Bacterial Infections; beta-Lactamase Inhibitors; Common Bile Duct Neoplasms; Female; Humans; Male; Middle Aged; Pancreatic Diseases; Pancreatic Juice; Pancreatic Neoplasms; Pancreaticoduodenectomy; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2008 |
Foot infections in diabetes (DFIs) in the out-patient setting: an Italian multicentre observational survey.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Anti-Bacterial Agents; Bacterial Infections; Diabetic Foot; Female; Humans; Italy; Male; Middle Aged; Outpatient Clinics, Hospital; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas Infections; Staphylococcal Infections; Young Adult | 2008 |
The effect of methylprednisolone on treatment in rats with induced sepsis.
Topics: Animals; Disease Models, Animal; Methylprednisolone; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Rats; Rats, Sprague-Dawley; Sepsis | 2009 |
Trends in antibacterial use in US academic health centers: 2002 to 2006.
Topics: Academic Medical Centers; Adult; Aminoglycosides; Anti-Bacterial Agents; Carbapenems; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; United States; Vancomycin | 2008 |
The use of piperacillin-tazobactam coated tympanostomy tubes against ciprofloxacin-resistant Pseudomonas biofilm formation: an in vitro study.
Topics: Anti-Bacterial Agents; Bacterial Adhesion; Bacteriological Techniques; Biofilms; Ciprofloxacin; Coated Materials, Biocompatible; Drug Resistance, Bacterial; Equipment Contamination; Equipment Design; Humans; Materials Testing; Microscopy, Electron, Scanning; Middle Ear Ventilation; Otitis Media, Suppurative; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prosthesis-Related Infections; Pseudomonas aeruginosa; Pseudomonas Infections; Silicones; Surface Properties | 2009 |
Acute exudative tonsillitis.
Topics: Acute Disease; Adult; Anti-Bacterial Agents; Anti-Inflammatory Agents; Humans; Hydrocortisone; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Streptococcal Infections; Streptococcus agalactiae; Tonsillitis | 2009 |
Imipenem-resistant Pseudomonas aeruginosa: risk factors for nosocomial infections.
Topics: Adult; Aged; Anti-Bacterial Agents; Case-Control Studies; Cross Infection; Drug Resistance, Multiple, Bacterial; Female; Humans; Imipenem; Length of Stay; Male; Microbial Sensitivity Tests; Middle Aged; Multivariate Analysis; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Factors; Vancomycin | 2008 |
Immune hemolysis due to piperacillin/tazobactam.
Topics: Anemia, Hemolytic, Autoimmune; Anti-Bacterial Agents; Coombs Test; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2009 |
Killing of Escherichia coli by beta-lactams at different inocula.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Ceftriaxone; Colony Count, Microbial; Ertapenem; Escherichia coli; Humans; Microbial Viability; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Time Factors | 2009 |
In vitro inferiority of ceftazidime compared with other beta-lactams for viridans group Streptococcus bacteremia in pediatric oncology patients: implications for antibiotic choices.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacteremia; beta-Lactam Resistance; Cefotaxime; Ceftazidime; Child; Drug Therapy, Combination; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Streptococcal Infections; Viridans Streptococci | 2009 |
Mortality rate in neonates infected with extended-spectrum beta lactamase-producing Klebsiella species and selective empirical use of meropenem.
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Cohort Studies; Drug Administration Schedule; Female; Humans; Infant, Newborn; Klebsiella; Klebsiella Infections; Male; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pregnancy; Regression Analysis; Retrospective Studies; Risk Factors; Survival Analysis; Thienamycins | 2009 |
A multicenter study on optimizing piperacillin-tazobactam use: lessons on why interventions fail.
Topics: Anti-Bacterial Agents; Colony Count, Microbial; Drug Resistance, Bacterial; Drug Utilization; Focus Groups; Health Knowledge, Attitudes, Practice; Hospitals, University; Hospitals, Veterans; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Practice Patterns, Physicians' | 2009 |
Health-related quality of life after intensive care unit discharge: A comparison between 2 standard antibiotic regimens.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Bacterial; Health Status; Humans; Intensive Care Units; Outcome Assessment, Health Care; Patient Discharge; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Quality of Life; Surveys and Questionnaires | 2009 |
Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; beta-Lactamases; Colony Count, Microbial; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Humans; Microbial Sensitivity Tests; Microbial Viability; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Time Factors | 2010 |
Efficacy of intravenous infusion of doripenem.
Topics: Carbapenems; Cross Infection; Doripenem; Humans; Imipenem; Infusions, Intravenous; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Ventilator-Associated | 2009 |
Abiotrophia/Granulicatella tubo-ovarian abscess in an adolescent virginal female.
Topics: Abscess; Aerococcaceae; Anti-Bacterial Agents; Carnobacteriaceae; Drug Therapy, Combination; Female; Gram-Positive Bacterial Infections; Humans; Metronidazole; Ovarian Cysts; Ovariectomy; Pelvic Inflammatory Disease; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tomography, X-Ray Computed; Young Adult | 2010 |
Steady-state pharmacokinetics and pharmacodynamics of piperacillin/tazobactam administered by prolonged infusion in hospitalised patients.
Topics: Adult; Aged; Anti-Bacterial Agents; Female; Gram-Negative Bacterial Infections; Humans; Infusions, Intravenous; Inpatients; Male; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Serum; United States | 2009 |
Resistance trends of Bacteroides fragilis group over an 8-year period, 1997-2004, in Korea.
Topics: Anti-Bacterial Agents; Bacteroides; Bacteroides fragilis; Cefoxitin; Chloramphenicol; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Metronidazole; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Republic of Korea | 2009 |
Susceptibilities of 23 Desulfovibrio isolates from humans.
Topics: Ampicillin; Anti-Bacterial Agents; Chloramphenicol; Clindamycin; Desulfovibrio; Fluoroquinolones; Humans; Metronidazole; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sulbactam | 2009 |
Moraxella lacunata septic arthritis in a patient with lupus nephritis.
Topics: Anti-Bacterial Agents; Arthritis, Infectious; Bacteremia; Bacterial Typing Techniques; Debridement; Female; Humans; Infusions, Intravenous; Lupus Nephritis; Moraxella; Moraxellaceae Infections; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Treatment Outcome; Young Adult | 2009 |
[Appendicitis in an HIV-positive South American immigrant].
Topics: Abdominal Abscess; Albendazole; Animals; Anthelmintics; Anti-HIV Agents; Appendectomy; Appendicitis; Ascariasis; Ascaris lumbricoides; Bacteroides fragilis; Bacteroides Infections; Combined Modality Therapy; Emigrants and Immigrants; Escherichia coli Infections; Female; HIV Infections; Humans; Immunocompromised Host; Intestinal Diseases, Parasitic; Jejunum; Paraguay; Penicillanic Acid; Peritonitis; Piperacillin; Piperacillin, Tazobactam Drug Combination; Young Adult | 2010 |
Expanded studies of piperacillin/tazobactam formulations: variations among branded product lots and assessment of 46 generic lots.
Topics: Anti-Bacterial Agents; Bacteria; Drugs, Generic; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam | 2009 |
Antipseudomonal activity of piperacillin/tazobactam: more than a decade of experience from the SENTRY Antimicrobial Surveillance Program (1997-2007).
Topics: Anti-Bacterial Agents; Global Health; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Sentinel Surveillance | 2009 |
Distribution of different carbapenem resistant clones of Acinetobacter baumannii in Tehran hospitals.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cefotaxime; Cross Infection; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Genes, Bacterial; Hospitals; Humans; Imipenem; Iran; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Thienamycins | 2009 |
Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients.
Topics: Area Under Curve; Bayes Theorem; Cross Infection; Drug Combinations; Female; Hospitalization; Humans; Infusions, Intravenous; Kidney; Kidney Function Tests; Male; Microbial Sensitivity Tests; Middle Aged; Models, Statistical; Monte Carlo Method; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Pneumococcal; Reproducibility of Results; Tazobactam; United States; United States Food and Drug Administration | 2010 |
Accounting for the development of antibacterial resistance in the cost effectiveness of ertapenem versus piperacillin/tazobactam in the treatment of diabetic foot infections in the UK.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Cost-Benefit Analysis; Decision Trees; Diabetic Foot; Direct Service Costs; Drug Costs; Drug Resistance, Bacterial; Ertapenem; Humans; Models, Biological; Models, Econometric; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Quality-Adjusted Life Years; Treatment Outcome; United Kingdom | 2009 |
Oriental cholangiohepatitis (clonorchiasis infestation) caused by Clonorchis sinensis.
Topics: Aged; Animals; Anthelmintics; Anti-Bacterial Agents; Clonorchiasis; Clonorchis sinensis; Emergency Service, Hospital; Female; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Praziquantel | 2012 |
Antimicrobial use among patients receiving palliative care consultation.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Decision Making; Drug Utilization; Female; Humans; Infections; Male; Michigan; Middle Aged; Palliative Care; Penicillanic Acid; Pilot Projects; Piperacillin; Piperacillin, Tazobactam Drug Combination; Practice Patterns, Physicians'; Retrospective Studies; Vancomycin | 2010 |
Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis.
Topics: Acinetobacter Infections; Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Carbapenems; Cefepime; Cephalosporins; Cohort Studies; Drug Therapy, Combination; Escherichia coli Infections; Female; Fluoroquinolones; Gram-Negative Bacterial Infections; Hospital Mortality; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Sepsis; Shock, Septic | 2010 |
Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Ciprofloxacin; Clinical Trials, Phase III as Topic; Doripenem; Enterobacteriaceae; Enterobacteriaceae Infections; Global Health; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prevalence | 2010 |
The interaction between piperacillin/tazobactam and assays for Aspergillus galactomannan and 1,3-beta-D-glucan in patients without risk factors for invasive fungal infections.
Topics: Adult; Aged; Anti-Bacterial Agents; Antigens, Fungal; Aspergillosis; Aspergillus; beta-Glucans; False Positive Reactions; Female; Galactose; Humans; Infusions, Intravenous; Male; Mannans; Microbiological Techniques; Middle Aged; Mycology; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Risk Factors | 2010 |
Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study.
Topics: Anti-Bacterial Agents; Bacteremia; France; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Peritonitis; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Thienamycins; Wound Infection | 2010 |
Implementation of an extended-infusion piperacillin-tazobactam program at an urban teaching hospital.
Topics: Anti-Bacterial Agents; Critical Care; Hospitals, Teaching; Humans; Infusion Pumps; Infusions, Intravenous; Medical Errors; Patient Care Team; Penicillanic Acid; Pharmacy Service, Hospital; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Quality Assurance, Health Care | 2010 |
Prior antimicrobial exposure and the risk for bloodstream infection with fluconazole-non-susceptible Candida strains.
Topics: Adult; Antifungal Agents; Candida; Candidiasis; Ciprofloxacin; Drug Resistance, Fungal; Fluconazole; Fungemia; Humans; Logistic Models; Odds Ratio; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Risk Factors | 2010 |
Topical piperacillin/tazobactam for recalcitrant pseudomonas aeruginosa keratitis.
Topics: Administration, Topical; Adolescent; Adult; Anti-Bacterial Agents; Corneal Ulcer; Drug Resistance; Eye Infections, Bacterial; Humans; Male; Middle Aged; Ophthalmic Solutions; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prognosis; Pseudomonas Infections; Retrospective Studies | 2010 |
Galactomannan detection from piperacillin-tazobactam brands available in the Brazilian market.
Topics: Anti-Bacterial Agents; Aspergillus; False Positive Reactions; Galactose; Immunoenzyme Techniques; Mannans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2009 |
High incidence of false-positive Aspergillus galactomannan test in multiple myeloma.
Topics: Amoxicillin; Antibiotic Prophylaxis; Antigens, Fungal; Artifacts; Aspergillosis; Aspergillus; False Positive Reactions; Galactose; Hematologic Diseases; Hematologic Neoplasms; Humans; Immunoglobulin G; Mannans; Multiple Myeloma; Myeloma Proteins; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Sensitivity and Specificity | 2010 |
Electrolytes imbalance: a rare side effect of piperacillin/ tazobactam therapy.
Topics: Aged; Anti-Bacterial Agents; Female; Femoral Neck Fractures; Humans; Hypokalemia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Respiratory Tract Infections | 2010 |
De novo generalised non-convulsive status epilepticus triggered by piperacillin/tazobactam.
Topics: Anti-Bacterial Agents; Electroencephalography; Female; Humans; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Status Epilepticus; Urinary Tract Infections | 2010 |
Microbiologic and clinical implications of bacteremia due to extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae with or without plasmid-mediated AmpC beta-lactamase DHA-1.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Bacterial Proteins; beta-Lactamases; Carbapenems; Case-Control Studies; Ciprofloxacin; Female; Humans; Klebsiella pneumoniae; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Plasmids; Young Adult | 2010 |
Case report: actinomycosis of the appendix--an unusual cause of acute appendicitis in children.
Topics: Actinomycosis; Acute Disease; Adolescent; Anti-Bacterial Agents; Appendectomy; Appendicitis; Cecal Diseases; Female; Humans; Penicillanic Acid; Penicillins; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prognosis; Treatment Outcome | 2010 |
Use of the lymphocyte transformation test in the diagnosis of DRESS syndrome induced by ceftriaxone and piperacillin-tazobactam: two case reports.
Topics: Adrenal Cortex Hormones; Adult; Anticonvulsants; beta-Lactams; Ceftriaxone; Cell Proliferation; Cells, Cultured; Colitis, Ulcerative; Drug Hypersensitivity; Eosinophilia; Epilepsy; Exanthema; Female; Histamine Antagonists; Humans; Lymphocyte Activation; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2010 |
Intravitreal piperacillin/tazobactam in the management of multidrug-resistant Pseudomonas aeruginosa endophthalmitis.
Topics: Anti-Bacterial Agents; Cataract Extraction; Drug Resistance, Multiple, Bacterial; Endophthalmitis; Eye Infections, Bacterial; Humans; Intravitreal Injections; Keratoplasty, Penetrating; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Visual Acuity; Vitreous Body | 2010 |
Therapeutic drug monitoring of piperacillin-tazobactam using spent dialysate effluent in patients receiving continuous venovenous hemodialysis.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Dialysis Solutions; Drug Monitoring; Female; Hemofiltration; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Renal Dialysis; Tazobactam | 2011 |
[In vitro synergism of ulifloxacin plus piperacillin/tazobactam against clinical isolates of Enterobacteriaceae producing extended-spectrum or AmpC-type β-lactamases].
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Drug Synergism; Enterobacteriaceae; Fluoroquinolones; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Piperazines | 2010 |
Severe acute hypokalaemia secondary to voriconazole. Uncommon pharmacological causes of hypokalaemia.
Topics: Acetamides; Amikacin; Anti-Bacterial Agents; Antifungal Agents; Candidiasis, Invasive; Drug Therapy, Combination; Humans; Hypokalemia; Linezolid; Lung Diseases, Fungal; Male; Middle Aged; Oxazolidinones; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Potassium Chloride; Pyrimidines; Triazoles; Voriconazole | 2011 |
Activity of ACHN-490 tested alone and in combination with other agents against Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Carbapenems; Cefepime; Cephalosporins; Doripenem; Imipenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa | 2011 |
Antithymocyte globulin-induced acute lung injury during transplantation for aplastic anemia.
Topics: Acute Lung Injury; Anemia, Aplastic; Animals; Anti-Bacterial Agents; Antilymphocyte Serum; Bacterial Infections; Bone Marrow Transplantation; Child; Cyclophosphamide; Horses; Humans; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sepsis; Transplantation Conditioning; Vancomycin; Vidarabine | 2011 |
Accuracy of automated and manual systems for susceptibility testing of Pseudomonas aeruginosa to piperacillin and piperacillin-tazobactam.
Topics: Anti-Bacterial Agents; Bacteriological Techniques; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Predictive Value of Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2011 |
Equal efficacy of a generic piperacillin/tazobactam formulation: results of a local screening protocol.
Topics: Anti-Bacterial Agents; Chemistry, Pharmaceutical; Drug Combinations; Drugs, Generic; Escherichia coli; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Staphylococcus aureus | 2011 |
Prevalence of antimicrobial resistant pathogens from blood cultures from Canadian hospitals: results of the CANWARD 2007-2009 study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Blood; Canada; Candida; Carbapenems; Child; Child, Preschool; Drug Resistance, Bacterial; Drug Resistance, Fungal; Emergency Service, Hospital; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Infant; Infant, Newborn; Intensive Care Units; Microbial Sensitivity Tests; Middle Aged; Outpatient Clinics, Hospital; Patients' Rooms; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Polymerase Chain Reaction; Prevalence; Sepsis | 2011 |
AmpG inactivation restores susceptibility of pan-beta-lactam-resistant Pseudomonas aeruginosa clinical strains.
Topics: Aztreonam; Bacterial Proteins; beta-Lactams; Cefepime; Ceftazidime; Cephalosporins; Drug Resistance, Bacterial; Membrane Transport Proteins; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Thienamycins | 2011 |
Impact of evaluating antibiotic concentrations in abdominal abscesses percutaneously drained.
Topics: Abdominal Abscess; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cefepime; Cephalosporins; Ciprofloxacin; Exudates and Transudates; Female; Fluconazole; Humans; Male; Metronidazole; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Suction; Treatment Outcome; Vancomycin | 2011 |
Effect of piperacillin-tazobactam coated β-tricalcium phosphate for mastoid obliteration in otitis media.
Topics: Animals; Calcium Phosphates; Coated Materials, Biocompatible; Disease Models, Animal; Guinea Pigs; Male; Mastoid; Otitis Media; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Plastic Surgery Procedures; Random Allocation; Reference Values; Tissue Scaffolds; Treatment Outcome; Tympanoplasty | 2011 |
In vitro efficiency of the piperacillin/tazobactam combination against inhibitor-resistant TEM- and complex mutant TEM-producing clinical strains of Escherichia coli.
Topics: Anti-Bacterial Agents; beta-Lactamases; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Humans; Microbial Sensitivity Tests; Microbial Viability; Mutant Proteins; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2011 |
Antibiotic resistance in Pseudomonas aeruginosa related to quinolone formulary changes: an interrupted time series analysis.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Cefepime; Cephalosporins; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Formularies, Hospital as Topic; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2011 |
Drug fever caused by piperacillin-tazobactam.
Topics: Achilles Tendon; Aged; Anti-Bacterial Agents; Drug Hypersensitivity; Fever; Humans; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2011 |
Superior in vitro activity of ertapenem and piperacillin/tazobactam against recent clinical isolates of Proteus mirabilis from intra-abdominal infections (SMART 2009-2010).
Topics: Abdominal Abscess; Anti-Bacterial Agents; beta-Lactams; Ertapenem; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Proteus Infections; Proteus mirabilis | 2011 |
The impact of a nationwide antibiotic restriction program on antibiotic usage and resistance against nosocomial pathogens in Turkey.
Topics: Acinetobacter; Anti-Bacterial Agents; Cefepime; Ceftazidime; Ceftriaxone; Cephalosporins; Cost Savings; Cross Infection; Drug Costs; Drug Prescriptions; Drug Resistance, Bacterial; Drug Utilization; Escherichia; Health Policy; Hospitals; Humans; Imipenem; Klebsiella; Meropenem; Methicillin Resistance; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas; Staphylococcus aureus; Teicoplanin; Thienamycins; Turkey; Vancomycin | 2011 |
Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy.
Topics: Aged; Anti-Bacterial Agents; beta-Lactams; Cefepime; Ceftazidime; Cephalosporins; Dose-Response Relationship, Drug; Female; Humans; Intensive Care Units; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Practice Guidelines as Topic; Prospective Studies; Pseudomonas aeruginosa; Renal Replacement Therapy; Shock, Septic; Thienamycins | 2011 |
Development and implementation of a piperacillin-tazobactam extended infusion guideline.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Guideline Adherence; Health Plan Implementation; Humans; Infusions, Intravenous; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Time Factors; Young Adult | 2011 |
Investigation of the clinical breakpoints of piperacillin-tazobactam against infections caused by Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Bacteremia; Cross Infection; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies | 2012 |
Kounis Syndrome induced by intravenous administration of piperacillin/tazobactam: a case report.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Coronary Vasospasm; Diagnosis, Differential; Electrocardiography; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Syndrome | 2012 |
Frequency and antibiogram of multi-drug resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Cefoperazone; Colistin; Cross-Sectional Studies; Disk Diffusion Antimicrobial Tests; Drug Resistance, Multiple, Bacterial; Enzyme Inhibitors; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Sulbactam | 2011 |
[Cefepime versus piperacillin/tazobactam with or without amikacin in the treatment of febrile hematological and oncological neutropenic patients in an internal medicine ward].
Topics: Adult; Aged; Amikacin; Anti-Bacterial Agents; Cefepime; Cephalosporins; Drug Therapy, Combination; Female; Fever; Hematologic Neoplasms; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Risk Factors; Treatment Outcome | 2010 |
The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: a multicenter study.
Topics: Aged; Anti-Bacterial Agents; Cohort Studies; Female; Gram-Negative Bacterial Infections; Hospital Mortality; Humans; Infusions, Intravenous; Length of Stay; Male; Middle Aged; Multivariate Analysis; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Survival Rate; Time Factors; Treatment Outcome | 2011 |
A rare cause of bacteremia in a pediatric patient with Down syndrome: Sphingomonas paucimobilis.
Topics: Bacteremia; Cross Infection; Down Syndrome; Gram-Negative Bacterial Infections; Humans; Infant; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia; Sphingomonas | 2011 |
Neonatal meningitis caused by Elizabethkingia meningoseptica in Saudi Arabia.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Flavobacteriaceae; Flavobacteriaceae Infections; Humans; Infant, Newborn; Male; Meningitis, Bacterial; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Saudi Arabia; Treatment Outcome | 2011 |
Analysis of isolated bacteria and short-term antimicrobial prophylaxis with tazobactam-piperacillin (1:4 ratio) for prevention of postoperative infections after radical cystectomy.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteria; Bacterial Infections; Cystectomy; Female; Humans; Japan; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Surgical Wound Infection; Treatment Outcome; Urinary Tract Infections | 2012 |
Necrotic intramuscular chloroma with infection: magnetic resonance imaging features.
Topics: Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Child; Contrast Media; Cytarabine; Diagnosis, Differential; Diffusion Magnetic Resonance Imaging; Gentamicins; Humans; Image Enhancement; Klebsiella Infections; Klebsiella pneumoniae; Leg; Leukemia, Myeloid, Acute; Magnetic Resonance Imaging; Male; Meropenem; Muscle Neoplasms; Necrosis; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sarcoma, Myeloid; Teicoplanin; Thienamycins; Treatment Outcome | 2011 |
[Effect of excipients on the preparation and properties of antibiotic solution for intravenous application].
Topics: Anti-Bacterial Agents; Citric Acid; Edetic Acid; Excipients; Infusions, Intravenous; Injections, Intravenous; Particle Size; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Solubility | 2011 |
Can we really use ß-lactam/ß-lactam inhibitor combinations for the treatment of infections caused by extended-spectrum ß-lactamase-producing bacteria?
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bacteremia; beta-Lactamase Inhibitors; Escherichia coli Infections; Female; Humans; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2012 |
β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts.
Topics: Aged; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bacteremia; beta-Lactam Resistance; beta-Lactamase Inhibitors; Escherichia coli; Escherichia coli Infections; Female; Humans; Male; Middle Aged; Multivariate Analysis; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Proportional Hazards Models; Prospective Studies; Spain | 2012 |
In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Colony Count, Microbial; Disease Models, Animal; Drug Combinations; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Humans; Klebsiella Infections; Klebsiella pneumoniae; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Penicillanic Acid; Phenotype; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thigh | 2012 |
Cholangitis with septic shock caused by Raoultella planticola.
Topics: Aged; Anti-Bacterial Agents; Cholangitis; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Immunocompromised Host; Male; Neoplasms; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Shock, Septic; Treatment Outcome | 2012 |
Should multivisceral transplantation be considered in patients colonized with multidrug-resistant Pseudomonas aeruginosa?
Topics: Anti-Bacterial Agents; Antifungal Agents; Child, Preschool; Disease Management; Drug Resistance, Multiple, Bacterial; Female; Fluconazole; Humans; Intestine, Small; Kidney Transplantation; Liver Transplantation; Organ Transplantation; Pancreas Transplantation; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections | 2012 |
Point mutations in the inc antisense RNA gene are associated with increased plasmid copy number, expression of blaCMY-2 and resistance to piperacillin/tazobactam in Escherichia coli.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; DNA Replication; Escherichia coli; Escherichia coli Infections; Gene Dosage; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Plasmids; Point Mutation; RNA, Antisense | 2012 |
Changes in the use of broad-spectrum antibiotics after cefepime shortage: a time series analysis.
Topics: Anti-Bacterial Agents; Cefepime; Cephalosporins; Drug Resistance, Bacterial; Drug Utilization; Health Policy; Hospitals; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Policy; Pseudomonas aeruginosa; Switzerland; Thienamycins; Time Factors | 2012 |
Dosing of piperacillin/tazobactam in a morbidly obese patient.
Topics: Adult; Anti-Bacterial Agents; Bacterial Infections; Chromatography, High Pressure Liquid; Drug Monitoring; Humans; Male; Obesity; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Serum | 2012 |
False positive galactomannan Platelia due to piperacillin-tazobactam.
Topics: Anti-Bacterial Agents; Antigens, Fungal; Artifacts; Aspergillosis; Biomarkers; Enzyme-Linked Immunosorbent Assay; False Positive Reactions; Fungemia; Galactose; Humans; Mannans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Reagent Kits, Diagnostic; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity | 2012 |
Continuous infusion of piperacillin/tazobactam in ventilator-associated pneumonia: a pilot study on efficacy and costs.
Topics: Aged; Aged, 80 and over; Chromatography, High Pressure Liquid; Drug Monitoring; Female; Health Care Costs; Humans; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Pilot Projects; Piperacillin; Piperacillin, Tazobactam Drug Combination; Plasma; Pneumonia, Ventilator-Associated; Treatment Outcome | 2012 |
A vesiculobullous eruption in a hospitalized patient. Diagnosis: Drug-induced linear IgA bullous dermatosis (LAD) with eosinophils.
Topics: Aged; Anti-Bacterial Agents; Drug Eruptions; Eosinophils; Female; Humans; Immunoglobulin A; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Skin Diseases, Vesiculobullous; Vancomycin | 2011 |
First-line treatment with cephalosporins in spontaneous bacterial peritonitis provides poor antibiotic coverage.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ascitic Fluid; Cephalosporins; Denmark; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Humans; Kaplan-Meier Estimate; Liver Cirrhosis; Male; Meropenem; Middle Aged; Mycoses; Penicillanic Acid; Peritonitis; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Thienamycins | 2012 |
Effect of body mass index on treatment of complicated intra-abdominal infections in hospitalized adults: comparison of ertapenem with piperacillin-tazobactam.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Body Mass Index; Ertapenem; Female; Humans; Intraabdominal Infections; Male; Middle Aged; Multicenter Studies as Topic; Obesity, Morbid; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Randomized Controlled Trials as Topic; Young Adult | 2012 |
Pseudomonas aeruginosa osteomyelitis of the cervical spine.
Topics: Cervical Vertebrae; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Osteomyelitis; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Radiography; Smoking | 2012 |
Post-operative infection and prophylactic antibiotic administration after radical cystectomy with orthotopic neobladder urinary diversion.
Topics: Adult; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Chi-Square Distribution; Cystectomy; Drug Resistance, Bacterial; Female; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Surgical Wound Infection; Urinary Diversion; Urinary Tract Infections | 2012 |
Rapid recovery from acute kidney injury in a patient with metformin-associated lactic acidosis and hypothermia.
Topics: Acidosis, Lactic; Acute Kidney Injury; Anti-Bacterial Agents; Comorbidity; Female; Humans; Hypothermia; Infusions, Intravenous; Metformin; Middle Aged; Multiple Organ Failure; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Renal Replacement Therapy; Sodium Bicarbonate; Urinary Tract Infections; Vasoconstrictor Agents | 2012 |
Pharmacokinetics and pharmacodynamics of piperacillin-tazobactam in 42 patients treated with concomitant CRRT.
Topics: Academic Medical Centers; Acute Kidney Injury; Adult; Aged; Alabama; Anti-Bacterial Agents; Chromatography, High Pressure Liquid; Drug Monitoring; Female; Humans; Kidney Failure, Chronic; Linear Models; Male; Middle Aged; Multivariate Analysis; Ohio; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Renal Dialysis | 2012 |
Broad-spectrum β-lactam antibiotics for treating experimental peritonitis in mice due to Klebsiella pneumoniae producing the carbapenemase OXA-48.
Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Cefotaxime; Ceftazidime; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Ertapenem; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Lethal Dose 50; Mice; Penicillanic Acid; Peritonitis; Piperacillin; Piperacillin, Tazobactam Drug Combination; Plasmids; Survival Rate | 2012 |
Meningitis and pneumonitis caused by pet rodents.
Topics: Adult; Animals; Anti-Bacterial Agents; C-Reactive Protein; Ceftriaxone; Ciprofloxacin; Female; Fusobacterium Infections; Humans; Hypoxia; Meningitis, Bacterial; Penicillanic Acid; Pets; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Rats; Respiratory Distress Syndrome; Streptobacillus; Thrombocytopenia | 2012 |
[Misleading improvement of abdominal tuberculosis with amikacin, within 72 hours].
Topics: Adrenal Cortex Hormones; Adult; Amikacin; Antirheumatic Agents; Antitubercular Agents; Arthritis, Rheumatoid; Drug Resistance, Microbial; Drug Therapy, Combination; Etanercept; Female; Humans; Immunocompromised Host; Immunoglobulin G; Immunosuppressive Agents; Methotrexate; Penicillanic Acid; Peritonitis, Tuberculous; Piperacillin; Piperacillin, Tazobactam Drug Combination; Receptors, Tumor Necrosis Factor; Recurrence; Streptomycin; Time Factors; Tuberculosis, Splenic | 2012 |
Comparative assessment of antimicrobial usage measures in the Department of Veterans Affairs.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Utilization Review; Hospitals, Veterans; Humans; Imipenem; Meropenem; Penicillanic Acid; Pilot Projects; Piperacillin; Piperacillin, Tazobactam Drug Combination; Thienamycins; United States; Vancomycin | 2012 |
Constructing unit-specific empiric treatment guidelines for catheter-related and primary bacteremia by determining the likelihood of inadequate therapy.
Topics: Anti-Bacterial Agents; Bacteremia; Catheter-Related Infections; Feasibility Studies; Female; Humans; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Practice Guidelines as Topic; Retrospective Studies; Treatment Failure | 2012 |
Lack of significant variability among different methods for calculating antimicrobial days of therapy.
Topics: Adult; Anti-Infective Agents; Ceftriaxone; Drug Dosage Calculations; Humans; Kidney Diseases; Ofloxacin; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Time Factors; Tobramycin; Vancomycin | 2012 |
A 9-Year retrospective review of antibiotic cycling in a surgical intensive care unit.
Topics: Anti-Bacterial Agents; Ceftazidime; Cilastatin; Cilastatin, Imipenem Drug Combination; Critical Care; Cross Infection; Drug Combinations; Drug Resistance, Bacterial; Enterobacter cloacae; Enterobacteriaceae Infections; Escherichia coli; Escherichia coli Infections; Humans; Imipenem; Infection Control; Klebsiella Infections; Klebsiella pneumoniae; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Surgical Wound Infection | 2012 |
Retrospective investigation of the clinical effects of tazobactam/piperacillin and sulbactam/ampicillin on aspiration pneumonia caused by Klebsiella pneumoniae.
Topics: Aged; Aged, 80 and over; Ampicillin; Anti-Bacterial Agents; Bacteria; C-Reactive Protein; Drug Therapy, Combination; Humans; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Aspiration; Retrospective Studies; Sulbactam; Treatment Outcome | 2012 |
Coma blisters with hypoxemic respiratory failure.
Topics: Amitriptyline; Anti-Bacterial Agents; Blister; Coma; Diazepam; Drug Therapy, Combination; Female; Humans; Mianserin; Mirtazapine; Oxycodone; Oxygen; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia; Pneumonia, Aspiration; Quadriplegia; Respiratory Insufficiency; Treatment Outcome; Young Adult | 2012 |
Piperacillin/tazobactam (Tazocin™) seems to be no longer responsible for false-positive results of the galactomannan assay.
Topics: Anti-Bacterial Agents; Aspergillosis; False Positive Reactions; Galactose; Hematopoietic Stem Cell Transplantation; Humans; Mannans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2012 |
Microbiological and clinical characteristics of diabetic foot infections in northern India.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Diabetic Foot; Female; Humans; India; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prevalence; Prospective Studies | 2012 |
Correlation between levofloxacin consumption and the incidence of nosocomial infections due to fluoroquinolone-resistant Escherichia coli.
Topics: Anti-Bacterial Agents; Carbapenems; Cephalosporins; Cross Infection; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Humans; Levofloxacin; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2016 |
Population pharmacokinetics of extended-infusion piperacillin-tazobactam in hospitalized patients with nosocomial infections.
Topics: Adult; Anti-Bacterial Agents; Cross Infection; Drug Administration Schedule; Female; Hospitalization; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Young Adult | 2012 |
Activity of beta-lactam beta-lactamase inhibitor combinations against extended spectrum Beta-lactamase producing Enterobacteriaceae in urinary isolates.
Topics: Amoxicillin; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; Cefoperazone; Clavulanic Acids; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sensitivity and Specificity; Sulbactam; Urinary Tract Infections | 2012 |
System-wide implementation of the use of an extended-infusion piperacillin/tazobactam dosing strategy: feasibility of utilization from a children's hospital perspective.
Topics: Adolescent; Anti-Bacterial Agents; Child; Child, Preschool; Feasibility Studies; Female; Hospitals, Pediatric; Humans; Infant; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2012 |
Piperacillin-tazobactam-induced acute interstitial nephritis with possible meropenem cross-sensitivity in a patient with osteomyelitis.
Topics: Acute Disease; Anti-Bacterial Agents; Drug Interactions; Drug Therapy, Combination; Humans; Male; Meropenem; Middle Aged; Nephritis, Interstitial; Osteomyelitis; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Thienamycins | 2012 |
Characteristics of initial compared with subsequent bacterial infections among hospitalised haemato-oncological patients.
Topics: Adult; Aged; Aged, 80 and over; Bacteremia; Bacterial Infections; Ceftazidime; Drug Resistance, Bacterial; Escherichia coli; Fever; Gram-Positive Bacteria; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Hospitalization; Humans; Israel; Meropenem; Middle Aged; Odds Ratio; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Thienamycins; Treatment Outcome; Young Adult | 2012 |
Piperacillin/tazobactam-induced neutropenia, thrombocytopenia, and fever during treatment of a diabetic foot infection.
Topics: Aged; Anti-Bacterial Agents; Diabetes Mellitus, Type 2; Diabetic Foot; Fever; Humans; Male; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Thrombocytopenia | 2013 |
In vitro susceptibilities of non-Enterobacteriaceae isolates from patients with intra-abdominal infections in the Asia-Pacific region from 2003 to 2010: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART).
Topics: Acinetobacter Infections; Aeromonas; Anti-Bacterial Agents; Asia; Australasia; Drug Resistance, Bacterial; Humans; Imipenem; Intraabdominal Infections; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Population Surveillance; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections | 2012 |
Epidemiology and antimicrobial susceptibility profiles of Gram-negative bacteria causing urinary tract infections in the Asia-Pacific region: 2009-2010 results from the Study for Monitoring Antimicrobial Resistance Trends (SMART).
Topics: Amikacin; Anti-Bacterial Agents; Asia; Australasia; beta-Lactamases; beta-Lactams; Carbapenems; Ceftazidime; Drug Resistance, Bacterial; Ertapenem; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prevalence; Prospective Studies; Urinary Tract Infections | 2012 |
Bacteremia of Gardnerella vaginalis after endometrial ablation.
Topics: Anti-Bacterial Agents; Bacteremia; Catheter Ablation; Endometrium; Female; Gardnerella vaginalis; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2012 |
Extended-spectrum β-lactamase producers reported as susceptible to piperacillin-tazobactam, cefepime, and cefuroxime in the era of lowered breakpoints and no confirmatory tests.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cefepime; Cefuroxime; Cephalosporins; Escherichia coli; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2012 |
The ecology of antibiotic use in the ICU: homogeneous prescribing of cefepime but not tazocin selects for antibiotic resistant infection.
Topics: Adult; Aged; Anti-Bacterial Agents; Cefepime; Cephalosporins; Drug Prescriptions; Drug Resistance, Bacterial; Female; Humans; Intensive Care Units; Length of Stay; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Middle Aged; Nasopharynx; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Staphylococcal Infections; Survival Rate | 2012 |
Piperacillin/tazobactam induced thrombocytopaenia--a delayed response.
Topics: Anti-Bacterial Agents; Diagnosis, Differential; Female; Follow-Up Studies; Humans; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Platelet Count; Sepsis; Thrombocytopenia; Time Factors | 2012 |
Pyogenic liver abscesses secondary to pylephlebitis complicating acute on chronic pancreatitis.
Topics: Anti-Bacterial Agents; Female; Humans; Liver Abscess, Pyogenic; Middle Aged; Pancreatitis, Chronic; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Portal Vein; Streptococcal Infections; Thrombophlebitis; Viridans Streptococci | 2012 |
Raoultella planticola bacteraemia.
Topics: Anti-Bacterial Agents; Bacteremia; Cholangitis; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2012 |
Pustular eruption in the ICU.
Topics: Acute Generalized Exanthematous Pustulosis; Amputation, Surgical; Anti-Bacterial Agents; Diagnosis, Differential; Drug Eruptions; Drug Therapy, Combination; Humans; Intensive Care Units; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Postoperative Complications; Vancomycin | 2012 |
Effective use of a clinical decision-support system to advance antimicrobial stewardship.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Decision Support Systems, Clinical; Drug Resistance, Microbial; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Practice Patterns, Physicians' | 2012 |
Antimicrobial susceptibility pattern and distribution of exoU and exoS in clinical isolates of Pseudomonas aeruginosa at a Malaysian hospital.
Topics: ADP Ribose Transferases; Adult; Anti-Bacterial Agents; Bacterial Proteins; Bacterial Toxins; Cefepime; Ceftazidime; Cephalosporins; Chi-Square Distribution; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Female; Gentamicins; Hospitals; Humans; Malaysia; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Polymerase Chain Reaction; Pseudomonas aeruginosa | 2012 |
Sudden hearing loss in a patient receiving piperacillin/tazobactam and daptomycin for diabetic foot infection.
Topics: Anti-Bacterial Agents; Daptomycin; Diabetes Mellitus, Type 2; Diabetic Foot; Hearing Loss, Sudden; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2013 |
Pilot study comparing sepsis management with and without electronic clinical practice guidelines in an academic emergency department.
Topics: Aged; Anti-Bacterial Agents; Clinical Protocols; Disease Management; Emergency Service, Hospital; Female; Hospitals, Teaching; Humans; Internet; Male; Middle Aged; Penicillanic Acid; Pilot Projects; Piperacillin; Piperacillin, Tazobactam Drug Combination; Practice Guidelines as Topic; Sepsis; Shock, Septic; Treatment Outcome | 2013 |
Case-control study of drug monitoring of β-lactams in obese critically ill patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Case-Control Studies; Cefepime; Ceftazidime; Cephalosporins; Drug Monitoring; Enzyme Inhibitors; Female; Humans; Male; Meropenem; Middle Aged; Obesity; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Renal Replacement Therapy; Sepsis; Shock, Septic; Tazobactam; Thienamycins; Young Adult | 2013 |
Continuous infusion of piperacillin/tazobactam in septic critically ill patients--a multicenter propensity matched analysis.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacteria; Critical Illness; Female; Humans; Infections; Intensive Care Units; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Portugal | 2012 |
Outcomes of extended-infusion piperacillin-tazobactam: a retrospective analysis of critically ill patients.
Topics: Aged; Anti-Bacterial Agents; Critical Illness; Drug Administration Schedule; Female; Gram-Negative Bacterial Infections; Humans; Infusions, Intravenous; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies | 2012 |
Steady-state pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese patients.
Topics: Adult; Anti-Bacterial Agents; Blood Chemical Analysis; Female; Humans; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Obesity; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Time Factors | 2013 |
Neglected obstructive pneumonia.
Topics: Adrenal Cortex Hormones; Aged; Anti-Bacterial Agents; Bronchoscopy; Foreign-Body Reaction; Humans; Larynx, Artificial; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia | 2012 |
Capnocytophaga canimorsus infection presenting with complete splenic infarction and thrombotic thrombocytopenic purpura: a case report.
Topics: Aged; Animals; Anti-Bacterial Agents; Bites and Stings; Capnocytophaga; Dogs; Gram-Negative Bacterial Infections; Humans; Imipenem; Male; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Purpura, Thrombotic Thrombocytopenic; Splenic Infarction; Thienamycins | 2012 |
Life-threatening piperacillin-induced immune haemolysis in a patient with cystic fibrosis.
Topics: Anemia, Hemolytic, Autoimmune; Anti-Bacterial Agents; Cystic Fibrosis; Humans; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Young Adult | 2013 |
[Drug resistance and molecular epidemiology of Shigella isolated from children with diarrhea].
Topics: Adolescent; Anti-Bacterial Agents; beta-Lactamases; Child; Child, Preschool; Diarrhea; Drug Resistance, Multiple, Bacterial; Feces; Female; Genotype; Humans; Male; Microbial Sensitivity Tests; Molecular Epidemiology; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Polymerase Chain Reaction; Sequence Analysis, DNA; Shigella | 2012 |
Effects of infection control measures on acquisition of five antimicrobial drug-resistant microorganisms in a tetanus intensive care unit in Vietnam.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Ceftazidime; Child; Child, Preschool; Ciprofloxacin; Drug Resistance, Microbial; Female; Gram-Negative Bacteria; Humans; Infant; Infant, Newborn; Infection Control; Intensive Care Units; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Tetanus; Vietnam; Young Adult | 2013 |
Purpura fulminans in a patient with paroxysmal nocturnal haemoglobinuria.
Topics: Amoxicillin; Anticoagulants; Blood Coagulation Tests; Citalopram; Contraindications; Drug Therapy, Combination; Enoxaparin; Hemoglobinuria, Paroxysmal; Humans; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Plasma; Platelet Transfusion; Prednisolone; Prednisone; Protein C Deficiency; Purpura Fulminans; Remission Induction; Virus Diseases; Vitamin K; Warfarin; Young Adult | 2013 |
Results of a two-center, before and after study of piperacillin-tazobactam versus ampicillin and gentamicin as empiric therapy for suspected sepsis at birth in neonates ≤ 1500 g.
Topics: Alkaline Phosphatase; Ampicillin; Apgar Score; Diaper Rash; Female; Gentamicins; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Infant, Very Low Birth Weight; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Sepsis; Treatment Outcome | 2013 |
Oxidized regenerated cellulose imitating pelvic abscess.
Topics: Abdominal Abscess; Anti-Bacterial Agents; Cellulose, Oxidized; Diagnosis, Differential; Drainage; Female; Humans; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tomography, X-Ray Computed | 2013 |
Doctor, I have a sore throat.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Diagnosis, Differential; Humans; Jugular Veins; Lemierre Syndrome; Male; Metronidazole; Penicillanic Acid; Pharyngitis; Piperacillin; Piperacillin, Tazobactam Drug Combination; Ultrasonography | 2013 |
International dissemination of Escherichia coli strains with discrepant behaviour in phenotypic antimicrobial susceptibility tests.
Topics: Anti-Bacterial Agents; Cluster Analysis; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Phenotype; Piperacillin; Piperacillin, Tazobactam Drug Combination; Reference Standards; Reproducibility of Results | 2013 |
Bacterial membrane disrupting dodecapeptide SC4 improves survival of mice challenged with Pseudomonas aeruginosa.
Topics: Animals; Anti-Bacterial Agents; Bacteremia; Cytokines; Disease Models, Animal; Inflammation Mediators; Male; Mice; Penicillanic Acid; Peptide Fragments; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Time Factors | 2013 |
Disseminated melioidosis presenting as septic arthritis.
Topics: Ankle Joint; Anti-Bacterial Agents; Arthritis, Infectious; Burkholderia pseudomallei; Diabetes Mellitus, Type 2; Humans; Knee Joint; Male; Melioidosis; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Recurrence; Synovial Fluid | 2012 |
Morganella morganii osteomyelitis complicated by secondary septic knee arthritis: a case report.
Topics: Anti-Bacterial Agents; Arthritis, Infectious; Enterobacteriaceae Infections; Fatal Outcome; Femur; Humans; Knee Joint; Magnetic Resonance Imaging; Male; Middle Aged; Morganella morganii; Osteomyelitis; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tibia | 2012 |
Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum β-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model.
Topics: Amoxicillin-Potassium Clavulanate Combination; Animals; Anti-Bacterial Agents; beta-Lactamases; Colony Count, Microbial; Escherichia coli; Escherichia coli Infections; Female; Imipenem; Injections, Intramuscular; Injections, Intraperitoneal; Intraabdominal Infections; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sepsis; Treatment Outcome | 2013 |
More potency assay results for generic non-USA lots of piperacillin/tazobactam and initial reports for generic meropenem compounds marketed in the USA.
Topics: Anti-Bacterial Agents; Drugs, Generic; Enterobacter cloacae; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Staphylococcus aureus; Thienamycins; United States | 2013 |
Drastic reduction of piperacillin-tazobactam concentrations in an in-vitro model of continuous venovenous hemofiltration: proposal of an innovative modality of administration to maintain them at constant concentration.
Topics: Anti-Bacterial Agents; Hemofiltration; In Vitro Techniques; Metabolic Clearance Rate; Models, Biological; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2013 |
The Pediatric Infectious Disease Journal® newsletter.
Topics: Anti-Bacterial Agents; Bacterial Infections; Child; Child, Preschool; Colistin; Humans; Infant; Infant, Newborn; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Public Health Administration; Virus Diseases | 2013 |
Drug resistance patterns of bacteria isolated from patients with nosocomial pneumonia at Tehran hospitals during 2009-2011.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Ceftriaxone; Cross Infection; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Hospitals; Humans; Iran; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Polymyxin B; Prevalence; Pseudomonas aeruginosa; Respiratory Tract Infections; Sputum; Staphylococcus aureus | 2013 |
Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Cohort Studies; Drug Therapy, Combination; Enzyme Inhibitors; Escherichia coli; Escherichia coli Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam; Treatment Outcome; Urinary Tract Infections | 2013 |
Proteomic changes in Bacteroides fragilis exposed to subinhibitory concentration of piperacillin/tazobactam.
Topics: Anti-Bacterial Agents; Bacteroides fragilis; Drug Resistance, Bacterial; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Proteomics | 2013 |
Optimization of continuous infusion of piperacillin-tazobactam in children with fever and neutropenia.
Topics: Adolescent; Anti-Bacterial Agents; Child; Female; Fever of Unknown Origin; Humans; Infusions, Intravenous; Male; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas Infections; Treatment Outcome | 2013 |
Steroids control paradoxical worsening of Mycobacterium ulcerans infection following initiation of antibiotic therapy.
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Aza Compounds; Buruli Ulcer; Debridement; Fluoroquinolones; Glucocorticoids; Humans; Male; Moxifloxacin; Mycobacterium ulcerans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prednisolone; Quinolines; Rifampin; Young Adult | 2013 |
Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?
Topics: Adult; Aged; Anti-Bacterial Agents; Creatinine; Critical Illness; Drug Delivery Systems; Female; Humans; Infusions, Intravenous; Kidney; Male; Meropenem; Metabolic Clearance Rate; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Thienamycins | 2013 |
Efficacy and safety of piperacillin/tazobactam versus biapenem in late elderly patients with nursing- and healthcare-associated pneumonia.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Cross Infection; Female; Hospitalization; Humans; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Retrospective Studies; Sputum; Thienamycins | 2013 |
Fixed drug eruption caused by piperacillin-tazobactam.
Topics: Aged; Anti-Bacterial Agents; Drug Eruptions; Female; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2013 |
Effect of clarithromycin in experimental empyema by multidrug-resistant Pseudomonas aeruginosa.
Topics: Adjuvants, Immunologic; Animals; Anti-Bacterial Agents; Apoptosis; Clarithromycin; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Empyema, Pleural; Humans; Interleukin-6; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pleural Effusion; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Tumor Necrosis Factor-alpha; U937 Cells | 2014 |
Clinical response at Day 3 of therapy and economic outcomes in hospitalized patients with acute bacterial skin and skin structure infection (ABSSSI).
Topics: Aged; Ampicillin; Anti-Bacterial Agents; Cefazolin; Female; Hospitalization; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Skin Diseases, Bacterial; Skin Diseases, Infectious; Sulbactam; Treatment Outcome; Vancomycin | 2013 |
Perioperative antibiotics for surgical site infection in pancreaticoduodenectomy: does the SCIP-approved regimen provide adequate coverage?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotic Prophylaxis; Child; Female; Humans; Male; Middle Aged; Pancreaticoduodenectomy; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Serum Albumin; Surgical Wound Infection | 2013 |
Antibiotics for the critically ill: more than just selecting appropriate initial therapy.
Topics: Critical Illness; Drug Delivery Systems; Female; Humans; Kidney; Male; Meropenem; Metabolic Clearance Rate; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Thienamycins | 2013 |
Physical compatibility of vancomycin and piperacillin sodium-tazobactam at concentrations typically used during prolonged infusions.
Topics: Anti-Bacterial Agents; Bacterial Infections; Drug Administration Schedule; Drug Combinations; Drug Stability; Humans; Infusions, Intravenous; Isotonic Solutions; Nephelometry and Turbidimetry; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Time Factors; Vancomycin | 2013 |
Imipenem versus piperacillin/tazobactam for empiric treatment of neutropenic fever in adults.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cohort Studies; Drug Substitution; Female; Fever; Humans; Imipenem; Male; Middle Aged; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Treatment Outcome; Young Adult | 2013 |
Acute localized exanthematous pustulosis on inguinal area secondary to piperacillin/tazobactam.
Topics: Acute Generalized Exanthematous Pustulosis; Adult; Anti-Bacterial Agents; Groin; Humans; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2014 |
Severe bone marrow suppression and hepatic dysfunction caused by piperacillin/tazobactam.
Topics: Adult; Agranulocytosis; Bone Marrow; Humans; Liver; Liver Diseases; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Thrombocytopenia | 2013 |
Detection of Escherichia coli and associated β-lactamases genes from diabetic foot ulcers by multiplex PCR and molecular modeling and docking of SHV-1, TEM-1, and OXA-1 β-lactamases with clindamycin and piperacillin-tazobactam.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Clindamycin; Diabetic Foot; Escherichia coli; Escherichia coli Infections; Gene Expression; Humans; Microbial Sensitivity Tests; Molecular Docking Simulation; Multiplex Polymerase Chain Reaction; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Structural Homology, Protein; Structure-Activity Relationship | 2013 |
Pharmacokinetic analysis of piperacillin administered with tazobactam in critically ill, morbidly obese surgical patients.
Topics: Aged; Anti-Bacterial Agents; Critical Illness; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Obesity, Morbid; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies | 2014 |
New insights in the production of aerosol antibiotics. Evaluation of the optimal aerosol production system for ampicillin-sulbactam, meropenem, ceftazidime, cefepime and piperacillin-tazobactam.
Topics: Aerosols; Ampicillin; Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Chemistry, Pharmaceutical; Equipment Design; Meropenem; Nebulizers and Vaporizers; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sulbactam; Thienamycins | 2013 |
Susceptibility to antibiotics of aerobic bacteria isolated from community acquired secondary peritonitis in children: therapeutic guidelines might not always fit with and everyday experience.
Topics: Ampicillin; Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Child; Community-Acquired Infections; Drug Resistance, Bacterial; Drug Therapy, Combination; Ertapenem; Gentamicins; Hospitals, Pediatric; Humans; Italy; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Peritonitis; Piperacillin; Piperacillin, Tazobactam Drug Combination; Practice Guidelines as Topic; Sulbactam; Thienamycins | 2013 |
Population pharmacokinetics of piperacillin/tazobactam in critically ill young children.
Topics: Bacterial Infections; Child; Child, Preschool; Cohort Studies; Critical Illness; Female; Humans; Infant; Intensive Care Units, Pediatric; Male; Monte Carlo Method; Penicillanic Acid; Philadelphia; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2014 |
Infectious aortitis in a liver transplant recipient.
Topics: Aged; Aorta; Aorta, Thoracic; Aortic Aneurysm, Abdominal; Aortitis; Bacteremia; Female; Humans; Liver; Liver Transplantation; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Radiography; Salmonella enteritidis; Salmonella Infections; Transplantation, Homologous | 2013 |
How long is antibiotic therapy necessary after urgent cholecystectomy for acute cholecystitis?
Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Antibiotic Prophylaxis; Cholecystectomy; Cholecystitis, Acute; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Postoperative Care; Prospective Studies; Risk Assessment; Surgical Wound Infection; Time Factors | 2013 |
Acute segmentary ulcerative duodenitis induced by Streptococcus pyogenes mimicking inflammatory bowel disease.
Topics: Abdominal Pain; Aged; Anti-Bacterial Agents; Diagnosis, Differential; Duodenitis; Endoscopy, Gastrointestinal; Female; Gastrointestinal Hemorrhage; Humans; Inflammatory Bowel Diseases; Penicillanic Acid; Peptic Ulcer; Piperacillin; Piperacillin, Tazobactam Drug Combination; Streptococcal Infections; Streptococcus pyogenes | 2013 |
Impact of Bolus dosing versus continuous infusion of Piperacillin and Tazobactam on the development of antimicrobial resistance in Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Colony Count, Microbial; Computer Simulation; Drug Administration Schedule; Drug Resistance, Bacterial; Humans; Infusions, Intravenous; Microbial Sensitivity Tests; Models, Statistical; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections | 2013 |
Hemolytic anemia as a result of piperacillin/tazobactam administration: a case report and discussion of pathophysiology.
Topics: Adult; Anemia, Hemolytic; Anti-Bacterial Agents; Female; Humans; Immunoglobulins, Intravenous; Immunologic Factors; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Young Adult | 2013 |
Interaction between caspofungin or voriconazole and cefoperazone-sulbactam or piperacillin-tazobactam by in vitro and in vivo methods.
Topics: Animals; Anti-Bacterial Agents; Antifungal Agents; Bacterial Infections; Candida albicans; Candidiasis; Caspofungin; Cefoperazone; Drug Interactions; Echinocandins; Female; Lipopeptides; Mice; Mice, Inbred BALB C; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pyrimidines; Sulbactam; Triazoles; Voriconazole | 2014 |
Suspected piperacillin-tazobactam induced nephrotoxicity in the pediatric oncology population.
Topics: Adolescent; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Kidney Diseases; Male; Neoplasms; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prognosis | 2014 |
Risk factors for Clostridium difficile-associated diarrhea among hospitalized adults with fecal toxigenic C. difficile colonization.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Proteins; Bacterial Toxins; Clostridioides difficile; Clostridium Infections; Diabetes Complications; Diarrhea; Feces; Female; Hospitalization; Hospitals, District; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Polymerase Chain Reaction; Prospective Studies; Proton Pump Inhibitors; Risk Factors; Taiwan | 2015 |
Acute renal failure associated with vancomycin and β-lactams for the treatment of osteomyelitis in diabetics: piperacillin-tazobactam as compared with cefepime.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Cefepime; Cephalosporins; Cohort Studies; Diabetes Complications; Drug Therapy, Combination; Humans; Incidence; Middle Aged; Osteomyelitis; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Vancomycin | 2014 |
[Concentration of tazobactam/piperacillin in the cerebrospinal fluid of patients with Haemophilus influenzae type B meningitis].
Topics: Anti-Bacterial Agents; Child, Preschool; Drug Therapy, Combination; Female; Humans; Male; Meningitis, Haemophilus; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Treatment Outcome | 2013 |
Risk factors for levofloxacin resistance in Stenotrophomonas maltophilia from respiratory tract in a regional hospital.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Case-Control Studies; Cross Infection; Drug Resistance, Bacterial; Drug Utilization; Female; Gram-Negative Bacterial Infections; Hospitals; Humans; Levofloxacin; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Respiratory Tract Infections; Risk Factors; Sputum; Stenotrophomonas maltophilia | 2015 |
In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; Carbapenems; Cefoperazone; Colistin; Cross Infection; Drug Resistance, Multiple, Bacterial; Drug Synergism; Humans; Microbial Sensitivity Tests; Minocycline; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sulbactam; Tigecycline | 2013 |
Evaluation of vancomycin in combination with piperacillin-tazobactam or oxacillin against clinical methicillin-resistant Staphylococcus aureus Isolates and vancomycin-intermediate S. aureus isolates in vitro.
Topics: Anti-Bacterial Agents; Drug Combinations; Drug Synergism; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Oxacillin; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Staphylococcus aureus; Vancomycin; Vancomycin Resistance | 2014 |
Pharmacokinetics of piperacillin/tazobactam in cancer patients with hematological malignancies and febrile neutropenia after chemotherapy.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Chemotherapy-Induced Febrile Neutropenia; Female; Hematologic Neoplasms; Humans; Leukocyte Count; Male; Middle Aged; Neutrophils; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Young Adult | 2013 |
In the literature. Piperacillin-tazobactam and extended-spectrum β-lactamase--producing Escherichia coli.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamases; Disease Models, Animal; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Humans; Mice; Microbial Sensitivity Tests; Nociceptive Pain; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Staphylococcal Infections | 2013 |
Risk factors associated with preoperative fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae in liver transplant recipients.
Topics: Adult; Amikacin; beta-Lactamases; beta-Lactams; Cefoxitin; Ciprofloxacin; Drug Resistance, Bacterial; End Stage Liver Disease; Enterobacter cloacae; Enterobacteriaceae; Enterobacteriaceae Infections; Escherichia coli; Escherichia coli Infections; Feces; Female; Humans; Imipenem; Klebsiella; Klebsiella Infections; Klebsiella pneumoniae; Liver Transplantation; Logistic Models; Male; Microbial Sensitivity Tests; Middle Aged; Multivariate Analysis; Penicillanic Acid; Peritonitis; Piperacillin; Piperacillin, Tazobactam Drug Combination; Preoperative Period; Risk Factors; Severity of Illness Index | 2014 |
A multicenter case-case control study for risk factors and outcomes of extensively drug-resistant Acinetobacter baumannii bacteremia.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Bacteremia; Carbapenems; Case-Control Studies; Central Venous Catheters; Cephalosporins; Coinfection; Drug Resistance, Bacterial; Female; Humans; Male; Microbial Sensitivity Tests; Neoplasms; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Polymyxin B; Respiratory Tract Infections; Risk Factors; Severity of Illness Index; Treatment Outcome | 2014 |
Piperacillin/tazobactam vs. cefoperazone/sulbactam in adult low-risk febrile neutropenia cases.
Topics: Anti-Bacterial Agents; Cefoperazone; Drug Combinations; Febrile Neutropenia; Female; Humans; Male; Middle Aged; Neoplasms; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Retrospective Studies; Sulbactam; Treatment Outcome | 2014 |
Population pharmacokinetics of tazobactam/piperacillin in Japanese patients with community-acquired pneumonia.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Anti-Bacterial Agents; Community-Acquired Infections; Female; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia | 2013 |
Prevention of Clostridium difficile spore formation by sub-inhibitory concentrations of tigecycline and piperacillin/tazobactam.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Clostridioides difficile; Humans; Metronidazole; Microbial Sensitivity Tests; Minocycline; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Ribotyping; Spores, Bacterial; Tazobactam; Tigecycline; Vancomycin | 2014 |
Empyema necessitatis following chest trauma.
Topics: Abscess; Anti-Bacterial Agents; Debridement; Diabetes Mellitus, Type 2; Disease Susceptibility; Empyema, Pleural; Hematoma; Humans; Male; Middle Aged; Obesity, Morbid; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pleural Effusion; Smoking; Streptococcal Infections; Streptococcus agalactiae; Thoracic Injuries; Wound Infection; Wounds, Nonpenetrating | 2014 |
Penicilliosis marneffei complicated with interstitial pneumonia.
Topics: Aged; Antifungal Agents; Humans; Itraconazole; Japan; Lung Diseases, Fungal; Lung Diseases, Interstitial; Male; Penicillanic Acid; Penicillium; Piperacillin; Piperacillin, Tazobactam Drug Combination; Thailand | 2014 |
Developmental pharmacokinetics of piperacillin and tazobactam using plasma and dried blood spots from infants.
Topics: Anti-Bacterial Agents; Dried Blood Spot Testing; Female; Humans; Infant; Infant, Newborn; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies | 2014 |
Prophylactic antibiotic therapy after inhalation injury.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Burn Units; Burns; Burns, Inhalation; Case-Control Studies; Female; Humans; Length of Stay; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Respiration, Artificial; Retrospective Studies; Tracheostomy; Young Adult | 2014 |
Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Ceftazidime; Cephalosporins; Imipenem; Meropenem; Microbial Sensitivity Tests; Mutation; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thienamycins | 2014 |
Treatment of suspected acute perforated appendicitis with antibiotics and interval appendectomy.
Topics: Abdominal Abscess; Abdominal Pain; Anti-Bacterial Agents; Appendectomy; Appendicitis; Child; Critical Pathways; Drug Administration Schedule; Drug Combinations; Fever; Humans; Intestinal Perforation; Patient Readmission; Penicillanic Acid; Peritonitis; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Suction; Time Factors; Treatment Outcome | 2014 |
Descending necrotizing mediastinitis: a conservative approach.
Topics: Anti-Bacterial Agents; Bacteroidaceae Infections; Chest Tubes; Drainage; Empyema, Pleural; Haemophilus Infections; Humans; Male; Mediastinitis; Mediastinum; Middle Aged; Necrosis; Penicillanic Acid; Peritonsillar Abscess; Piperacillin; Piperacillin, Tazobactam Drug Combination; Rupture, Spontaneous; Streptococcal Infections; Tomography, X-Ray Computed | 2014 |
Reduction in false-positive Aspergillus serum galactomannan enzyme immunoassay results associated with use of piperacillin-tazobactam in the United States.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Aspergillosis; Aspergillus; Diagnostic Tests, Routine; Drug Contamination; False Positive Reactions; Female; Galactose; Humans; Immunoenzyme Techniques; Mannans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Serum; United States | 2014 |
Comparative evaluation of six phenotypic methods for detecting extended-spectrum beta-lactamase-producing Enterobacteriaceae.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bacterial Typing Techniques; beta-Lactamases; beta-Lactams; Cefepime; Cefotaxime; Ceftazidime; Cephalosporins; Enterobacteriaceae; False Negative Reactions; False Positive Reactions; Female; Humans; India; Male; Microbial Sensitivity Tests; Penicillanic Acid; Phenotype; Piperacillin; Piperacillin, Tazobactam Drug Combination; Predictive Value of Tests | 2014 |
Population pharmacokinetic analysis of piperacillin in burn patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Burns; Computer Simulation; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Models, Statistical; Monte Carlo Method; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Young Adult | 2014 |
Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime.
Topics: Acute Kidney Injury; Adult; Aged; Anti-Bacterial Agents; Cefepime; Cephalosporins; Cohort Studies; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Treatment Outcome; Vancomycin | 2014 |
Overwhelming Capnocytophaga canimorsus infection in a patient with asplenia.
Topics: Animals; Anti-Bacterial Agents; Capnocytophaga; Dogs; Gram-Negative Bacterial Infections; Humans; Immunocompromised Host; Male; Middle Aged; Penicillanic Acid; Pets; Piperacillin; Piperacillin, Tazobactam Drug Combination; Postoperative Complications; Splenectomy; Zoonoses | 2014 |
Rearrangement of a large novel Pseudomonas aeruginosa gene island in strains isolated from a patient developing ventilator-associated pneumonia.
Topics: Anti-Bacterial Agents; Clindamycin; DNA, Bacterial; Electrophoresis, Gel, Pulsed-Field; Gene Rearrangement; Genetic Variation; Genome, Bacterial; Genomic Islands; Humans; Longitudinal Studies; Molecular Typing; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections; Sequence Analysis, DNA | 2014 |
Individualization of piperacillin dosing for critically ill patients: dosing software to optimize antimicrobial therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Bayes Theorem; Creatinine; Critical Illness; Drug Dosage Calculations; Drug Therapy, Computer-Assisted; Female; Humans; Male; Metabolic Clearance Rate; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Precision Medicine; Pseudomonas aeruginosa; Young Adult | 2014 |
In vitro and in vivo activities of piperacillin-tazobactam and meropenem at different inoculum sizes of ESBL-producing Klebsiella pneumoniae.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; Disease Models, Animal; Klebsiella Infections; Klebsiella pneumoniae; Lung; Male; Meropenem; Mice, Inbred BALB C; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Survival Analysis; Thienamycins | 2014 |
Against all odds. Conservative management of Boerhaave's syndrome.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Bacterial Agents; Antifungal Agents; Drainage; Esophageal Perforation; Fluconazole; Humans; Male; Mediastinal Diseases; Metronidazole; Pantoprazole; Parenteral Nutrition; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pleural Effusion; Proton Pump Inhibitors | 2014 |
Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam.
Topics: Acute Kidney Injury; Adult; Aged; Anti-Bacterial Agents; Cohort Studies; Drug Therapy, Combination; Female; Hospitalization; Humans; Incidence; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Vancomycin | 2014 |
Extended-Infusion versus standard-infusion piperacillin-tazobactam for sepsis syndromes at a tertiary medical center.
Topics: Aged; Anti-Bacterial Agents; Cost-Benefit Analysis; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Infusions, Intravenous; Length of Stay; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Sepsis; Survival Analysis; Syndrome; Tertiary Healthcare | 2014 |
Epidemic and virulence characteristic of Shigella spp. with extended-spectrum cephalosporin resistance in Xiaoshan District, Hangzhou, China.
Topics: Adolescent; Adult; Anti-Bacterial Agents; beta-Lactamases; Cefepime; Cephalosporin Resistance; Cephalosporins; Child; Child, Preschool; China; Ciprofloxacin; Dysentery, Bacillary; Female; Galanin; Genes, Bacterial; Genotype; Humans; Male; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Polymerase Chain Reaction; Shigella; Substance P; Virulence | 2014 |
Meropenem versus piperacillin-tazobactam as empiric therapy for febrile neutropenia in pediatric oncology patients.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Child; Child, Preschool; Drug Therapy, Combination; Febrile Neutropenia; Female; Humans; Infant; Male; Meropenem; Neoplasms; Neutrophils; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Thienamycins; Young Adult | 2014 |
[Mechanism of drug resistance of carbapenems-resistant Acinetobacter baumannii and the application of a combination of drugs in vitro].
Topics: Acinetobacter baumannii; Acinetobacter Infections; Ampicillin; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Carbapenems; Cefepime; Cephalosporins; Drug Resistance; Humans; In Vitro Techniques; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Pharmaceutical Preparations; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sulbactam; Thienamycins | 2014 |
Unusual presentation of PRES in the postnatal period.
Topics: Adult; Anti-Bacterial Agents; Antihypertensive Agents; Critical Care; Diagnosis, Differential; Female; Fluid Therapy; Follow-Up Studies; Headache; Humans; Labetalol; Magnesium Sulfate; Magnetic Resonance Imaging; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Posterior Leukoencephalopathy Syndrome; Postpartum Period; Seizures; Sepsis; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Clinical effectiveness and safety of tazobactam/piperacillin 4.5 g for the prevention of febrile infectious complication after prostate biopsy.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Biopsy, Needle; Body Temperature; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Fever; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Prostate; Prostatic Diseases; Risk Factors; Urinary Tract Infections | 2014 |
Cerebral abscess due to Serratia marcescens.
Topics: Amikacin; Anti-Bacterial Agents; Brain Abscess; Drainage; Frontal Lobe; Humans; Infant; Infant, Newborn; Infant, Newborn, Diseases; Long Term Adverse Effects; Magnetic Resonance Imaging; Male; Neurosurgical Procedures; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sepsis; Serratia marcescens; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Vancomycin and piperacillin-tazobactam against methicillin-resistant Staphylococcus aureus and vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.
Topics: Anti-Bacterial Agents; Drug Synergism; Methicillin Resistance; Microbial Sensitivity Tests; Models, Biological; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Staphylococcus aureus; Vancomycin; Vancomycin Resistance | 2014 |
Piperacillin/tazobactam-induced neurotoxicity in a hemodialysis patient: a case report.
Topics: Aged; Female; Humans; Neurotoxicity Syndromes; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Renal Dialysis; Renal Insufficiency, Chronic | 2015 |
Vancomycin-resistant Clostridium innocuum bacteremia following oral vancomycin for Clostridium difficile infection.
Topics: Administration, Oral; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Clostridium; Clostridium Infections; Cytomegalovirus Infections; Humans; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Treatment Outcome; Vancomycin; Vancomycin Resistance | 2014 |
Clinical manifestations and prognostic factors of Morganella morganii bacteremia.
Topics: Age Factors; Aged; Aged, 80 and over; Ampicillin; Anti-Bacterial Agents; Bacteremia; Cephalosporins; Community-Acquired Infections; Cross Infection; Drug Resistance, Bacterial; Enterobacteriaceae Infections; Female; Gentamicins; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Morganella morganii; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Risk Factors; Taiwan | 2015 |
In vivo efficacy of ceftolozane against Pseudomonas aeruginosa in a rabbit experimental model of pneumonia: comparison with ceftazidime, piperacillin/tazobactam and imipenem.
Topics: Animal Structures; Animals; Anti-Bacterial Agents; Bacterial Load; Ceftazidime; Cephalosporins; Colony Count, Microbial; Disease Models, Animal; Female; Humans; Imipenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Treatment Outcome | 2014 |
Efficacy of a Ceftazidime-Avibactam combination in a murine model of Septicemia caused by Enterobacteriaceae species producing ampc or extended-spectrum β-lactamases.
Topics: Animals; Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Ceftazidime; Drug Combinations; Escherichia coli; Escherichia coli Infections; Klebsiella Infections; Klebsiella pneumoniae; Male; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sepsis | 2014 |
Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extended-spectrum β-lactamase-producing Proteus mirabilis.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Carbapenems; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Proteus Infections; Proteus mirabilis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2014 |
Mutation-driven β-lactam resistance mechanisms among contemporary ceftazidime-nonsusceptible Pseudomonas aeruginosa isolates from U.S. hospitals.
Topics: Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Cefepime; Ceftazidime; Cephalosporins; Cross Infection; Gene Expression Regulation, Bacterial; Humans; Membrane Transport Proteins; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Porins; Pseudomonas aeruginosa; Pseudomonas Infections | 2014 |
Effect of adding piperacillin-tazobactam to automated dispensing cabinets on promptness of first-dose antibiotics in hospitalized patients.
Topics: Academic Medical Centers; Administration, Intravenous; Adult; Aged; Anti-Bacterial Agents; Automation; Female; Humans; Male; Medication Systems, Hospital; Middle Aged; Penicillanic Acid; Pharmacists; Pharmacy Service, Hospital; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Time Factors | 2014 |
Higher risk of neutropenia associated with piperacillin-tazobactam compared with ticarcillin-clavulanate in children.
Topics: Adolescent; Anti-Bacterial Agents; Child; Child, Preschool; Clavulanic Acids; Cohort Studies; Female; Humans; Infant; Male; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Risk Assessment; Ticarcillin | 2015 |
An optimized mouse thigh infection model for enterococci and its impact on antimicrobial pharmacodynamics.
Topics: Ampicillin; Anaerobiosis; Animals; Anti-Bacterial Agents; Disease Models, Animal; Enterococcus faecalis; Female; Gram-Positive Bacterial Infections; Mice, Inbred ICR; Microbial Sensitivity Tests; Mucins; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sulbactam; Vancomycin | 2015 |
Bacterial and fungal infections in the early post-transplantation period after liver transplantation: etiologic agents and their susceptibility.
Topics: Adult; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antifungal Agents; Bacterial Infections; Female; Fluconazole; Fungi; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Intestines; Liver Transplantation; Male; Middle Aged; Mycoses; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Postoperative Complications; Prospective Studies | 2014 |
Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in febrile neutropenic children.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Cefepime; Cephalosporins; Child; Escherichia coli; Escherichia coli Infections; Febrile Neutropenia; Female; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies | 2015 |
Do formulation differences between the reference listed drug and generic piperacillin-tazobactam impact reconstitution?
Topics: Administration, Intravenous; Anti-Bacterial Agents; Chemistry, Pharmaceutical; Drugs, Generic; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam | 2015 |
Antibiotic therapy and clinical outcomes of Pseudomonas aeruginosa (PA) bacteraemia.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; Ceftazidime; Drug Therapy, Combination; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Treatment Outcome | 2014 |
β-Lactam pharmacokinetics during extracorporeal membrane oxygenation therapy: A case-control study.
Topics: Adult; Anti-Bacterial Agents; beta-Lactams; Case-Control Studies; Extracorporeal Membrane Oxygenation; Female; Humans; Male; Meropenem; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas Infections; Sepsis; Serum; Thienamycins; Treatment Outcome | 2015 |
A new causative bacteria of infective endocarditis, Bergeyella cardium sp. nov.
Topics: Adult; Anti-Bacterial Agents; Ceftriaxone; Cluster Analysis; DNA, Bacterial; DNA, Ribosomal; Endocarditis; Flavobacteriaceae; Hospitals; Humans; Korea; Male; Microbial Sensitivity Tests; Middle Aged; Molecular Sequence Data; Penicillanic Acid; Phylogeny; Piperacillin; Piperacillin, Tazobactam Drug Combination; RNA, Ribosomal, 16S; Sequence Analysis, DNA; Treatment Outcome | 2015 |
A single-center evaluation of the risk for colonization or bacteremia with piperacillin-tazobactam- and cefepime-resistant bacteria in patients with acute leukemia receiving fluoroquinolone prophylaxis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Cefepime; Cephalosporins; Drug Resistance, Bacterial; Female; Fluoroquinolones; Humans; Leukemia; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Post-Exposure Prophylaxis; Random Allocation; Retrospective Studies; Risk Factors; Young Adult | 2016 |
[Experimental study on concentrations and pharmacokinetics of antibiotics in bile and evaluation of their microbicidal potential].
Topics: Animals; Anti-Bacterial Agents; Bile; Cefoperazone; Drug Combinations; Meropenem; Metronidazole; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Rabbits; Random Allocation; Sulbactam; Thienamycins | 2014 |
Risk factors for piperacillin/tazobactam-resistant Gram-negative infection in hematology/oncology patients with febrile neutropenia.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Case-Control Studies; Drug Resistance, Multiple, Bacterial; Febrile Neutropenia; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hematologic Neoplasms; Humans; Male; Middle Aged; Neoplasms; Penicillanic Acid; Penicillin Resistance; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Risk Factors; Young Adult | 2015 |
Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Cohort Studies; Enterobacteriaceae Infections; Escherichia coli; Female; Humans; Klebsiella oxytoca; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Propensity Score; Proportional Hazards Models; Proteus mirabilis; Survival Rate; Time Factors | 2015 |
Nephrotoxicity induced by piperacillin–tazobactam in late elderly Japanese patients with nursing and healthcare associated pneumonia.
Topics: Aged; Aged, 80 and over; Aging; Anti-Bacterial Agents; Asian People; Cross Infection; Female; Humans; Kidney Diseases; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial | 2014 |
Microbiological and clinical features of four cases of catheter-related infection by Methylobacterium radiotolerans.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Catheter-Related Infections; Child; Ciprofloxacin; Female; Gram-Negative Bacterial Infections; Humans; Levofloxacin; Male; Methylobacterium; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Young Adult | 2015 |
Clinical Impact of Discordant Prescribing of Fluoroquinolones and Alternative Treatments in Escherichia coli Pyelonephritis.
Topics: Adult; Anti-Bacterial Agents; Carbapenems; Ceftriaxone; Drug Resistance, Bacterial; Escherichia coli Infections; Female; Fluoroquinolones; Guidelines as Topic; Humans; Length of Stay; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pyelonephritis; Retrospective Studies; Treatment Outcome | 2016 |
Comparison of the risk of acquiring in vitro resistance to doripenem and tazobactam/piperacillin by CTX-M-15-producing Escherichia coli.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Colony Count, Microbial; Doripenem; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Proteins; Hydrolysis; Microbial Sensitivity Tests; Mutation Rate; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Risk Factors; RNA, Messenger | 2015 |
Antibiotics "just-in-case" in a patient with aspiration pneumonitis.
Topics: Anti-Bacterial Agents; Cerebral Palsy; Clostridioides difficile; Enterocolitis, Pseudomembranous; Epilepsy, Tonic-Clonic; Fatal Outcome; Humans; Male; Metronidazole; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Aspiration; Radiography; Vancomycin | 2015 |
Piperacillin-induced DRESS: distinguishing features observed in a clinical and allergy study of 8 patients.
Topics: Adult; Aged; Anti-Bacterial Agents; Drug Hypersensitivity; Female; Humans; Lymphocyte Activation; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Syndrome | 2014 |
Surgical antibiotic prophylaxis in children: adherence to indication, choice of agent, timing, and duration.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Antibiotic Prophylaxis; Child; Child, Preschool; Choice Behavior; Female; Guideline Adherence; Hospitals; Humans; Infant; Italy; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Surgical Wound Infection; Young Adult | 2015 |
Impact of a Dynamic Microbiological Environment on the Clinical Efficacy of Ertapenem and Piperacillin/Tazobactam in the Treatment of Complicated Community-Acquired Intra-Abdominal Infection in Spain: A Cost-Consequence Analysis.
Topics: Anti-Bacterial Agents; APACHE; beta-Lactams; Clinical Trials, Phase III as Topic; Community-Acquired Infections; Cost-Benefit Analysis; Decision Trees; Double-Blind Method; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Ertapenem; Humans; Intraabdominal Infections; Length of Stay; Models, Economic; Monte Carlo Method; Multicenter Studies as Topic; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Spain | 2015 |
A Non-inferiority Pilot Study Comparing the Clinical Efficacy and Safety of Generic Wide-spectrum Antibiotic Use in Septic Oncology Patients.
Topics: Administration, Intravenous; Anti-Bacterial Agents; Cefoperazone; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Drugs, Generic; Female; Humans; Imipenem; Male; Middle Aged; Oncology Service, Hospital; Penicillanic Acid; Pilot Projects; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Retrospective Studies; Sepsis; Sulbactam; Treatment Outcome | 2015 |
Non-carbapenem therapy of urinary tract infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Catheter-Related Infections; Ceftazidime; Community-Acquired Infections; Cross Infection; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Fluoroquinolones; Hospitalization; Hospitals, University; Humans; Immunocompromised Host; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prevalence; Prostatitis; Recurrence; Retrospective Studies; Risk Factors; Urinary Tract Infections; Young Adult | 2015 |
Clinical and Economic Impact of Empirical Extended-Infusion Piperacillin-Tazobactam in a Community Medical Center.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Female; Health Care Costs; Hospital Mortality; Humans; Infusions, Intravenous; Length of Stay; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies | 2015 |
Population Pharmacokinetics and Pharmacodynamics of Piperacillin/Tazobactam in Patients with Nosocomial Infections.
Topics: Anti-Bacterial Agents; Body Weight; Cross Infection; Female; Humans; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Models, Biological; Monte Carlo Method; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam | 2016 |
Epidemiology of antimicrobial resistance in an oncology center in eastern India.
Topics: Acinetobacter; Amikacin; Anti-Bacterial Agents; Antifungal Agents; Bacterial Infections; Cancer Care Facilities; Carbapenems; Ceftazidime; Ciprofloxacin; Clindamycin; Disk Diffusion Antimicrobial Tests; Drug Resistance, Bacterial; Enterobacteriaceae; Feces; Fluconazole; Gentamicins; Humans; India; Methicillin-Resistant Staphylococcus aureus; Mycoses; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas; Yeasts | 2015 |
Cystic Fibrosis and Piperacillin-tazobactam: Adverse Reactions.
Topics: Anti-Bacterial Agents; Cystic Fibrosis; Humans; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Young Adult | 2015 |
Piperacillin/tazobactam-induced myoclonic jerks in a man with chronic renal failure.
Topics: Anti-Bacterial Agents; Humans; Kidney Failure, Chronic; Legionnaires' Disease; Male; Middle Aged; Myoclonus; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2015 |
Fever and Reversible Laboratory Abnormalities Associated with Prolonged Use of Piperacillin-Tazobactam in Children.
Topics: Anti-Bacterial Agents; Child; Child, Preschool; Drug-Related Side Effects and Adverse Reactions; Fever; Humans; Infant; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies | 2015 |
Performance of the Baxter Infusor LV10 under hyperbaric conditions.
Topics: Anti-Bacterial Agents; Ceftriaxone; Dopamine; Elastomers; Hyperbaric Oxygenation; Infusion Pumps; Infusions, Intravenous; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Temperature; Time Factors; Vancomycin | 2015 |
Carbapenems Versus Piperacillin-Tazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Carbapenems; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Hospital Mortality; Humans; Intraabdominal Infections; Length of Stay; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Skin Diseases, Bacterial; Soft Tissue Infections | 2015 |
Comparison of acute renal injury associated with intermittent and extended infusion piperacillin/tazobactam.
Topics: Acute Kidney Injury; Aged; Anti-Bacterial Agents; Drug Administration Schedule; Female; Humans; Incidence; Infusions, Intravenous; Longevity; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies | 2015 |
Adherence to European Association of Urology Guidelines on Prophylactic Antibiotics: An Important Step in Antimicrobial Stewardship.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Ciprofloxacin; Drug Resistance, Bacterial; Escherichia coli; Europe; Female; Gentamicins; Guideline Adherence; Humans; Klebsiella; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Practice Guidelines as Topic; Trimethoprim, Sulfamethoxazole Drug Combination; Urologic Surgical Procedures; Urology | 2016 |
Penetration of piperacillin-tazobactam into human prostate tissue and dosing considerations for prostatitis based on site-specific pharmacokinetics and pharmacodynamics.
Topics: Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Area Under Curve; Escherichia coli; Humans; Infusions, Intravenous; Klebsiella; Male; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prostate; Prostatic Hyperplasia; Prostatitis; Proteus; Pseudomonas aeruginosa; Transurethral Resection of Prostate | 2015 |
[Propionibacterium granulosum bare-metal stent infection after drug-eluting balloon].
Topics: Aged, 80 and over; Alloys; Amoxicillin; Angioplasty, Balloon, Coronary; Anti-Bacterial Agents; Arteriosclerosis Obliterans; Bacteremia; Coronary Disease; Coronary Restenosis; Device Removal; Equipment Contamination; Female; Femoral Artery; Gentamicins; Gram-Positive Bacterial Infections; Humans; Immunosuppressive Agents; Paclitaxel; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Popliteal Artery; Propionibacterium; Prosthesis-Related Infections; Stents; Tomography, Emission-Computed, Single-Photon | 2015 |
Antimicrobial Disk Susceptibility Testing of Leptospira spp. Using Leptospira Vanaporn Wuthiekanun (LVW) Agar.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Gentamicins; Leptospira; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Rifampin; Trimethoprim, Sulfamethoxazole Drug Combination | 2015 |
Clinical evaluation of the need for carbapenems to treat community-acquired and healthcare-associated pneumonia.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Community-Acquired Infections; Cross Infection; Female; Hospital Mortality; Humans; Male; Middle Aged; Needs Assessment; Organizational Policy; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Prognosis; Pseudomonas Infections | 2015 |
Pharmacokinetics of an extended 4-hour infusion of piperacillin-tazobactam in critically ill patients undergoing continuous renal replacement therapy.
Topics: Aged; Anti-Bacterial Agents; Critical Illness; Female; Hemodiafiltration; Humans; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Tertiary Care Centers | 2015 |
Broncholithiasis presenting as bronchiectasis and recurrent pneumonias.
Topics: Anti-Bacterial Agents; Bronchial Diseases; Bronchiectasis; Bronchoalveolar Lavage; Chest Pain; Dyspnea; Female; Fever; Humans; Lithiasis; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia; Recurrence; Treatment Outcome; Vancomycin | 2015 |
Efficacy and safety of tazobactam/piperacillin as an empirical treatment for the patients of adult and child with febrile neutropenia in Japan.
Topics: Adult; Aged; Anti-Bacterial Agents; Child; Child, Preschool; Febrile Neutropenia; Female; Fever; Humans; Infant; Japan; Leukocyte Count; Male; Middle Aged; Neutrophils; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Young Adult | 2015 |
Microbiologic clearance following transition from standard infusion piperacillin-tazobactam to extended-infusion for persistent Gram-negative bacteremia and possible endocarditis: A case report and review of the literature.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; beta-Lactams; Endocarditis; Gram-Negative Bacterial Infections; Humans; Infusions, Intravenous; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2015 |
Retrospective cohort study of inappropriate piperacillin-tazobactam use for lower respiratory tract and skin and soft tissue infections: Opportunities for antimicrobial stewardship.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Antimicrobial Stewardship; Cohort Studies; Community-Acquired Infections; Cross Infection; Drug Utilization; Female; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia; Retrospective Studies; Skin Diseases, Infectious; Soft Tissue Infections | 2015 |
Understanding Gram-negative Central Line-Associated Blood Stream Infection in a Surgical Trauma ICU.
Topics: Adult; Aged; Bacteremia; Catheter-Related Infections; Catheterization, Central Venous; Cohort Studies; Comprehension; Cross Infection; Female; Follow-Up Studies; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospital Mortality; Humans; Incidence; Intensive Care Units; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Risk Assessment; Survival Rate; Tertiary Care Centers; Treatment Outcome; Urban Population; Virginia | 2015 |
Mutations in β-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal Cephalosporins.
Topics: Adaptation, Physiological; Amino Acid Sequence; Amino Acid Substitution; Anti-Bacterial Agents; Aztreonam; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Cefepime; Ceftazidime; Cephalosporins; Gene Expression; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Protein Structure, Secondary; Protein Structure, Tertiary; Pseudomonas aeruginosa; Tazobactam; Ticarcillin | 2015 |
The incidence and features of systemic reactions to skin prick tests.
Topics: Adolescent; Adult; Allergens; Anaphylaxis; Child; Child, Preschool; Erythema; Female; Food Hypersensitivity; Humans; Infant; Male; Middle Aged; Nut Hypersensitivity; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Retrospective Studies; Skin Tests; Urticaria; Young Adult | 2015 |
Drug-induced immune-mediated thrombocytopenia in the intensive care unit.
Topics: Device Removal; Female; Humans; Immunoglobulin G; Intensive Care Units; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prosthesis-Related Infections; Purpura, Thrombocytopenic, Idiopathic; Vancomycin | 2015 |
A case of pulmonary Serratia marcescens granuloma radiologically mimicking metastatic malignancy and tuberculosis infection.
Topics: Anti-Bacterial Agents; Diagnosis, Differential; Female; Hospitalization; Humans; Opportunistic Infections; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia; Radiography, Thoracic; Serratia Infections; Serratia marcescens; Tomography, X-Ray Computed; Treatment Outcome; Tuberculosis | 2015 |
High-risk febrile neutropenia and its management in children with solid tumors and lymphoma.
Topics: Amikacin; Anti-Bacterial Agents; C-Reactive Protein; Calcitonin; Calcitonin Gene-Related Peptide; Child; Febrile Neutropenia; Female; Humans; Imipenem; Lymphoma; Male; Neoplasms; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Protein Precursors | 2015 |
Infected Abdominal Aortic Aneurysm Attributable to Haemophilus influenzae: Rapid Changes of Imaging Findings.
Topics: Aneurysm, Infected; Anti-Bacterial Agents; Aortic Aneurysm, Abdominal; Aortography; Blood Vessel Prosthesis Implantation; C-Reactive Protein; Ciprofloxacin; Diagnostic Imaging; Haemophilus Infections; Haemophilus influenzae; Humans; Leukocyte Count; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Ribotyping; Tomography, X-Ray Computed | 2015 |
Extracorporeal Elimination of Piperacillin/Tazobactam during Molecular Adsorbent Recirculating System Therapy.
Topics: Adult; Anti-Bacterial Agents; Female; Humans; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sorption Detoxification | 2015 |
Patient and physician predictors of patient receipt of therapies recommended by a computerized decision support system when initially prescribed broad-spectrum antibiotics: a cohort study.
Topics: Academic Medical Centers; Aged; Anti-Bacterial Agents; Carbapenems; Cohort Studies; Decision Support Systems, Clinical; Drug Therapy, Computer-Assisted; Drug Utilization; Female; Guideline Adherence; Humans; Inappropriate Prescribing; Intensive Care Units; Kidney Diseases; Male; Middle Aged; Patient Admission; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Practice Patterns, Physicians'; Singapore | 2016 |
Sub-Inhibitory Concentration of Piperacillin-Tazobactam May be Related to Virulence Properties of Filamentous Escherichia coli.
Topics: Animals; Anti-Bacterial Agents; Biofilms; Disease Models, Animal; Escherichia coli; Escherichia coli Infections; Intraabdominal Infections; Locomotion; Metabolism; Mice; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Virulence | 2016 |
Abolished ventilation and perfusion of lung caused by blood clot in the left main bronchus: auto-downregulation of pulmonary arterial blood supply.
Topics: Bronchoscopy; Cough; Down-Regulation; Dyspnea; Fever; Gentamicins; Humans; Hypertension, Pulmonary; Lung; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia; Pulmonary Embolism; Tomography, Emission-Computed, Single-Photon; Treatment Outcome; Ventilation-Perfusion Ratio | 2015 |
A Fatal Case of Nosocomial Legionnaires' Disease: Implications From an Extensive Environmental Investigation and Isolation of the Bacterium From Blood Culture.
Topics: Cross Infection; Environmental Exposure; Equipment Contamination; Fatal Outcome; Female; Humans; Italy; Legionella pneumophila; Legionnaires' Disease; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2015 |
Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DA
Topics: Aged; Anti-Bacterial Agents; Blood Chemical Analysis; Critical Illness; Female; Humans; Infusions, Intravenous; Intensive Care Units; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Thienamycins; Treatment Outcome | 2016 |
63-Year-Old Woman With Generalized Fatigue and Left Flank Pain.
Topics: Acute Disease; Anti-Bacterial Agents; Catheterization, Central Venous; Diagnosis, Differential; Drug Administration Routes; Escherichia coli; Fatigue; Female; Flank Pain; Fluid Therapy; Humans; Levofloxacin; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pyelonephritis; Systemic Inflammatory Response Syndrome; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Antimicrobial Susceptibilities of Aerobic and Facultative Gram-Negative Bacilli from Intra-abdominal Infections in Patients from Seven Regions in China in 2012 and 2013.
Topics: Amikacin; Ampicillin; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Cefoxitin; China; Ciprofloxacin; Community-Acquired Infections; Cross Infection; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Ertapenem; Gene Expression; Humans; Imipenem; Intraabdominal Infections; Levofloxacin; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sulbactam | 2016 |
Top Guns: The "Maverick" and "Goose" of Empiric Therapy.
Topics: Adult; Aged; Aged, 80 and over; Animals; Anti-Bacterial Agents; Bacterial Infections; Critical Illness; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Renal Insufficiency; Retrospective Studies; Risk Assessment; Vancomycin | 2016 |
Piperacillin/tazobactam continuous infusion at 12G/1.5G per day in CF patients results in target plasma-concentrations.
Topics: Anti-Bacterial Agents; Cystic Fibrosis; Dose-Response Relationship, Drug; Humans; Infusions, Intravenous; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2016 |
Impact of the MIC of piperacillin/tazobactam on the outcome for patients with bacteraemia due to Enterobacteriaceae: the Bacteraemia-MIC project.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacteremia; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Hospitals, University; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Spain; Survival Analysis; Treatment Outcome; Young Adult | 2016 |
Nonoperative treatment of acute appendicitis in children: A feasibility study.
Topics: Acute Disease; Adolescent; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Appendectomy; Appendicitis; beta-Lactamase Inhibitors; Child; Child, Preschool; Cost-Benefit Analysis; Drug Therapy, Combination; Feasibility Studies; Female; Humans; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Quality of Life; Recurrence; Treatment Failure | 2016 |
Population Pharmacokinetics and Pharmacodynamics of Extended-Infusion Piperacillin and Tazobactam in Critically Ill Children.
Topics: Age Factors; Anti-Bacterial Agents; Area Under Curve; Child; Child, Preschool; Computer Simulation; Critical Illness; Drug Administration Schedule; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Glomerular Filtration Rate; Half-Life; Humans; Infant; Intensive Care Units; Male; Microbial Sensitivity Tests; Monte Carlo Method; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sex Factors | 2016 |
Drug Fever Induced by Piperacillin/Tazobactam in a Scoliosis Patient: A Case Report.
Topics: Adult; Anti-Bacterial Agents; Drug Combinations; Female; Fever; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Postoperative Complications; Scoliosis | 2015 |
A pilot study on pharmacokinetic/pharmacodynamic target attainment in critically ill patients receiving piperacillin/tazobactam.
Topics: Adult; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Critical Illness; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Pilot Projects; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies | 2016 |
The unexpected benefits of the national piperacillin/tazobactam shortage on antibiotic stewardship.
Topics: Anti-Bacterial Agents; Clostridioides difficile; Drug Prescriptions; Drug Resistance; Drug Utilization; Enterobacteriaceae; Humans; Klebsiella pneumoniae; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Serratia marcescens; Staphylococcus aureus | 2016 |
Silver- and fluoride-containing mesoporous bioactive glasses versus commonly used antibiotics: Activity against multidrug-resistant bacterial strains isolated from patients with burns.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Aztreonam; Burns; Carbenicillin; Cefepime; Ceftazidime; Ceftriaxone; Cell Survival; Cephalosporins; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Fluorides; Gentamicins; Glass; Humans; Imipenem; Meropenem; Mice; Microbial Sensitivity Tests; NIH 3T3 Cells; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Silver; Thienamycins; Tobramycin; Wound Infection | 2016 |
Evaluation of CTX-M steady-state mRNA, mRNA half-life and protein production in various STs of Escherichia coli.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Disk Diffusion Antimicrobial Tests; Escherichia coli; Genotype; Humans; Immunoblotting; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA Stability; RNA, Messenger; Tazobactam | 2016 |
Serum β-lactam concentrations in critically ill patients with cirrhosis: a matched case-control study.
Topics: Aged; Anti-Bacterial Agents; Belgium; Case-Control Studies; Chromatography, High Pressure Liquid; Critical Illness; Databases, Factual; Drug Monitoring; Female; Humans; Liver Cirrhosis; Logistic Models; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Multivariate Analysis; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sepsis; Thienamycins | 2016 |
Effectiveness of Patient Choice in Nonoperative vs Surgical Management of Pediatric Uncomplicated Acute Appendicitis.
Topics: Adolescent; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Appendectomy; Appendicitis; Child; Ciprofloxacin; Family; Female; Health Care Costs; Humans; Laparoscopy; Male; Metronidazole; Patient Participation; Patient Preference; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Treatment Outcome | 2016 |
Rapid-Onset Thrombocytopenia Following Piperacillin-Tazobactam Reexposure.
Topics: Aged; Anti-Bacterial Agents; Coronary Artery Bypass; Diagnosis, Differential; Humans; Hypersensitivity, Delayed; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia; Postoperative Complications; Thrombocytopenia | 2015 |
Antimicrobial susceptibility of clinical Enterobacteriaceae isolates at the emergency department in a regional hospital: A threat of extended spectrum beta-lactamase-producers among nursing home residents.
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Blood; Drug Resistance, Multiple, Bacterial; Emergency Service, Hospital; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Male; Meropenem; Microbial Sensitivity Tests; Nursing Homes; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Proteus Infections; Proteus mirabilis; Retrospective Studies; Sputum; Taiwan; Thienamycins; Urine | 2016 |
A Common But Not so Typical Elevated Anion Gap.
Topics: Acetone; Acidosis; Adult; Anti-Bacterial Agents; Blood Glucose; Confusion; Diabetes Complications; Fever; Fluid Therapy; Humans; Leg Injuries; Male; Methicillin-Resistant Staphylococcus aureus; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sepsis; Sodium Bicarbonate; Staphylococcal Infections; Vancomycin | 2016 |
In Vitro Activity of Ceftazidime-Avibactam against Contemporary Pseudomonas aeruginosa Isolates from U.S. Medical Centers by Census Region, 2014.
Topics: Academic Medical Centers; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactam Resistance; Ceftazidime; Censuses; Drug Combinations; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Public Health Surveillance; Thienamycins; United States | 2016 |
Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam during high volume haemodiafiltration in patients with septic shock.
Topics: Aged; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Female; Hemodiafiltration; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Shock, Septic | 2016 |
Impact of an Antimicrobial Stewardship Program on Patient Safety in Veterans Prescribed Vancomycin.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Anti-Bacterial Agents; Creatinine; Drug Therapy, Combination; Female; Hospital Departments; Humans; Interrupted Time Series Analysis; Male; Middle Aged; Patient Safety; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Risk Factors; Vancomycin; Veterans | 2016 |
Visual and absorbance analyses of admixtures containing vancomycin and piperacillin-tazobactam at commonly used concentrations.
Topics: Anti-Bacterial Agents; Chemical Precipitation; Drug Compounding; Drug Incompatibility; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sodium Chloride; Time Factors; Vancomycin | 2016 |
In vitro susceptibility of multi-drug resistant Pseudomonas aeruginosa and extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolated from clinical specimens at Bugando Medical Centre, Tanzania to Piperacillin-Tazobactam.
Topics: Anti-Bacterial Agents; beta-Lactamases; Drug Resistance, Multiple, Bacterial; Humans; In Vitro Techniques; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Tanzania | 2014 |
Piperacillin population pharmacokinetics in critically ill patients with multiple organ dysfunction syndrome receiving continuous venovenous haemodiafiltration: effect of type of dialysis membrane on dosing requirements.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Body Weight; Chromatography, Liquid; Critical Illness; Female; Hemodiafiltration; Humans; Infusions, Intravenous; Male; Mass Spectrometry; Microbial Sensitivity Tests; Middle Aged; Multiple Organ Failure; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Plasma; Prospective Studies; Tertiary Care Centers; Young Adult | 2016 |
Prospective Comparison of Acute Kidney Injury During Treatment With the Combination of Piperacillin-Tazobactam and Vancomycin Versus the Combination of Cefepime or Meropenem and Vancomycin.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cefepime; Cephalosporins; Cohort Studies; Drug Therapy, Combination; Female; Humans; Male; Meropenem; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Thienamycins; Treatment Outcome; Vancomycin | 2017 |
Comparative Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam or Cefepime: A Retrospective Cohort Study.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Arkansas; Cefepime; Cephalosporins; Critical Illness; Drug Therapy, Combination; Female; Humans; Incidence; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Vancomycin | 2016 |
Impact of de-escalation of beta-lactam antibiotics on the emergence of antibiotic resistance in ICU patients: a retrospective observational study.
Topics: Aged; Anti-Bacterial Agents; beta-Lactams; Ceftazidime; Drug Resistance, Microbial; Female; Humans; Intensive Care Units; Male; Meropenem; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Thienamycins | 2016 |
Persistent supravenous erythematous eruption-like changes from antibiotics.
Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Aged; Anti-Bacterial Agents; Antibodies, Monoclonal, Murine-Derived; Catheter-Related Infections; Drug Eruptions; Erythema; Female; Humans; Infusions, Intravenous; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Skin; Veins | 2016 |
Is high-dose β-lactam therapy associated with excessive drug toxicity in critically ill patients?
Topics: Adult; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Chemical and Drug Induced Liver Injury; Cholestasis; Critical Illness; Drug Monitoring; Female; Humans; Male; Meropenem; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Renal Replacement Therapy; Retrospective Studies; Seizures; Thienamycins; Thrombocytopenia | 2016 |
Epidemiology of Acute Kidney Injury among Patients Receiving Concomitant Vancomycin and Piperacillin-Tazobactam: Opportunities for Antimicrobial Stewardship.
Topics: Acute Kidney Injury; Adult; Aged; Anti-Bacterial Agents; Case-Control Studies; Drug Therapy, Combination; Female; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Logistic Models; Male; Michigan; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Vancomycin | 2016 |
Targeted benefits of prolonged-infusion piperacillin-tazobactam in an in vitro infection model of Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Humans; In Vitro Techniques; Infusions, Intravenous; Microbial Sensitivity Tests; Monte Carlo Method; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections | 2016 |
Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Enterobacteriaceae; Female; Humans; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies | 2016 |
Impact of a Multimodal Approach in Prevention of Surgical Site Infection in Hepatic Transplant Recipients.
Topics: Administration, Cutaneous; Adult; Ampicillin; Anti-Bacterial Agents; Anti-Infective Agents, Local; Antibiotic Prophylaxis; Cefazolin; Chlorhexidine; Drug Administration Schedule; Drug Therapy, Combination; Ether; Female; Gentamicins; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Infusions, Intravenous; Liver Transplantation; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sulbactam; Surgical Wound Infection; Transplant Recipients | 2016 |
In Vivo and In Vitro Efficacy of Minocycline-Based Combination Therapy for Minocycline-Resistant Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Anti-Bacterial Agents; Biofilms; Cefepime; Cephalosporins; Colistin; Drug Resistance, Multiple, Bacterial; Gentamicins; Imipenem; Meropenem; Mice; Microbial Sensitivity Tests; Minocycline; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia; Taiwan; Thienamycins | 2016 |
Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice.
Topics: Animals; Anti-Bacterial Agents; CD4-Positive T-Lymphocytes; Cilastatin; Cilastatin, Imipenem Drug Combination; Colon; Drug Combinations; Feces; Female; Flow Cytometry; Gastrointestinal Microbiome; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imipenem; Interleukin-23; Mice; Mice, Inbred C57BL; Penicillanic Acid; Phylogeny; Piperacillin; Piperacillin, Tazobactam Drug Combination; Transplantation, Homologous; Verrucomicrobia | 2016 |
Pharmacokinetics and Pharmacodynamics of Extended Infusion Versus Short Infusion Piperacillin-Tazobactam in Critically Ill Patients Undergoing CRRT.
Topics: Acute Kidney Injury; Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Critical Illness; Dialysis Solutions; Female; Hemodiafiltration; Humans; Infusions, Intravenous; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Time Factors | 2016 |
Outcomes of an extended-infusion piperacillin-tazobactam protocol implementation in a community teaching hospital adult intensive care unit.
Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Cohort Studies; Delayed-Action Preparations; Female; Hospitals, Community; Hospitals, Teaching; Humans; Intensive Care Units; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas Infections; Treatment Outcome | 2016 |
An Immunocompromised Child with Bloodstream Infection Caused by Two Escherichia coli Strains, One Harboring NDM-5 and the Other Harboring OXA-48-Like Carbapenemase.
Topics: Adolescent; Amikacin; Anti-Bacterial Agents; Aztreonam; Bacterial Proteins; beta-Lactamases; beta-Lactams; Ciprofloxacin; Ertapenem; Escherichia coli; Female; Gentamicins; Humans; Immunocompromised Host; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam; Thienamycins; Tobramycin | 2016 |
Impact of computerized pre-authorization of broad spectrum antibiotics in Pseudomonas aeruginosa at a children's hospital in Japan.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Carbapenems; Cefepime; Ceftazidime; Cephalosporins; Hospitals; Humans; Japan; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tokyo | 2016 |
[The activity of moxalactam against Enterobacteriaceae and anaerobia in vitro].
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; Cefoperazone; Enterobacteriaceae; Escherichia coli; Imipenem; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Moxalactam; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Proteus; Thienamycins | 2016 |
Evaluation of an alternative extended-infusion piperacillin-tazobactam dosing strategy for the treatment of gram-negative infections.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Cohort Studies; Delayed-Action Preparations; Drug Administration Schedule; Female; Gram-Negative Bacterial Infections; Humans; Infusions, Intravenous; Kentucky; Male; Middle Aged; Patient Readmission; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Treatment Outcome | 2016 |
Piperacillin-Tazobactam Induced Interstitial Nephritis, Hepatitis and Serum Sckness-Like Illness.
Topics: Adult; Anti-Bacterial Agents; Chemical and Drug Induced Liver Injury; Female; Humans; Nephritis, Interstitial; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia; Serum Sickness | 2016 |
Drug fever induced by piperacillin/tazobactam in an elderly patient with underlying human immunodeficiency virus (HIV) infection.
Topics: Anti-Bacterial Agents; Cholecystitis, Acute; Fever; HIV Infections; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2016 |
Variability of piperacillin concentrations in relation to tazobactam concentrations in critically ill patients.
Topics: Aged; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Critical Illness; Drug Monitoring; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Serum | 2016 |
IMP-27, a Unique Metallo-β-Lactamase Identified in Geographically Distinct Isolates of Proteus mirabilis.
Topics: Aztreonam; beta-Lactamases; beta-Lactams; Ceftazidime; Drug Resistance, Bacterial; Ertapenem; Hydrolysis; Integrons; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Proteus Infections; Proteus mirabilis; United States | 2016 |
[Study on drug sensitivity against Comamonas testosteroni by Kirby-Bauer disk diffusion method].
Topics: Anti-Bacterial Agents; Cefepime; Cephalosporins; Comamonas testosteroni; Imipenem; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Thienamycins | 2016 |
Vitamin T overdose?: examining the phenomenon of widespread use of the broad spectrum antimicrobial piperacillin/tazobactam.
Topics: Anti-Bacterial Agents; Australia; Guideline Adherence; Humans; Inappropriate Prescribing; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Surveys and Questionnaires | 2016 |
Target attainment analysis and optimal sampling designs for population pharmacokinetic study on piperacillin/tazobactam in neonates and young infants.
Topics: Anti-Bacterial Agents; Blood Specimen Collection; Computer Simulation; Drug Administration Schedule; Humans; Infant; Infant, Newborn; Infusions, Intravenous; Microbial Sensitivity Tests; Models, Biological; Monte Carlo Method; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2016 |
Standard dosing of piperacillin and meropenem fail to achieve adequate plasma concentrations in ICU patients.
Topics: Aged; Anti-Bacterial Agents; Female; Glomerular Filtration Rate; Humans; Intensive Care Units; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Thienamycins | 2016 |
Piperacillin/tazobactam-induced immune-mediated thrombocytopenia in the intensive care unit.
Topics: Anti-Bacterial Agents; Humans; Intensive Care Units; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Thrombocytopenia | 2016 |
Molecular modeling and redesign of alginate lyase from Pseudomonas aeruginosa for accelerating CRPA biofilm degradation.
Topics: Acetylation; Alginates; Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; Biocatalysis; Biofilms; Ciprofloxacin; Cloning, Molecular; Drug Resistance, Bacterial; Drug Synergism; Drug Therapy, Combination; Escherichia coli; Gene Expression; Glucuronic Acid; Hexuronic Acids; Hydrolysis; Kinetics; Molecular Dynamics Simulation; Mutation; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Polysaccharide-Lyases; Protein Domains; Protein Engineering; Protein Structure, Secondary; Pseudomonas aeruginosa; Recombinant Proteins; Sequence Alignment; Structural Homology, Protein | 2016 |
Proposed breakpoint of piperacillin/tazobactam against extended spectrum β-lactamases producing bacteria in bacteremia.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Bacteria; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Enterobacteriaceae; Female; Humans; Japan; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Tazobactam | 2017 |
Bypass graft infection and bacteremia caused by Anaerostipes caccae: First report of human infection caused by a recently described gut anaerobe.
Topics: Adult; Amoxicillin-Potassium Clavulanate Combination; Anastomosis, Surgical; Anti-Bacterial Agents; beta-Lactams; Blood Culture; Clostridiales; Ertapenem; Female; Gram-Positive Bacterial Infections; Humans; Metronidazole; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Surgical Wound Infection; Vancomycin | 2016 |
Pseudomonas mendocina native valve infective endocarditis: a case report.
Topics: Anti-Bacterial Agents; Bandages; Debridement; Endocarditis, Bacterial; Heart Valve Diseases; Humans; Leg Ulcer; Male; Middle Aged; Pain; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas Infections; Pseudomonas mendocina; Treatment Outcome | 2016 |
Emphysematous pyelonephritis in a renal allograft.
Topics: Anti-Bacterial Agents; Comorbidity; Diabetes Mellitus; Diabetic Ketoacidosis; Drug Therapy, Combination; Emphysema; Humans; Hypertension; Kidney Transplantation; Male; Middle Aged; Norepinephrine; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Postoperative Complications; Pyelonephritis; Tomography, X-Ray Computed; Transplantation, Homologous; Vancomycin | 2017 |
Antimicrobial Monotherapy versus Combination Therapy for the Treatment of Complicated Intra-Abdominal Infections.
Topics: Academic Medical Centers; Aged; Anti-Bacterial Agents; Cohort Studies; Drug Therapy, Combination; Female; Humans; Intensive Care Units; Intraabdominal Infections; Length of Stay; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Time Factors; Treatment Outcome; Vancomycin | 2016 |
The U.S. Food and Drug Administration announcement suggests the need to revisit guidelines for antibiotic use after EUS-FNA.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Antibiotic Prophylaxis; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Postoperative Care; Practice Guidelines as Topic; United States; United States Food and Drug Administration | 2016 |
Piperacillin-Tazobactam-induced Adverse Drug Events in Pediatric Patients on Outpatient Parenteral Antimicrobial Therapy.
Topics: Adolescent; Anti-Bacterial Agents; Bacterial Infections; Child; Child, Preschool; Female; Humans; Infant; Infusions, Parenteral; Kaplan-Meier Estimate; Male; Outpatients; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2017 |
Piperacillin-induced mild haemolytic anaemia in a 44-year-old patient with cystic fibrosis.
Topics: Adult; Anemia, Hemolytic; Anti-Bacterial Agents; Cystic Fibrosis; Female; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2016 |
In Vitro-In Vivo Discordance with Humanized Piperacillin-Tazobactam Exposures against Piperacillin-Tazobactam-Resistant/Pan-β-Lactam-Susceptible Escherichia coli.
Topics: Animals; Anti-Bacterial Agents; Cephalosporins; Colistin; Culture Media; Disease Models, Animal; Drug Administration Schedule; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Humans; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tobramycin; Treatment Outcome | 2016 |
Using a simple point-prevalence survey to define appropriate antibiotic prescribing in hospitalised children across the UK.
Topics: Adolescent; Anti-Bacterial Agents; Carbapenems; Child; Child, Hospitalized; Child, Preschool; Cross-Sectional Studies; Drug Prescriptions; Drug Resistance, Microbial; Drug Utilization; Female; Health Care Surveys; Hospitalization; Hospitals; Humans; Inappropriate Prescribing; Infant; Male; Pediatrics; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Practice Patterns, Physicians'; State Medicine; Surveys and Questionnaires; United Kingdom | 2016 |
Pneumoretroperitoneum and pneumomediastinum after Stapled Anopexy Is conservative treatment possible?
Topics: Anastomotic Leak; Anti-Bacterial Agents; Combined Modality Therapy; Conservative Treatment; Hemorrhoids; Humans; Male; Mediastinal Emphysema; Metronidazole; Middle Aged; Parenteral Nutrition, Total; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Postoperative Complications; Retropneumoperitoneum; Surgical Stapling; Tomography, X-Ray Computed | 2016 |
Trends in antimicrobial resistance among Bacteroides species and Parabacteroides species in the United States from 2010-2012 with comparison to 2008-2009.
Topics: Anti-Infective Agents; Bacteroides; Bacteroides fragilis; Bacteroides Infections; Bacteroidetes; beta-Lactamase Inhibitors; Carbapenems; Drug Resistance, Microbial; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; United States | 2017 |
Clinical Outcomes of Extended Versus Intermittent Infusion of Piperacillin/Tazobactam in Critically Ill Patients: A Prospective Clinical Trial.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Critical Illness; Female; Humans; Intensive Care Units; Length of Stay; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies | 2017 |
Clinical characteristics and antimicrobial susceptibilities of anaerobic bacteremia in an acute care hospital.
Topics: Anaerobiosis; Anti-Infective Agents; Bacteremia; Bacteria, Anaerobic; Bacteroides; Carbapenems; Clindamycin; Clostridium; Drug Resistance, Microbial; Fusobacterium; Gram-Positive Bacteria; Humans; Intraabdominal Infections; Metronidazole; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Propionibacterium; Retrospective Studies | 2017 |
Nephrotoxicity during Vancomycin Therapy in Combination with Piperacillin-Tazobactam or Cefepime.
Topics: Acute Kidney Injury; Adult; Aged; Anti-Bacterial Agents; Cefepime; Cephalosporins; Female; Humans; Kidney; Male; Middle Aged; Multivariate Analysis; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Vancomycin | 2017 |
Complicated acute appendicitis presenting as a rapidly progressive soft tissue infection of the abdominal wall: a case report.
Topics: Abdominal Pain; Abdominal Wall; Anti-Bacterial Agents; Appendectomy; Appendicitis; Emphysema; Escherichia coli Infections; Female; Humans; Middle Aged; Penicillanic Acid; Peritonitis; Piperacillin; Piperacillin, Tazobactam Drug Combination; Reoperation; Soft Tissue Infections; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Agranulocytosis occurrence following recent acute infectious mononucleosis.
Topics: Adolescent; Agranulocytosis; Anti-Bacterial Agents; Disease Progression; Epstein-Barr Virus Infections; Female; Fever; Humans; Infectious Mononucleosis; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Treatment Failure | 2017 |
Assessing the risk of false positive serum galactomannan among patients receiving piperacillin/tazobactam for febrile neutropenia.
Topics: Anti-Bacterial Agents; Antigens, Fungal; False Positive Reactions; Febrile Neutropenia; Female; Galactose; Humans; Invasive Pulmonary Aspergillosis; Male; Mannans; Microbiological Techniques; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2017 |
Effective Antibiotic Conservation by Emergency Antimicrobial Stewardship During a Drug Shortage.
Topics: Academic Medical Centers; Anti-Bacterial Agents; Antimicrobial Stewardship; Hospital Mortality; Humans; Length of Stay; Linear Models; Meropenem; Missouri; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Thienamycins | 2017 |
Frequency of empiric antibiotic de-escalation in an acute care hospital with an established Antimicrobial Stewardship Program.
Topics: Acute Disease; Aged; Anti-Bacterial Agents; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Hospital Mortality; Humans; Length of Stay; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia; Retrospective Studies; Sepsis; Vancomycin | 2016 |
Risk of Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin-Tazobactam Compared to Those on Vancomycin and Cefepime.
Topics: Acute Kidney Injury; Adult; Aged; Anti-Bacterial Agents; Cefepime; Cephalosporins; Combined Modality Therapy; Drug Therapy, Combination; Female; Humans; Length of Stay; Male; Middle Aged; Odds Ratio; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prognosis; Retrospective Studies; Risk; Severity of Illness Index; Vancomycin | 2017 |
Spontaneous Nasal Septal Abscess Presenting as a Soft Tissue Mass in a Child.
Topics: Abscess; Amoxicillin; Anti-Bacterial Agents; Child; Emergency Service, Hospital; Epistaxis; Fever; Humans; Magnetic Resonance Imaging; Male; Methicillin-Resistant Staphylococcus aureus; Nasal Septum; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Rupture, Spontaneous; Tomography, X-Ray Computed; Vancomycin | 2017 |
Prevalence and antimicrobial susceptibility of Acinetobacter spp. isolated from meat.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Ampicillin; Animals; Anti-Bacterial Agents; Cattle; Ceftazidime; Chickens; Ciprofloxacin; Cross Infection; DNA-Directed RNA Polymerases; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prevalence; Red Meat; Sulbactam; Swine; Trimethoprim, Sulfamethoxazole Drug Combination | 2017 |
Disseminated tungiasis in a 78-year-old woman from Tanzania: a case report.
Topics: Aged; Animals; Anti-Bacterial Agents; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Ectoparasitic Infestations; Extremities; Female; Ferrous Compounds; Folic Acid; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Poverty Areas; Quality of Life; Sepsis; Severity of Illness Index; Tanzania; Tetanus Toxoid; Tolvaptan; Treatment Outcome; Tunga; Tungiasis; Vitamins | 2016 |
Photo Quiz: A 44-Year-Old Kidney Transplant Patient with Pneumonia.
Topics: Acute Kidney Injury; Adult; Anti-Bacterial Agents; Bacterial Proteins; Bacterial Toxins; beta-Lactamases; Clostridioides difficile; Enterobacter cloacae; Female; Humans; Imipenem; Kidney Failure, Chronic; Kidney Transplantation; Metronidazole; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia; Respiratory Insufficiency; Vancomycin | 2017 |
Antimicrobial susceptibility of Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Asia-Pacific countries: SMART 2013-2015.
Topics: Acinetobacter baumannii; Amikacin; Anti-Infective Agents; Asia; beta-Lactamases; beta-Lactams; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacter; Ertapenem; Gram-Negative Bacteria; Hospitalization; Humans; Imipenem; Intraabdominal Infections; Klebsiella pneumoniae; Levofloxacin; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Urinary Tract Infections | 2017 |
Detection of Piperacillin-Tazobactam-Resistant/Pan-β-Lactam-Susceptible Escherichia coli with Current Automated Susceptibility Test Systems.
Topics: Anti-Bacterial Agents; beta-Lactamases; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2017 |
[Clinical analysis for patients with continuous ambulatory peritoneal dialysis associated peritonitis].
Topics: Abdominal Pain; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Candidiasis; Catheters; Diarrhea; Drug Resistance, Bacterial; Enterococcus faecalis; Escherichia coli; Fever; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Imipenem; Klebsiella pneumoniae; Microbial Sensitivity Tests; Mycoses; Penicillanic Acid; Peritoneal Dialysis; Peritoneal Dialysis, Continuous Ambulatory; Peritonitis; Piperacillin; Piperacillin, Tazobactam Drug Combination; Recurrence; Retrospective Studies; Staphylococcus epidermidis; Staphylococcus haemolyticus; Vomiting | 2016 |
Potentiation of ceftazidime by avibactam against β-lactam-resistant Pseudomonas aeruginosa in an in vitro infection model.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactam Resistance; beta-Lactamase Inhibitors; Ceftazidime; Drug Synergism; Kinetics; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Tandem Mass Spectrometry; Thienamycins | 2017 |
Comparison of Rates of Nephrotoxicity Associated with Vancomycin in Combination with Piperacillin-Tazobactam Administered as an Extended versus Standard Infusion.
Topics: Acute Kidney Injury; Aged; Anti-Bacterial Agents; Cohort Studies; Creatinine; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Intensive Care Units; Logistic Models; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Tertiary Care Centers; Time Factors; Vancomycin | 2017 |
Piperacillin-tazobactam-induced linear IgA bullous dermatosis presenting clinically as Stevens-Johnson syndrome/toxic epidermal necrolysis overlap.
Topics: Anti-Bacterial Agents; Diagnosis, Differential; Humans; Linear IgA Bullous Dermatosis; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Stevens-Johnson Syndrome | 2017 |
Topics: Achromobacter denitrificans; Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Stenotrophomonas maltophilia; Tazobactam; Thienamycins | 2017 |
Non-surgical treatment of diabetic foot osteomyelitis.
Topics: Aged; Anti-Bacterial Agents; Ciprofloxacin; Diabetes Mellitus, Type 2; Diabetic Foot; Humans; Male; Osteomyelitis; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Treatment Outcome | 2017 |
A propensity score-matched analysis of the impact of minimum inhibitory concentration on mortality in patients with Pseudomonas aeruginosa bacteraemia treated with piperacillin/tazobactam.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactamase Inhibitors; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Propensity Score; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Risk Factors; Survival Analysis | 2017 |
Antibiotic resistance & pathogen profile in ventilator-associated pneumonia in a tertiary care hospital in India.
Topics: Amikacin; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; India; Intensive Care Units; Klebsiella; Methicillin Resistance; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Ventilator-Associated; Pseudomonas; Staphylococcus aureus; Tertiary Care Centers; Vancomycin-Resistant Enterococci | 2016 |
Increased Time to Initial Antimicrobial Administration Is Associated With Progression to Septic Shock in Severe Sepsis Patients.
Topics: Adult; Aged; Anti-Bacterial Agents; Ceftriaxone; Comorbidity; Disease Progression; Female; Hospital Mortality; Humans; Length of Stay; Levofloxacin; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Sepsis; Sex Factors; Shock, Septic; Time Factors; Time-to-Treatment; Vasoconstrictor Agents | 2017 |
Acute kidney injury in patients treated with vancomycin and piperacillin-tazobactam: A retrospective cohort analysis.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Drug Therapy, Combination; Female; Humans; Incidence; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Vancomycin | 2017 |
Human herpes virus-6 encephalitis causing severe anterograde amnesia associated with rituximab, azathioprine and prednisolone combination therapy for dermatomyositis.
Topics: Acyclovir; Adult; Amnesia, Anterograde; Antiviral Agents; Azathioprine; B-Lymphocytes; Dermatomyositis; Encephalitis, Viral; Female; Herpesvirus 6, Human; Humans; Immunologic Factors; Lymphocyte Depletion; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prednisolone; Rituximab; Roseolovirus Infections | 2017 |
Bacteremia with Raoultella planticola in the setting of acute pancreatitis complicated with acute cholangitis.
Topics: Acute Disease; Anti-Bacterial Agents; Bacteremia; Cholangitis; Enterobacteriaceae; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Pancreatitis, Acute Necrotizing; Panniculitis; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2017 |
Repeated Piperacillin-Tazobactam Plasma Concentration Measurements in Severely Obese Versus Nonobese Critically Ill Septic Patients and the Risk of Under- and Overdosing.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Body Mass Index; Critical Illness; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method; Obesity; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Shock, Septic | 2017 |
Acute Kidney Injury in Patients Treated with IV Beta-Lactam/Beta-Lactamase Inhibitor Combinations.
Topics: Acute Kidney Injury; Adult; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactams; Cohort Studies; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Treatment Outcome; Vancomycin | 2017 |
Prevalence, patient characteristics and outcomes of a novel piperacillin/tazobactam-resistant, pan-β-lactam-susceptible phenotype in Enterobacteriaceae: implications for selective reporting.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Connecticut; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Enterobacteriaceae; Enterobacteriaceae Infections; Escherichia coli; Female; Humans; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Phenotype; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prevalence; Retrospective Studies; Risk Factors; Treatment Outcome | 2017 |
Risk factors associated with fluoroquinolone-resistant enterococcal urinary tract infections in a tertiary care university hospital in north India.
Topics: Ciprofloxacin; Cross Infection; Drug Resistance, Bacterial; Enterococcus; Female; Fluoroquinolones; Hospitals, University; Humans; India; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pregnancy; Risk Factors; Tertiary Care Centers; Urinary Tract Infections | 2016 |
Role of piperacillin/tazobactam as a carbapenem-sparing antibiotic for treatment of acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Hospitals, University; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pyelonephritis; Republic of Korea; Retrospective Studies; Survival Analysis; Treatment Failure; Young Adult | 2017 |
Trends in Drug Resistance of
Topics: Acinetobacter baumannii; Amikacin; Anti-Infective Agents; Cefepime; Cefoperazone; Ceftazidime; Cephalosporins; China; Colistin; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Levofloxacin; Microbial Sensitivity Tests; Minocycline; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sulbactam | 2017 |
Clinical features and antimicrobial resistance profiles of important Enterobacteriaceae pathogens in Guangzhou representative of Southern China, 2001-2015.
Topics: Amikacin; Anti-Bacterial Agents; Blood; Carbapenems; Ceftazidime; Cephalosporins; China; Disk Diffusion Antimicrobial Tests; Drug Resistance, Bacterial; Enterobacter; Enterobacteriaceae; Escherichia coli; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sputum; Urinary Tract | 2017 |
Antimicrobial resistance in the Bacteroides fragilis group in faecal microbiota from healthy Danish children.
Topics: Anti-Bacterial Agents; Bacteroides fragilis; Bacteroides Infections; Child; Clindamycin; Denmark; Drug Resistance, Bacterial; Feces; Humans; Meropenem; Metronidazole; Microbial Sensitivity Tests; Microbiota; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Surveys and Questionnaires; Thienamycins | 2017 |
Dose optimization of piperacillin/tazobactam in critically ill children.
Topics: Adolescent; Anti-Bacterial Agents; Bacterial Infections; Child; Child, Preschool; Critical Illness; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infant; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Monte Carlo Method; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Tazobactam | 2017 |
Use of Population Pharmacokinetics and Electronic Health Records to Assess Piperacillin-Tazobactam Safety in Infants.
Topics: Anti-Bacterial Agents; Area Under Curve; Cross Infection; Electronic Health Records; Female; Humans; Infant; Infant, Newborn; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies | 2017 |
Piperacillin-tazobactam versus cefepime incidence of acute kidney injury in combination with vancomycin and tobramycin in pediatric cystic fibrosis patients.
Topics: Acute Kidney Injury; Adolescent; Anti-Bacterial Agents; Cefepime; Cephalosporins; Child; Cystic Fibrosis; Drug Therapy, Combination; Female; Hospitalization; Humans; Incidence; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Tobramycin; Vancomycin | 2017 |
The Effect of a Piperacillin/Tazobactam Shortage on Antimicrobial Prescribing and Clostridium difficile Risk in 88 US Medical Centers.
Topics: Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Drug Prescriptions; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Treatment Outcome; United States | 2017 |
Enteritis with pneumatosis intestinalis following rotavirus immunisation in an infant with short bowel syndrome.
Topics: Enteritis; Humans; Infant; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumatosis Cystoides Intestinalis; Rotavirus Vaccines; Short Bowel Syndrome; Treatment Outcome; Vaccines, Attenuated | 2017 |
Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections.
Topics: Adult; Anti-Bacterial Agents; Cephalosporins; Cost-Benefit Analysis; Hospitalization; Humans; Middle Aged; Monte Carlo Method; Mortality; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Quality-Adjusted Life Years; United States; Urinary Tract Infections | 2017 |
A Simple Microsoft Excel Method to Predict Antibiotic Outbreaks and Underutilization.
Topics: Academic Medical Centers; Anti-Bacterial Agents; Confidence Intervals; Disease Outbreaks; Forecasting; Health Services Misuse; Humans; Intensive Care Units; Models, Theoretical; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Software | 2017 |
Hospital Length of Stay Among Patients Receiving Intermittent Versus Prolonged Piperacillin/Tazobactam Infusion in the Intensive Care Units.
Topics: Aged; Anti-Bacterial Agents; Bacterial Infections; Critical Illness; Female; Hospital Mortality; Humans; Infusions, Intravenous; Intensive Care Units; Length of Stay; Linear Models; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies | 2018 |
Target attainment with continuous dosing of piperacillin/tazobactam in critical illness: a prospective observational study.
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Chromatography, Liquid; Critical Illness; Female; Humans; Male; Middle Aged; Netherlands; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Plasma; Prospective Studies; Tandem Mass Spectrometry; Young Adult | 2017 |
Measurement of piperacillin plasma concentrations in cancer patients with suspected infection.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Female; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Time Factors | 2017 |
Acute kidney injury risk associated with piperacillin/tazobactam compared with cefepime during vancomycin therapy in hospitalised patients: a cohort study stratified by baseline kidney function.
Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cefepime; Cephalosporins; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Risk Assessment; Vancomycin; Young Adult | 2017 |
Cost-effectiveness of ceftolozane/tazobactam plus metronidazole compared with piperacillin/tazobactam as empiric therapy for the treatment of complicated intra-abdominal infections based on the in-vitro surveillance of bacterial isolates in the UK.
Topics: Anti-Bacterial Agents; Bacteriological Techniques; Cephalosporins; Clinical Protocols; Drug Combinations; Drug Therapy, Combination; Female; Gram-Negative Bacterial Infections; Humans; Intraabdominal Infections; Male; Metronidazole; Models, Econometric; Monte Carlo Method; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Quality-Adjusted Life Years; Tazobactam; United Kingdom | 2017 |
Mouse model of colonization of the digestive tract with Acinetobacter baumannii and subsequent pneumonia.
Topics: Acinetobacter; Acinetobacter Infections; Animals; Anti-Bacterial Agents; Bacterial Translocation; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Gastrointestinal Tract; Immunosuppression Therapy; Lung; Mice; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial | 2017 |
In vitro susceptibility and resistance phenotypes in contemporary Enterobacter isolates in a university hospital in Crete, Greece.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Cefepime; Cephalosporins; Child; Colistin; Drug Resistance, Multiple, Bacterial; Enterobacter; Enterobacteriaceae Infections; Greece; Hospitals, University; Humans; Microbial Sensitivity Tests; Minocycline; Penicillanic Acid; Phenotype; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tigecycline | 2017 |
[Usefulness of piperacillin/tazobactam resistance as a predictor of OXA-48 carbapenemase in Enterobacteriaceae].
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Drug Resistance, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2017 |
[A case of coccidioidomycosis in Turkey imported from the United States of America].
Topics: Adult; Amoxicillin-Potassium Clavulanate Combination; Antifungal Agents; Arizona; Coccidioides; Coccidioidomycosis; Fluconazole; Humans; Itraconazole; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pleura; Recurrence; Spores, Fungal; Travel; Turkey | 2017 |
Carbapenemase-Producing Enterobacteriaceae Isolates from Edo State, Nigeria.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenem-Resistant Enterobacteriaceae; Cefotaxime; Ceftazidime; Disk Diffusion Antimicrobial Tests; Enterobacteriaceae Infections; Ertapenem; Fluoroquinolones; Humans; Nigeria; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2017 |
The clinical significance of pneumonia in patients with respiratory specimens harbouring multidrug-resistant Pseudomonas aeruginosa: a 5-year retrospective study following 5667 patients in four general ICUs.
Topics: Aged; Amikacin; Anti-Bacterial Agents; Case-Control Studies; Colistin; Drug Resistance, Multiple, Bacterial; Female; Humans; Immunocompromised Host; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Ventilators, Mechanical | 2017 |
Clinical impact of non-antibiotic recommendations by a multi-disciplinary antimicrobial stewardship team.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antimicrobial Stewardship; Carbapenems; Communicable Diseases; Female; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Retrospective Studies; Survival Analysis; Treatment Outcome; Young Adult | 2017 |
Comparison of the therapeutic efficacy of fluoroquinolone and non-fluoroquinolone treatment in patients with Elizabethkingia meningoseptica bacteraemia.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; Chryseobacterium; Cross Infection; Female; Flavobacteriaceae Infections; Fluoroquinolones; Humans; Male; Microbial Sensitivity Tests; Minocycline; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Taiwan; Trimethoprim, Sulfamethoxazole Drug Combination | 2018 |
First report of cavitary pneumonia due to community-acquired Acinetobacter pittii, study of virulence and overview of pathogenesis and treatment.
Topics: Acinetobacter; Acinetobacter Infections; Amikacin; Animals; Caenorhabditis elegans; Community-Acquired Infections; Cross Infection; Female; France; Humans; Middle Aged; Multilocus Sequence Typing; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Virulence | 2017 |
Impact of renal replacement modalities on the clearance of piperacillin-tazobactam administered via continuous infusion in critically ill patients.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Chromatography; Critical Illness; Female; Hemofiltration; Humans; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Plasma; Prospective Studies; Renal Insufficiency; Time Factors | 2017 |
Pharmacokinetics of piperacillin-tazobactam in plasma, peritoneal fluid and peritoneum of surgery patients, and dosing considerations based on site-specific pharmacodynamic target attainment.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ascitic Fluid; beta-Lactamase Inhibitors; Female; Humans; Inflammatory Bowel Diseases; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Peritoneum; Piperacillin; Piperacillin, Tazobactam Drug Combination; Plasma; Preoperative Care; Prospective Studies; Young Adult | 2017 |
Empiric antibiotic protocols for cancer patients with neutropenia: a single-center study of treatment efficacy and mortality in patients with bacteremia.
Topics: Adult; Anti-Bacterial Agents; Bacteremia; Blood Culture; Carbapenem-Resistant Enterobacteriaceae; Cefazolin; Clinical Protocols; Enterobacteriaceae Infections; Gentamicins; Humans; Imipenem; Microbial Sensitivity Tests; Middle Aged; Neoplasms; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Staphylococcal Infections; Staphylococcus aureus; Streptococcal Infections; Streptococcus | 2018 |
Topics: Adult; Anti-Bacterial Agents; Diagnosis, Differential; Female; Humans; Immunocompromised Host; Lung Diseases; Lupus Erythematosus, Systemic; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tomography, X-Ray Computed | 2017 |
Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study.
Topics: Adolescent; Amikacin; Aminoglycosides; Anti-Bacterial Agents; Bacteremia; Carbapenems; Cephalosporins; Child; Child, Preschool; Drug Resistance, Multiple, Bacterial; Female; Fever; Fluoroquinolones; Humans; Male; Meropenem; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Thienamycins | 2017 |
Exacerbation of bronchiectasis by Pseudomonas monteilii: a case report.
Topics: Adult; Bronchiectasis; Humans; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas; Pseudomonas Infections; Random Amplified Polymorphic DNA Technique; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2017 |
Discitis and
Topics: Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Clostridium Infections; Discitis; Humans; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Treatment Outcome | 2017 |
Between fire and ice: refractory hypothermia and warmth-induced pain in inherited erythromelalgia.
Topics: Anti-Bacterial Agents; Child; Cold Temperature; Erythromelalgia; Female; Furosemide; Hot Temperature; Humans; Hypothermia; Mutation, Missense; NAV1.7 Voltage-Gated Sodium Channel; Pain; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Polyethylene Glycols; Rewarming; Skin Diseases, Vesiculobullous; Sodium Potassium Chloride Symporter Inhibitors; Surface-Active Agents; Thyroxine; Treatment Outcome; Vancomycin | 2017 |
Bacteraemia and liver abscess due to
Topics: Abdominal Pain; Anti-Bacterial Agents; Bacteremia; Ceftriaxone; Fusobacterium Infections; Fusobacterium necrophorum; Humans; Liver Abscess; Male; Metronidazole; Middle Aged; Nausea; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sepsis; Treatment Outcome; Vomiting | 2017 |
Dosing antibiotics in neonates: review of the pharmacokinetic data.
Topics: Adult; Aminoglycosides; Anti-Bacterial Agents; beta-Lactams; Birth Weight; Body Size; Cephalosporins; Child; Clindamycin; Glycopeptides; Humans; Infant; Infant, Newborn; Medication Reconciliation; Meropenem; Metronidazole; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Thienamycins | 2017 |
Influence of β-Lactam Infusion Strategy on Acute Kidney Injury.
Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cefepime; Cephalosporins; Drug Therapy, Combination; Female; Humans; Kidney; Male; Meropenem; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Thienamycins | 2017 |
Plasmid-Mediated Colistin Resistance Gene mcr-1 in an Escherichia coli ST10 Bloodstream Isolate in the Sultanate of Oman.
Topics: Amikacin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; Colistin; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Gene Expression; Humans; Membrane Proteins; Microbial Sensitivity Tests; Oman; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Plasmids; Protein Isoforms; Tetracycline; Trimethoprim, Sulfamethoxazole Drug Combination | 2018 |
Does compliance with antibiotic prophylaxis in pediatric simple appendicitis matter?
Topics: Adolescent; Anti-Bacterial Agents; Antibiotic Prophylaxis; Appendectomy; Appendicitis; Cefepime; Cephalosporins; Child; Child, Preschool; Drug Therapy, Combination; Female; Follow-Up Studies; Guideline Adherence; Humans; Infant; Infant, Newborn; Logistic Models; Male; Metronidazole; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Practice Guidelines as Topic; Preoperative Care; Retrospective Studies; Surgical Wound Infection; Treatment Outcome | 2017 |
Using Population Pharmacokinetic Modeling and Monte Carlo Simulations To Determine whether Standard Doses of Piperacillin in Piperacillin-Tazobactam Regimens Are Adequate for the Management of Febrile Neutropenia.
Topics: Aged; Anti-Bacterial Agents; Bacterial Infections; Creatinine; Febrile Neutropenia; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2017 |
Frequency of Acute Kidney Injury Caused by Tazobactam/Piperacillin in Patients with Pneumonia and Chronic Kidney Disease: A Retrospective Observational Study.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Retrospective Studies; Treatment Outcome | 2017 |
Dose-Exposure Simulation for Piperacillin-Tazobactam Dosing Strategies in Infants and Young Children.
Topics: Age Factors; Anti-Bacterial Agents; Child, Preschool; Computer Simulation; Dose-Response Relationship, Drug; Humans; Infant; Infusions, Intravenous; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Time Factors | 2017 |
Vancomycin vs. Vancomycin/Piperacillin-Tazobactam-Associated Acute Kidney Injury in Noncritically Ill Patients at a Tertiary Care Military Treatment Facility.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Drug Therapy, Combination; Female; Hospitals, Military; Humans; Incidence; Logistic Models; Male; Middle Aged; Military Personnel; Odds Ratio; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Tazobactam; Tertiary Care Centers; Vancomycin | 2017 |
Increased Risk of Acute Kidney Injury in Critically Ill Children Treated With Vancomycin and Piperacillin/Tazobactam.
Topics: Acute Kidney Injury; Adolescent; Anti-Bacterial Agents; Ceftriaxone; Child; Child, Preschool; Critical Illness; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Infant; Intensive Care Units, Pediatric; Logistic Models; Male; Odds Ratio; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Vancomycin | 2017 |
Topics: Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Ciprofloxacin; Drug Combinations; Drug Resistance, Multiple, Bacterial; Febrile Neutropenia; Humans; Iatrogenic Disease; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia; Practice Guidelines as Topic; Pseudomonas aeruginosa; Pseudomonas Infections; Sepsis; Tazobactam; Thienamycins; Tobramycin | 2017 |
Investigation of the Efficacy of an Administration Plan for Tazobactam/Piperacillin (TAZ/PIPC) and the Incidence of Kidney and Hepatic Disorders.
Topics: Aged; Aged, 80 and over; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Chemical and Drug Induced Liver Injury; Creatinine; Drug Administration Schedule; Female; Humans; Incidence; Kidney Diseases; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Treatment Outcome | 2017 |
Automated direct screening for resistance of Gram-negative blood cultures using the BD Kiestra WorkCell.
Topics: Ampicillin; Anti-Bacterial Agents; Bacteremia; Blood Culture; Ceftriaxone; Ciprofloxacin; Disk Diffusion Antimicrobial Tests; Drug Resistance, Bacterial; Gentamicins; Gram-Negative Bacteria; Humans; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Thienamycins | 2018 |
Association of Acute Kidney Injury With Concomitant Vancomycin and Piperacillin/Tazobactam Treatment Among Hospitalized Children.
Topics: Acute Kidney Injury; Adolescent; Anti-Bacterial Agents; Child; Child, Preschool; Databases, Factual; Drug Therapy, Combination; Female; Hospital Mortality; Hospitalization; Humans; Length of Stay; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Risk Assessment; United States; Vancomycin | 2017 |
Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactam Resistance; beta-Lactamases; Cefepime; Ceftazidime; Cephalosporins; Drug Combinations; Gene Expression; Humans; Los Angeles; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thienamycins | 2017 |
Increasing Evidence of the Nephrotoxicity of Piperacillin/Tazobactam and Vancomycin Combination Therapy-What Is the Clinician to Do?
Topics: Anti-Bacterial Agents; Combined Modality Therapy; Drug Therapy, Combination; Humans; Kidney; Kidney Diseases; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sepsis; Vancomycin | 2017 |
Peculiar purulence: Hypervirulent Klebsiella pneumoniae causing pyomyositis.
Topics: Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Humans; Klebsiella Infections; Klebsiella pneumoniae; Levofloxacin; Liver Abscess; Male; Middle Aged; Penicillanic Acid; Phenotype; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pyomyositis; Vancomycin | 2017 |
Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazoba
Topics: Amikacin; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Hospitals; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thienamycins | 2018 |
Heteroresistance to Piperacillin-Tazobactam in Clinical Isolates of Escherichia coli Sequence Type 131.
Topics: Anti-Bacterial Agents; beta-Lactamases; Drug Resistance, Multiple, Bacterial; Escherichia coli; Humans; Microbial Sensitivity Tests; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam | 2018 |
Extensive colonization with carbapenemase-producing microorganisms in Romanian burn patients: infectious consequences from the Colectiv fire disaster.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Burns; Colistin; Disasters; Enterobacter cloacae; Humans; Kanamycin; Klebsiella pneumoniae; Linezolid; Microbial Sensitivity Tests; Netherlands; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Providencia; Pseudomonas aeruginosa; Romania; Silver Sulfadiazine | 2018 |
A UHPLC-MS/MS method for the simultaneous determination of piperacillin and tazobactam in plasma (total and unbound), urine and renal replacement therapy effluent.
Topics: Calibration; Chromatography, High Pressure Liquid; Critical Illness; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Plasma; Renal Replacement Therapy; Sensitivity and Specificity; Tandem Mass Spectrometry; Tazobactam; Urine | 2018 |
Antibiotic Resistance in Diabetic Foot Soft Tissue Infections: A Series From Greece.
Topics: Aged; Anti-Bacterial Agents; Biological Availability; Diabetic Foot; Drug Resistance, Microbial; Female; Greece; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Middle Aged; Patient Selection; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas; Soft Tissue Infections | 2017 |
Simplifying Piperacillin/Tazobactam Dosing: Pharmacodynamics of Utilizing Only 4.5 or 3.375 g Doses for Patients With Normal and Impaired Renal Function.
Topics: Anti-Bacterial Agents; Dose-Response Relationship, Drug; Enterobacteriaceae; Humans; Infusions, Intravenous; Kidney; Microbial Sensitivity Tests; Monte Carlo Method; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Renal Insufficiency | 2017 |
Appropriate non-carbapenems are not inferior to carbapenems as initial empirical therapy for bacteremia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a propensity score weighted multicenter cohort study.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; Carbapenem-Resistant Enterobacteriaceae; Ciprofloxacin; Escherichia coli; Escherichia coli Infections; Female; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Meropenem; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Propensity Score; Retrospective Studies; Tertiary Care Centers; Thienamycins; Treatment Outcome | 2018 |
Pediatric acute kidney injury induced by concomitant vancomycin and piperacillin-tazobactam.
Topics: Acute Kidney Injury; Adolescent; Anti-Bacterial Agents; Child; Child, Preschool; Cohort Studies; Databases, Factual; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Humans; Infant; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Saudi Arabia; Vancomycin | 2018 |
[Piperacillin/Tazobactam Shortage: Central Restriction and Alternative Recommendations as Effective Antibiotic-Stewardship Intervention at a Maximal Care Hospital].
Topics: Anti-Bacterial Agents; Antimicrobial Stewardship; Cross Infection; Hospitals; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Practice Guidelines as Topic | 2018 |
Co-administration of vancomycin and piperacillin-tazobactam is associated with increased renal dysfunction in adult and pediatric burn patients.
Topics: Acute Kidney Injury; Adolescent; Adult; Analysis of Variance; Anti-Bacterial Agents; Burns; Child; Child, Preschool; Cilastatin; Cilastatin, Imipenem Drug Combination; Cohort Studies; Creatinine; Drug Combinations; Drug Therapy, Combination; Female; Humans; Imipenem; Incidence; Infections; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Texas; Vancomycin | 2017 |
Considerable variation of trough β-lactam concentrations in older adults hospitalized with infection-a prospective observational study.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Bacterial Infections; beta-Lactams; Cefotaxime; Drug Monitoring; Female; Humans; Length of Stay; Male; Meropenem; Patient Readmission; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Sepsis; Sweden; Thienamycins | 2018 |
Differences in suppression of regrowth and resistance despite similar initial bacterial killing for meropenem and piperacillin/tazobactam against Pseudomonas aeruginosa and Escherichia coli.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; Escherichia coli; Escherichia coli Infections; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2018 |
Topics: Anti-Bacterial Agents; Bursitis; Debridement; Elbow Injuries; Gram-Positive Bacterial Infections; Humans; Male; Middle Aged; Olecranon Process; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Propionibacterium acnes; Soft Tissue Injuries; Staphylococcal Infections; Staphylococcus epidermidis; Treatment Outcome; Vancomycin | 2018 |
Evaluation of antimicrobial stewardship (AS) for appropriate use of antimicrobial agents.
Topics: Anti-Bacterial Agents; Antimicrobial Stewardship; Carbapenems; Hospital Mortality; Hospitalization; Humans; Length of Stay; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Penicillanic Acid; Pharmaceutical Services; Pharmacists; Piperacillin; Piperacillin, Tazobactam Drug Combination; Staphylococcal Infections | 2017 |
Bullous eyelid.
Topics: Administration, Intravenous; Anti-Bacterial Agents; Diagnosis, Differential; Eyelid Diseases; Eyelids; Fasciitis, Necrotizing; Female; Humans; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Streptococcal Infections; Streptococcus pyogenes; Vancomycin | 2018 |
Role Of Conservative Management In Emphysematous Gastritis.
Topics: Adult; Anti-Bacterial Agents; Conservative Treatment; Emphysema; Female; Fluid Therapy; Gastric Mucosa; Gastritis; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tomography, X-Ray Computed; Vancomycin | 2018 |
[Enterobacteriaceae susceptibility to piperacillin/tazobactam in a Chilean pediatric hospital].
Topics: Anti-Bacterial Agents; Child; Child, Preschool; Chile; Drug Resistance, Bacterial; Enterobacteriaceae; Female; Hospitals, Pediatric; Humans; Infant; Male; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Reference Values | 2017 |
Effects of pH on the Antibiotic Resistance of Bacteria Recovered from Diabetic Foot Ulcer Fluid
Topics: Anti-Bacterial Agents; Diabetic Foot; Drug Resistance, Microbial; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Staphylococcal Infections; Wound Healing | 2018 |
Platelet Dysfunction and Intracerebral Hemorrhage in a Patient Treated with Empiric Piperacillin-Tazobactam in the Neurocritical Care Unit.
Topics: Anti-Bacterial Agents; Blood Platelet Disorders; Blood Platelets; Cerebral Hemorrhage; Critical Care; Empirical Research; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Treatment Outcome | 2018 |
Therapeutic drug monitoring of piperacillin and tazobactam by RP-HPLC of residual blood specimens.
Topics: Blood Specimen Collection; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Drug Monitoring; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sepsis; Tazobactam | 2018 |
[Retrospective Analysis of Factors Decreasing the Efficacy of Tazobactam/Piperacillin for Pneumonia in Elderly Patients].
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Bacterial Agents; Chronic Disease; Cross Infection; Female; Hospitals; Humans; Male; Multivariate Analysis; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Respiratory Tract Diseases; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2018 |
Nephrotoxicity of piperacillin/tazobactam combined with vancomycin: should it be a concern?
Topics: Acute Kidney Injury; Adult; Aged; Creatinine; Drug Therapy, Combination; Female; Humans; Kidney; Logistic Models; Male; Meropenem; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Staphylococcal Infections; Thienamycins; Vancomycin | 2018 |
Gram negative anaerobe susceptibility testing in clinical isolates using Sensititre and Etest methods.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Carbapenems; Disk Diffusion Antimicrobial Tests; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2018 |
Simplification of first-line antibacterial regimen for complicated appendicitis in children is associated with better adherence to guidelines and reduced use of antibiotics.
Topics: Adolescent; Anti-Bacterial Agents; Appendicitis; Cefotaxime; Child; Drug Therapy, Combination; Female; Gentamicins; Guideline Adherence; Humans; Length of Stay; Male; Metronidazole; Penicillanic Acid; Peritonitis; Piperacillin; Piperacillin, Tazobactam Drug Combination; Postoperative Complications; Practice Guidelines as Topic; Retrospective Studies | 2018 |
Piperacillin Population Pharmacokinetics in Critically Ill Adults During Sustained Low-Efficiency Dialysis.
Topics: Adult; Aged; Anti-Bacterial Agents; Critical Illness; Female; Humans; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Renal Dialysis; Renal Replacement Therapy; Tazobactam | 2018 |
Pyopericardium progressing to tamponade in a patient with immune thrombocytopenia.
Topics: Acute Disease; Aged; Anti-Bacterial Agents; Cardiac Tamponade; Disease Progression; Drainage; Female; Humans; Penicillanic Acid; Pericardial Effusion; Pericarditis, Constrictive; Piperacillin; Piperacillin, Tazobactam Drug Combination; Purpura, Thrombocytopenic, Idiopathic; Staphylococcal Infections; Staphylococcus aureus; Tomography, X-Ray Computed; Vancomycin | 2018 |
Antimicrobial Susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa Isolates from United States Medical Centers Stratified by Infection Type: Results from the International Network for Optimal Resistance Monitoring (INFORM) Surveillance Program,
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Colistin; Cross Infection; Drug Combinations; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins; United States | 2018 |
Onset of Hemophagocytic Lymphohistiocytosis during Piperacillin-Tazobactam Therapy in Three Children with Acute Focal Bacterial Nephritis.
Topics: Acute Disease; Bone Marrow; Child; Child, Preschool; Female; Humans; Lymphohistiocytosis, Hemophagocytic; Male; Nephritis; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tomography, X-Ray Computed | 2018 |
Topics: Aged; Anti-Bacterial Agents; Azithromycin; Campylobacter Infections; Coinfection; Colitis, Ulcerative; Feces; Female; Fever; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas Infections; Sigmoidoscopy; Treatment Outcome | 2018 |
Piperacillin-Tazobactam: Extended Infusion Versus Continuous Infusion.
Topics: Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam | 2018 |
[Analysis of the distribution characteristics and drug resistance of non-fermenting bacterial infection in intensive care unit from 2009 to 2015]
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Infections; Cefepime; Cefoperazone; Cephalosporins; Cross Infection; Drug Resistance; Drug Resistance, Bacterial; Gram-Negative Bacteria; Humans; Imipenem; Intensive Care Units; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Retrospective Studies; Thienamycins | 2016 |
Pharmacodynamic Target Attainment for Cefepime, Meropenem, and Piperacillin-Tazobactam Using a Pharmacokinetic/Pharmacodynamic-Based Dosing Calculator in Critically Ill Patients.
Topics: Anti-Bacterial Agents; Cefepime; Critical Illness; Female; Humans; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Tazobactam | 2018 |
Antimicrobial prophylaxis for transurethral resection of bladder tumor: A retrospective comparison of preoperative single-dose administration of piperacillin and tazobactam/piperacillin.
Topics: Administration, Intravenous; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteriuria; Female; Fever; Humans; Male; Piperacillin; Piperacillin, Tazobactam Drug Combination; Preoperative Period; Retrospective Studies; Tazobactam; Urinary Bladder Neoplasms | 2018 |
Cefepime challenge after piperacillin/tazobactam-induced thrombocytopenia.
Topics: Adult; Anti-Bacterial Agents; Cefepime; Female; Humans; Immunity, Humoral; Male; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Aspiration; Tazobactam; Thrombocytopenia | 2019 |
Adequacy of empiric gram-negative coverage for septic patients at an academic medical center.
Topics: Academic Medical Centers; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cefepime; Cephalosporins; Female; Gram-Negative Bacteria; Humans; Levofloxacin; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Sepsis; Shock, Septic; Virginia; Young Adult | 2019 |
Stability Studies of Antipyocyanic Beta-Lactam Antibiotics Used in Continuous Infusion.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactams; Cefepime; Ceftazidime; Cilastatin; Cilastatin, Imipenem Drug Combination; Imipenem; Meropenem; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam | 2019 |
Novel insights into the chemistry of an old medicine: A general degradative pathway for penicillins from a piperacillin/tazobactam stability study.
Topics: Anti-Bacterial Agents; Bacterial Infections; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam | 2019 |
Piperacillin-tazobactam concentration target attainment in children with cancer.
Topics: Child; Fever; Humans; Neoplasms; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2019 |
Population pharmacokinetics of piperacillin in febrile children receiving cancer chemotherapy: the impact of body weight and target on an optimal dosing regimen.
Topics: Adolescent; Anti-Bacterial Agents; Bacterial Infections; Body Weight; Child; Child, Preschool; Female; Fever; Glomerular Filtration Rate; Humans; Infant; Male; Microbial Sensitivity Tests; Neoplasms; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam | 2019 |
Vancomycin/Piperacillin-tazobactam Nephrotoxicity in the Critically Ill.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Critical Illness; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Vancomycin | 2020 |
Subtherapeutic piperacillin concentrations in neurocritical patients.
Topics: Adult; Aged; Anti-Bacterial Agents; Critical Care; Critical Illness; Female; Humans; Intensive Care Units; Kidney; Kidney Function Tests; Male; Middle Aged; Multivariate Analysis; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Pseudomonas aeruginosa; Retrospective Studies; Risk Factors | 2019 |
Population Pharmacokinetics and Safety of Piperacillin-Tazobactam Extended Infusions in Infants and Children.
Topics: Anti-Bacterial Agents; Child; Child, Preschool; Cross Infection; Female; Humans; Infant; Male; Microbial Sensitivity Tests; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2019 |
Safety of Subcutaneous Piperacillin/Tazobactam Administration Compared to Intravenous Administration: Propensity Score-Matched Cohort Study.
Topics: Administration, Intravenous; Anti-Bacterial Agents; Cohort Studies; Drug Therapy, Combination; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Propensity Score | 2020 |
Lack of synergistic nephrotoxicity between vancomycin and piperacillin/tazobactam in a rat model and a confirmatory cellular model.
Topics: Acute Kidney Injury; Animals; Anti-Bacterial Agents; Drug Therapy, Combination; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Rats; Rats, Sprague-Dawley; Retrospective Studies; Vancomycin | 2020 |
Is Piperacillin-Tazobactam Really Comparable to Carbapenem for the Treatment of Pyelonephritis Caused by Extended-Spectrum β-Lactamase-Producing Organisms?
Topics: beta-Lactamases; Carbapenems; Humans; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pyelonephritis | 2020 |
Sensitization phenotypes in immediate reactions to piperacillin-tazobactam.
Topics: Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Phenotype; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2020 |
Severe bleeding caused by piperacillin/tazobactam-induced platelet dysfunction
.
Topics: Aged; Anti-Bacterial Agents; Blood Platelet Disorders; Cross Infection; Humans; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Ventilator-Associated | 2020 |
Tolerance and microbiological efficacy of cefepime or piperacillin/tazobactam in combination with vancomycin as empirical antimicrobial therapy of prosthetic joint infection: a propensity-matched cohort study.
Topics: Acute Kidney Injury; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Cefepime; Cohort Studies; Drug Therapy, Combination; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Vancomycin | 2020 |
Time above the MIC of Piperacillin-Tazobactam as a Predictor of Outcome in Pseudomonas aeruginosa Bacteremia.
Topics: Adult; Anti-Bacterial Agents; Bacteremia; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies | 2020 |
Piperacillin/tazobactam-induced coagulopathy in a patient through a vitamin K-dependent mechanism.
Topics: Aged; Anti-Bacterial Agents; Female; Humans; Intensive Care Units; Piperacillin; Piperacillin, Tazobactam Drug Combination; Vitamin K | 2021 |
Short Versus Extended Duration Vancomycin and Piperacillin/Tazobactam and the Incidence of Acute Kidney Injury in Noncritically Ill Patients.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Drug Therapy, Combination; Humans; Incidence; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Vancomycin | 2021 |
Pharmacodynamic evaluation of intermittent versus extended and continuous infusions of piperacillin/tazobactam in a hollow-fibre infection model against Klebsiella pneumoniae.
Topics: Anti-Bacterial Agents; Infusions, Intravenous; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa | 2020 |
[Plasmatic concentracion of piperacillin/tazobactam in pediatric patients on ECMO support. Preliminary analysis].
Topics: Anti-Bacterial Agents; Child; Extracorporeal Membrane Oxygenation; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2020 |
Nephrotoxicity of concomitant piperacillin/tazobactam and teicoplanin compared with monotherapy.
Topics: Acute Kidney Injury; Adult; Anti-Bacterial Agents; Drug Therapy, Combination; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Teicoplanin; Vancomycin | 2021 |
A Much-Anticipated Leap Forward in β-Lactam Drug Allergy: Phenotyping Reactions to Piperacillin/Tazobactam.
Topics: beta-Lactams; Drug Hypersensitivity; Humans; Phenotype; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2020 |
Nephrotoxicity of teicoplanin-based combination therapy: focus on piperacillin/tazobactam and other anti-pseudomonal β-lactams.
Topics: Acute Kidney Injury; Adult; Aged; Anti-Bacterial Agents; beta-Lactams; Cohort Studies; Drug Therapy, Combination; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Teicoplanin | 2021 |
Evaluation of First-Dose, Intravenous Push Penicillins and Carbapenems in the Emergency Department.
Topics: Ampicillin; Anti-Bacterial Agents; Carbapenems; Emergency Service, Hospital; Ertapenem; Humans; Penicillins; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Sulbactam | 2022 |
Risk of Acute Kidney Injury and Clostridioides difficile Infection With Piperacillin/Tazobactam, Cefepime, and Meropenem With or Without Vancomycin.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Cefepime; Clostridioides; Drug Therapy, Combination; Humans; Meropenem; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Vancomycin | 2021 |
[Pharmacokinetics and therapeutic monitoring of piperacillin/tazobactam].
Topics: Anti-Bacterial Agents; beta-Lactams; Humans; Microbial Sensitivity Tests; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2020 |
Imipenem-resistant Pseudomonas aeruginosa treated with piperacillin/tazobactam in a patient with severe pneumonia: a case report and related literature review.
Topics: Aged; Female; Humans; Imipenem; Microbial Sensitivity Tests; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia; Pseudomonas aeruginosa; Tazobactam | 2021 |
An unusual case of piperacillin-tazobactam-induced fever, eosinophilia, thrombocytopenia and liver damage.
Topics: Adult; Eosinophilia; Humans; Liver; Male; Piperacillin; Piperacillin, Tazobactam Drug Combination; Thrombocytopenia; Young Adult | 2022 |
Combination of vancomycin plus piperacillin and risk of acute kidney injury: a worldwide pharmacovigilance database analysis.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Drug Therapy, Combination; Humans; Pharmacovigilance; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Vancomycin | 2021 |
Piperacillin-tazobactam-induced haemolytic anaemia after multiple courses of therapy.
Topics: Anemia, Hemolytic; Anti-Bacterial Agents; Drug Therapy, Combination; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2021 |
Outpatient therapy with piperacillin/tazobactam using elastomeric pumps in patients with Pseudomonas aeruginosa infection.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Outpatients; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies | 2021 |
A retrospective cohort study assessing acute kidney injury and renal recovery among septic patients empirically treated with vancomycin piperacillin-tazobactam versus vancomycin cefepime.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Cefepime; Drug Therapy, Combination; Female; Humans; Male; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Sepsis; Vancomycin | 2022 |
Meropenem and piperacillin-tazobactam levels for critical care patients during empiric therapy.
Topics: Anti-Bacterial Agents; Critical Care; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2021 |
Delayed hypersensitivity reactions to piperacillin-tazobactam.
Topics: Humans; Hypersensitivity, Delayed; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2021 |
Reply to "Delayed hypersensitivity reactions to piperacillin-tazobactam".
Topics: Humans; Hypersensitivity, Delayed; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2021 |
Ceftriaxone versus tazobactam/piperacillin and carbapenems in the treatment of aspiration pneumonia: A propensity score matching analysis.
Topics: Anti-Bacterial Agents; Carbapenems; Ceftriaxone; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Aspiration; Propensity Score; Retrospective Studies | 2021 |
An Unrecognized Problem in Optimizing Antimicrobial Therapy: Significant Residual Volume Remaining in Intravenous Tubing With Extended-Infusion Piperacillin-Tazobactam.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Humans; Infusions, Intravenous; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Residual Volume | 2023 |
Risk factors for acute kidney injury in vancomycin and piperacillin/tazobactam combination therapy: A retrospective study.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Drug Therapy, Combination; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Risk Factors; Vancomycin | 2021 |
Comparative incidence of acute kidney injury in patients on vancomycin therapy in combination with cefepime, piperacillin-tazobactam or meropenem.
Topics: Acute Kidney Injury; Adult; Anti-Bacterial Agents; Cefepime; Drug Therapy, Combination; Humans; Incidence; Meropenem; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Vancomycin | 2022 |
Incidence of acute kidney injury after teicoplanin- or vancomycin- and piperacillin/tazobactam combination therapy: A comparative study using propensity score matching analysis.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Cohort Studies; Drug Therapy, Combination; Humans; Incidence; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Propensity Score; Retrospective Studies; Teicoplanin; Vancomycin | 2021 |
Clinical utiliy of a model-based piperacillin dose in neonates with early-onset sepsis.
Topics: Anti-Bacterial Agents; Humans; Infant; Infant, Newborn; Microbial Sensitivity Tests; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Sepsis | 2022 |
Impact of Area Under the Concentration-Time Curve on the Prevalence of Vancomycin-Induced Nephrotoxicity in Combination With Tazobactam/Piperacillin or Cefepime: A Single-Institution Retrospective Study.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Bayes Theorem; Cefepime; Drug Therapy, Combination; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prevalence; Retrospective Studies; Vancomycin | 2021 |
A puerperal patient with agranulocytosis during tazobactam / piperacillin administration : A case report.
Topics: Adult; Agranulocytosis; Anti-Bacterial Agents; Drug Therapy, Combination; Female; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2021 |
Vancomycin with concomitant piperacillin/tazobactam vs. cefepime or meropenem associated acute kidney injury in the critically ill: A multicenter propensity score-matched study.
Topics: Acute Kidney Injury; Adult; Anti-Bacterial Agents; Cefepime; Cohort Studies; Critical Illness; Drug Therapy, Combination; Humans; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Propensity Score; Retrospective Studies; Vancomycin | 2022 |
Continuous infusion of piperacillin-tazobactam significantly improves target attainment in children with cancer and fever.
Topics: Anti-Bacterial Agents; Body Weight; Child; Febrile Neutropenia; Fever; Humans; Neoplasms; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies | 2022 |
The concomitant use of vancomycin and piperacillin-tazobactam is associated with acute kidney injury (AKI) in extremely low birth weight infants (ELBW).
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Case-Control Studies; Drug Therapy, Combination; Female; Humans; Infant, Extremely Low Birth Weight; Infant, Newborn; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Sepsis; Vancomycin | 2022 |
Therapeutic drug monitoring of meropenem and piperacillin-tazobactam in the Singapore critically ill population - A prospective, multi-center, observational study (BLAST 1).
Topics: Adult; Anti-Bacterial Agents; beta-Lactams; Critical Illness; Drug Monitoring; Humans; Meropenem; Microbial Sensitivity Tests; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Singapore | 2022 |
Using Japanese big data to investigate novel factors and their high-risk combinations that affect vancomycin-induced nephrotoxicity.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Big Data; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Humans; Japan; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Vancomycin | 2022 |
In vitro study of elution kinetics and biological activity of piperacillin/tazobactam and gentamicin in acrylic bone cement.
Topics: Anti-Bacterial Agents; Bone Cements; Gentamicins; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Polymethyl Methacrylate; Tazobactam | 2022 |
Efficacy of piperacillin-tazobactam and cefotaxime against Escherichia coli hyperproducing TEM-1 in a mouse peritonitis infection model.
Topics: Animals; Anti-Bacterial Agents; Antigens, CD; beta-Lactamases; Cefotaxime; Escherichia coli; Escherichia coli Infections; Mice; Microbial Sensitivity Tests; Neoplasm Proteins; Peritonitis; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam | 2022 |
Concerns about study design and suggestion of additional analysis of therapeutic drug monitoring-guided piperacillin/tazobactam therapy for patients with sepsis.
Topics: Anti-Bacterial Agents; Drug Monitoring; Drug Therapy, Combination; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sepsis | 2022 |
Evaluation of Intravenous Push Piperacillin-Tazobactam on Time to Antibiotic Administration in Emergency Department Patients with Sepsis.
Topics: Anti-Bacterial Agents; Emergency Service, Hospital; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Sepsis | 2023 |
Population pharmacokinetics of piperacillin/tazobactam in critically ill Korean patients and the effects of extracorporeal membrane oxygenation.
Topics: Adult; Anti-Bacterial Agents; Critical Illness; Extracorporeal Membrane Oxygenation; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Republic of Korea; Tazobactam | 2022 |
Concerns about study design and suggestion of additional analysis of therapeutic drug monitoring-guided piperacillin/tazobactam therapy for patients with sepsis. Author's reply.
Topics: Anti-Bacterial Agents; Drug Monitoring; Drug Therapy, Combination; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sepsis | 2022 |
The TARGET trial as a plea for model-informed precision dosing of piperacillin/tazobactam in patients with sepsis.
Topics: Anti-Bacterial Agents; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sepsis | 2022 |
Population pharmacokinetics of piperacillin in critically ill children including those undergoing continuous kidney replacement therapy.
Topics: Anti-Bacterial Agents; Child; Critical Illness; Humans; Microbial Sensitivity Tests; Piperacillin; Piperacillin, Tazobactam Drug Combination; Renal Replacement Therapy | 2022 |
Comment on: Pharmacodynamic evaluation of intermittent versus extended and continuous infusions of piperacillin/tazobactam in a hollow-fibre infection model against Klebsiella pneumoniae.
Topics: Anti-Bacterial Agents; Infusions, Intravenous; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2022 |
Antimicrobial resistance, virulence factors, and genotypes of Pseudomonas aeruginosa clinical isolates from Gorgan, northern Iran.
Topics: Amikacin; Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Colistin; Deoxyribonucleases; Drug Resistance, Bacterial; Genotype; Gentamicins; Humans; Imipenem; Iran; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Pancreatic Elastase; Phospholipases; Piperacillin; Piperacillin, Tazobactam Drug Combination; Polymyxin B; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Virulence Factors | 2022 |
Pharmacodynamic evaluation of piperacillin/tazobactam versus meropenem against extended-spectrum β-lactamase-producing and non-producing Escherichia coli clinical isolates in a hollow-fibre infection model.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Escherichia coli; Escherichia coli Infections; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2022 |
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Aorta; Drug Therapy, Combination; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Thrombocytopenia; Vancomycin | 2022 |
Retrospective Cohort Study of the Incidence of Acute Kidney Injury with Vancomycin Area under the Curve-Based Dosing with Concomitant Piperacillin-Tazobactam Compared to Meropenem or Cefepime.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Cefepime; Drug Therapy, Combination; Humans; Incidence; Meropenem; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Vancomycin | 2022 |
Clinical effectiveness of branded versus generic piperacillin-tazobactam for treating severe community-acquired pneumonia.
Topics: Anti-Bacterial Agents; Community-Acquired Infections; Drugs, Generic; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia; Treatment Outcome | 2022 |
Is therapeutic drug monitoring really helpful for managing piperacillin/tazobactam therapy in critically ill patients?
Topics: Anti-Bacterial Agents; Critical Illness; Drug Monitoring; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2022 |
Nephrotoxicity of Vancomycin in Combination With Beta-Lactam Agents: Ceftolozane-Tazobactam vs Piperacillin-Tazobactam.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; beta-Lactams; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Humans; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Tazobactam; Vancomycin | 2023 |
Clearance of Piperacillin-Tazobactam and Vancomycin During Continuous Renal Replacement With Regional Citrate Anticoagulation.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Anticoagulants; Citrates; Citric Acid; Critical Illness; Humans; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam; Vancomycin | 2023 |
Development and evaluation of uncertainty quantifying machine learning models to predict piperacillin plasma concentrations in critically ill patients.
Topics: Anti-Bacterial Agents; Critical Illness; Humans; Machine Learning; Piperacillin; Piperacillin, Tazobactam Drug Combination; Uncertainty | 2022 |
Pharmacodynamic evaluation of intermittent versus extended and continuous infusions of piperacillin/tazobactam in a hollow-fibre infection model against Escherichia coli clinical isolates.
Topics: Anti-Bacterial Agents; Ceftriaxone; Escherichia coli; Escherichia coli Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2022 |
A ray of hope in the discord: is adding piperacillin-tazobactam to vancomycin truly more nephrotoxic?
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Drug Therapy, Combination; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Vancomycin | 2022 |
Definitive antibiotic treatment with a third-generation cephalosporin and with piperacillin-tazobactam worked well for some children with Serratia bacteraemia.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; Cephalosporins; Child; Female; Humans; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Serratia; Thrombocytopenia | 2022 |
Simultaneous infusion of two incompatible antibiotics: Impact of the choice of infusion device and concomitant simulated fluid volume support on the particulate load and the drug mass flow rates.
Topics: Anti-Bacterial Agents; Drug Incompatibility; Infusions, Intravenous; Infusions, Parenteral; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Vancomycin | 2022 |
Burn Injury and Augmented Renal Clearance: A Case for Optimized Piperacillin-Tazobactam Dosing.
Topics: Anti-Bacterial Agents; Burns; Critical Illness; Humans; Microbial Sensitivity Tests; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam | 2023 |
Optimal antipseudomonal ꞵ-lactam drug dosing recommendations in critically-ill Asian patients receiving CRRT.
Topics: Anti-Bacterial Agents; Body Weight; Cefepime; Ceftazidime; Critical Illness; Humans; Lactams; Meropenem; Microbial Sensitivity Tests; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2022 |
Piperacillin Population Pharmacokinetics and Dosing Regimen Optimization in Critically Ill Children Receiving Continuous Renal Replacement Therapy.
Topics: Anti-Bacterial Agents; Child; Child, Preschool; Continuous Renal Replacement Therapy; Critical Illness; Humans; Piperacillin; Piperacillin, Tazobactam Drug Combination; Renal Replacement Therapy | 2022 |
Piperacillin/tazobactam and risk of acute kidney injury in adults hospitalized with infection without vancomycin: a multi-centre real-world data analysis.
Topics: Acute Kidney Injury; Adult; Anti-Bacterial Agents; Ceftazidime; Data Analysis; Drug Therapy, Combination; Female; Humans; Meropenem; Middle Aged; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Vancomycin | 2023 |
Effect of restricting piperacillin/tazobactam prescription on rates of antimicrobial resistance in gram-negative bacteria and antibiotic consumption.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Drug Resistance, Bacterial; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prescriptions; Retrospective Studies | 2023 |
Impact of piperacillin unbound fraction variability on dosing recommendations in critically ill patients.
Topics: Anti-Bacterial Agents; Critical Illness; Humans; Microbial Sensitivity Tests; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2023 |
Relationship between piperacillin concentrations, clinical factors and piperacillin/tazobactam-associated acute kidney injury.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Child; Drug Therapy, Combination; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Tazobactam; Vancomycin; Young Adult | 2023 |
Piperacillin/Tazobactam Dose Optimization in the Setting of Piperacillin/Tazobactam-susceptible, Carbapenem-resistant Pseudomonas aeruginosa: Time to Reconsider Susceptible Dose Dependent.
Topics: Anti-Bacterial Agents; Carbapenems; Humans; Infusions, Intravenous; Microbial Sensitivity Tests; Mitomycin; Monte Carlo Method; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Tazobactam | 2023 |
Evaluation of the safety of piperacillin-tazobactam extended infusion in pediatric cystic fibrosis patients.
Topics: Acute Kidney Injury; Adolescent; Anti-Bacterial Agents; Child; Child, Preschool; Cystic Fibrosis; Drug Therapy, Combination; Humans; Infant, Newborn; Infusions, Intravenous; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies | 2023 |
Deconstructing the 2023 Clinical and Laboratory Standards Institute Revised Piperacillin-Tazobactam Breakpoints Against Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections | 2023 |
Population Pharmacokinetics of Piperacillin/Tazobactam Across the Adult Lifespan.
Topics: Aged; Anti-Bacterial Agents; Canada; Creatinine; Frailty; Humans; Longevity; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam | 2023 |
Association between emergency department sepsis order set design and delay to second dose piperacillin-tazobactam administration.
Topics: Adult; Anti-Bacterial Agents; Emergency Service, Hospital; Humans; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Sepsis; Tazobactam | 2023 |
Cross-reactivity between piperacillin-tazobactam and cefoperazone-sulbactam in drug-induced immune thrombocytopenia.
Topics: Aged; Anti-Bacterial Agents; Cefoperazone; Humans; Male; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Purpura, Thrombocytopenic, Idiopathic; Sulbactam | 2023 |
Effectiveness of third-generation cephalosporins or piperacillin compared with cefepime or carbapenems for severe infections caused by wild-type AmpC β-lactamase-producing Enterobacterales: A multi-centre retrospective propensity-weighted study.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cefepime; Cephalosporins; Humans; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies | 2023 |
A Large-Scale Multicenter Retrospective Study on Nephrotoxicity Associated With Empiric Broad-Spectrum Antibiotics in Critically Ill Patients.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Cefepime; Critical Illness; Drug Therapy, Combination; Humans; Meropenem; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Vancomycin | 2023 |
Piperacillin-Tazobactam Compared With Cefoxitin as Antimicrobial Prophylaxis for Pancreatoduodenectomy: A Randomized Clinical Trial.
Topics: Adult; Aged; Anti-Bacterial Agents; Cefoxitin; Humans; Male; Pancreatic Fistula; Pancreaticoduodenectomy; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sepsis; Surgical Wound Infection | 2023 |
Efficacy and safety of piperacillin-tazobactam compared with meropenem in treating complicated urinary tract infections including acute pyelonephritis due to extended-spectrum β-lactamase-producing
Topics: Adult; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pyelonephritis; Retrospective Studies; Urinary Tract Infections | 2023 |
A case of Robinsoniella peoriensis bacteremia during using piperacillin-tazobactam.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Female; Fever; Humans; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Vancomycin | 2023 |
International survey of antibiotic dosing and monitoring in adult intensive care units.
Topics: Adult; Aminoglycosides; Anti-Bacterial Agents; Critical Illness; Cross-Sectional Studies; Humans; Intensive Care Units; Meropenem; Piperacillin; Piperacillin, Tazobactam Drug Combination; Surveys and Questionnaires; Vancomycin | 2023 |
Iohexol-Measured Glomerular Filtration Rate and Urinary Biomarker Changes between Vancomycin and Vancomycin Plus Piperacillin-Tazobactam in a Translational Rat Model.
Topics: Acute Kidney Injury; Animals; Anti-Bacterial Agents; Biomarkers; Drug Therapy, Combination; Glomerular Filtration Rate; Iohexol; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Rats; Rats, Sprague-Dawley; Retrospective Studies; Vancomycin | 2023 |
The clinical efficacy of cefoperazone-sulbactam versus piperacillin-tazobactam in the treatment of severe community-acquired pneumonia.
Topics: Anti-Bacterial Agents; Cefoperazone; Community-Acquired Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia; Retrospective Studies; Sulbactam; Treatment Outcome | 2023 |
Early treatment response to piperacillin/tazobactam in patients with bloodstream infections caused by non-ESBL ampicillin/sulbactam-resistant Escherichia coli: a binational cohort study.
Topics: Adult; Ampicillin; Anti-Bacterial Agents; Bacteremia; Cephalosporins; Cohort Studies; Escherichia coli; Escherichia coli Infections; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Quinolones; Retrospective Studies; Sulbactam | 2023 |
The Relationship of Comorbid Diseases and Empirical Antibiotic Usage with Superinfection in COVID-19 Patients.
Topics: Anti-Bacterial Agents; Azithromycin; COVID-19; Humans; Moxifloxacin; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Superinfection | 2023 |
Microdialysis as a safe and feasible method to study target-site piperacillin-tazobactam disposition in septic piglets and children.
Topics: Animals; Anti-Bacterial Agents; Child; Humans; Microdialysis; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sepsis; Swine; Tazobactam | 2023 |
Letter responding to performance of updated
Topics: Anti-Bacterial Agents; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2023 |
The Editors' reply to "Letter responding to performance of updated
Topics: Anti-Bacterial Agents; Humans; Microbial Sensitivity Tests; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa | 2023 |
Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial.
Topics: Acute Kidney Injury; Adult; Anti-Bacterial Agents; Cefepime; Coma; Delirium; Drug Therapy, Combination; Female; Humans; Kidney; Male; Middle Aged; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Sepsis | 2023 |